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AROMATASE INHIBITORS PRODUCE HYPERSENSITIVITY IN EXPERIMENTAL 
MODELS OF PAIN: STUDIES IN VIVO AND IN ISOLATED SENSORY NEURONS 
 
Aromatase inhibitors (AIs) are the current standard of care for the treatment of 
hormone receptor positive breast cancer in postmenopausal women. Nearly one-half of 
patients receiving AI therapy develop musculoskeletal toxicity that is characterized by 
joint and/or muscle pain and approximately one-fourth of patients discontinue their 
therapy as a result of musculoskeletal pain. Since there are no effective strategies for 
prevention or treatment, insight into the mechanisms of AI-induced pain is critical to 
improve treatment. However, there are few studies of AI effects in animal models of 
nociception. To determine whether AIs produce hypersensitivity in animal models of 
pain, I examined the effects of AI administration on mechanical, thermal, and chemical 
sensitivity in rats. The results demonstrate that (1) repeated injection of 5 mg/kg 
letrozole in male rats produces mechanical, but not thermal, hypersensitivity that 
extinguishes when drug dosing is stopped; (2) administering a single dose of 1 or 5 
mg/kg letrozole in ovariectomized (OVX) rats also induces mechanical hypersensitivity, 
without altering thermal sensitivity and (3) a single dose of 5 mg/kg letrozole or daily 
dosing of letrozole or exemestane in male rats augments flinching behavior induced by 
intraplantar ATP injection. To determine whether the effects of AIs on nociceptive 
behaviors are mediated by activation or sensitization of peptidergic sensory neurons, I 
determined whether letrozole exposure alters release of calcitonin gene-related peptide 
(CGRP) from isolated rat sensory neurons and from sensory nerve endings in rat spinal 
cord slices. No changes in basal, capsaicin-evoked or high extracellular potassium-
evoked CGRP release were observed in sensory neuronal cultures acutely or chronically 
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 exposed to letrozole. Furthermore, letrozole exposure did not alter the ability of ATP to 
augment CGRP release from sensory neurons in culture. Finally, chronic letrozole 
treatment did not augment neuropeptide release from spinal cord slices. Taken together, 
these results do not support altered release of this neuropeptide into the spinal cord as 
mediator of letrozole-induced mechanical hypersensitivity and suggest the involvement 
of other mechanisms. Results from this dissertation provide a new experimental model 
for AI-induced hypersensitivity that could be beneficial in delineating mechanisms 
mediating pain during AI therapy. 
 
David A. Flockhart, M.D., Ph.D., Chair 
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 INTRODUCTION 
 
Clinical trials conducted over decades have demonstrated that aromatase 
inhibitors (AIs) are effective therapies for hormone sensitive breast cancer in 
postmenopausal women. Therapeutic outcomes have improved as increasingly potent 
AIs were introduced into clinical use, providing indirect evidence for a relationship 
between estrogen suppression and clinical efficacy (Geisler and Lonning, 2005a). In 
many breast cancer patients, therapeutic doses of the third generation aromatase 
inhibitors anastrozole, exemestane, and letrozole, achieve sufficient suppression of 
blood estrogen concentrations to inhibit growth of estrogen-sensitive tumors. 
Consequently, treatment of hormone receptor positive breast cancer with AIs is widely 
accepted as an effective therapy in postmenopausal women (Aebi et al., 2011; Burstein 
et al., 2010) and guidance issued by the American Society of Clinical Oncology 
recommends AIs as first-line therapy or as sequential treatment after tamoxifen. 
 
The occurrence of side effects during chemotherapy with many agents can 
become a limiting factor for overall drug tolerability. Recent clinical studies describe up 
to 50% of breast cancer patients developing painful joints and muscles within weeks to 
months of initiating AI therapy (Crew et al., 2007; Henry et al., 2007). Approximately 
25% of all breast cancer patients discontinue AI therapy as a result of intolerable drug-
induced musculoskeletal pain (Henry et al., 2012). Although many studies have been 
conducted to identify clinical factors and biomarkers to predict which patients will 
develop AI-induced pain, factors with strong associations have not been identified and 
findings have been largely inconsistent between studies. Furthermore, although the 
general consensus is that these adverse effects are secondary to reduced estrogens, no 
conclusive study has addressed this basic mechanistic premise (Felson and Cummings, 
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 2005; Henry et al., 2008). Clinical studies of AI-induced pain in breast cancer patients 
are complicated by an underlying incidence of musculoskeletal pain in postmenopausal 
women and by prior treatment with chemotherapy regimens or tamoxifen, which may 
themselves induce or influence the risk of developing musculoskeletal pain. To date, 
mechanisms causing AI-induced musculoskeletal pain remain unknown, and 
consequently, no clearly recognized therapies exist for prevention or treatment. 
 
In spite of the importance of understanding how AIs may alter pain pathways, 
there are few studies of AI effects using animal assays for nociception that may provide 
insight into toxicity induced by this widely prescribed class of drugs. The objective of this 
proposal is to establish a model for AI-induced pain and investigate the potential 
contribution of nociceptive sensory neurons. The central hypothesis is that aromatase 
inhibitors sensitize sensory neurons, resulting in pain during AI treatment.  
 
Aromatase 
 
Discovery and biochemistry of aromatase 
The discovery and characterization of aromatase proved to be one of the first 
characterizations of a molecular drug target for rational development of cancer 
therapies. Early in the characterization of sex steroids, it was thought that androgens 
with a 19-carbon backbone may serve as estrogen precursors.  The first indirect 
experimental evidence of the metabolism of androgens into estrogens was shown by 
Seinach and Kun, who observed enhanced estrogenic activity in urine after 
administering unlabeled testosterone to men (Sodersten et al., 2014; Steinach and Kun, 
1937). This observation was confirmed nearly 20 years later when Baggett and 
colleagues demonstrated conversion of radiolabeled testosterone to estrogens by the 
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 human ovary (Baggett et al., 1956). The reaction was believed to involve a cytochrome 
P450 enzyme due to the ability of aminoglutethimidine, a known inhibitor of adrenal 
P450-mediated hydroxylation, to inhibit the “aromatization” reaction (Chakraborty et al., 
1972). However, the enzyme was unique among P450s due to the inability of carbon 
monoxide to inhibit the reaction, the standard method at that time for determining P450-
mediated reactions. Aromatase catalyzes the conversion of C19-androgens to C18-
estrogens through a three-step reaction that sequentially generates 19-hydroxy and 19-
aldehyde intermediates before the final aromatization step (Ryan, 1959). As shown in 
Figure 1, endogenous substrates include androstenedione, testosterone, and 16α-
androstenedione, which are metabolized to estrone, 17β-estradiol, and estriol, 
respectively. The formation of estriol is most prominent in human pregnancies, where 
maternal and fetal liver form 16α-hydroxy-dehydroepiandrosterone sulfate that is 
converted to 16α-hydroxy-androstenedione by sulfatase and isomerase enzymes and 
converted to estriol by placental aromatase and 17-hydroxysteroid dehydrogenase. Late 
in gestation, approximately 90% of the 16α-hydroxy-dehydroepiandrosterone sulfate 
entering the placenta is derived from the fetal compartment and only 10% from the 
mother (Siiteri and MacDonald, 1966). Endogenous androgens, such as 
dihydrotestosterone, and estrogens have been shown to inhibit aromatase activity, 
however it is unclear whether endogenous concentrations of these steroids modulate 
enzymatic activity under physiologic conditions (Shimizu et al., 1993; Wozniak and 
Hutchison, 1993). 
 
Isolation and characterization of the aromatase enzyme and the gene encoding 
this protein was initially described in human tissues and subsequent studies identified 
the orthologous molecules in other organisms. Human aromatase is the product of the 
CYP19A1 gene residing on chromosome 15q21. Analyses of cDNA libraries from 
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 different tissues revealed complex tissue-specific regulation and expression of CYP19A1 
that is determined by the use of eleven alternative promoters in the 93 kb 5′-noncoding 
region of the gene. Initiating transcription at one of the tissue-specific promoters 
generates a unique exon I that is subsequently spliced to the splice acceptor site of exon 
II, creating tissue-specific messenger ribonucleic acid (mRNA) (Bulun et al., 2003; Chow 
et al., 2009). However, a common translation start site in exon II results in an identical 
translated protein produced in all tissues. Comparative genomic analysis of human and 
mouse CYP19A1 has demonstrated that the gene structures in humans and rodents are 
closely related (Chow et al., 2009). Alignments of aromatase amino-acid sequences 
between human and rats or mice demonstrate 77.3% sequence homology between 
these species and key substrate binding site and catalytic residues are highly conserved 
(Ghosh et al., 2009) (Figure 2). Antibodies raised against purified proteins from human 
placental microsomes suggested aromatase may exist as two isoforms with approximate 
molecular weights of 50 to 51 and 55 kDa (Harada, 1988; Mendelson et al., 1985). 
Furthermore, aromatase activity in rat microsomes can be inhibited by antibodies raised 
against human aromatase, suggesting the CYP19A1 orthologs encode enzymes with 
similar isotopes (Osawa et al., 1987). 
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Figure 1. Endogenous substrates and products of aromatase. 
 
5 
 
  
Figure 2. Alignment of amino acid sequences of human, rat and mouse aromatase. 
Aromatase protein sequences from rat (NP_058781) and mouse (NP_031836) were 
aligned to the human sequence (NP_000094) using ClustalW. Amino acids residues are 
depicted by standard one-letter codes. Amino acid residues in the aligned rat and mouse 
sequences that exactly match those in human aromatase are indicated by dots. Amino 
acids predicted to form the active site are shaded in green, while residues that form 
putative active-site access channel are shaded in yellow. Residues predicted to directly 
contribute to the aromatization reaction are shaded in red (Ala306, Asp309 and Thr310). 
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 Contribution of aromatase activity to tissue estrogen concentrations 
Estrogen content in a cell or tissue is the net result of processes that result in 
new molecules arriving in the cell (in situ synthesis by aromatase, diffusion or active 
transport from the local environment: neighboring cells or blood supply) and processes 
that eliminate the steroid (in situ metabolism, diffusion or active transport out of the cell). 
The availability of estrogens for uptake into the cell will be determined by the steroid in 
the blood and extra-cellular metabolism of sex steroids. Oxidative metabolism and 
conjugative metabolism by glucuronidation, sulfonation, and/or O-methylation in the liver 
are all processes that mediate the metabolic disposition of estrogens in humans (Lee et 
al., 2001; Raftogianis et al., 2000; Zhu and Lee, 2005) and rodents (Brooks et al., 1965; 
Holler et al., 1977). These estrogen metabolites are terminally eliminated in the urine 
and feces. Routes of metabolic disposition of blood-borne estrogens by the liver have 
also been identified in organs such as the brain, suggesting in situ metabolism of 
estrogens may be a mechanism to limit or terminate estrogen signaling (Reddy et al., 
1981).  
 
While aromatase was first characterized in the ovaries and early studies of 
estrogens focused on the endocrine actions of these steroids, other tissues are known to 
synthesize estrogens. Studies led by Christopher Longcope, Paul MacDonald, and 
Pentti Siiteri challenged the standing dogma that steroid hormones were only produced 
in endocrine glands such as the adrenals, ovaries, and testes. In order to characterize 
aromatization in vivo, these studies utilized a technique now termed “total body 
aromatization”, where tracer doses of an androgen (e.g. 4-14C-∆4-androstenedione or 
14C-An) and an estrogen (e.g. 6,7-3H-estrone or 3H-Es), labeled with different radioactive 
isotopes, are administered simultaneously. The fraction of administered androgen that is 
converted to a specific estrogen is estimated by taking the ratio of the molar ratio of 14C-
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 Es / 3H-Es measured in the blood or urine to the molar ratio of 14C-An / 3H-Es 
administered. In oophorectomized and adrenalectomized young adult females and 
normal adult males, these investigators observed formation of estrone and estradiol 
following intravenous dosing of radiolabeled androstenedione, demonstrating extra-
ovarian and extra-adrenal sources of aromatase activity (Longcope et al., 1969; 
MacDonald et al., 1967). Additional studies demonstrated higher conversion of 
androstenedione to estrogens in obese men and women, suggesting that adipose may 
be an important contributing source of aromatase activity (Grodin et al., 1973; Kley et al., 
1980). Indeed, subsequent experiments demonstrated aromatization of androgens in 
excised human adipose tissue (Schindler et al., 1972). 
 
In humans and rodents, concentrations of unconjugated estrogens have been 
shown to be several fold higher in tissue than in the blood; conversely, concentrations of 
estrone sulfate and other conjugates estrogens are much lower in tissues compared with 
blood. For example, in women, estradiol and estrone concentrations have been reported 
to be 1.6 to 12-fold and 2.5 to 5-fold higher in breast tissue than plasma (Geisler et al., 
2001; Lonning et al., 2009). These findings are consistent with a study estimating uptake 
and formation of estrone in the breast from 24 postmenopausal women with breast 
cancer (Larionov et al., 2002). During steady-state infusions of 3H-labelled 
androstenedione and 14C-labelled estrone, a median breast tissue:plasma ratio of 14C-
estrone of 6 was observed in normal tissue, consistent with diffusion and or active 
uptake of blood estrone and sequestration by binding (Larionov et al., 2002). By 
measuring 3H-estrone in breast tissue of these patients, aromatase activity in the breast 
was estimated to account for a median of 15% of local radiolabeled estrone 
concentrations (Larionov et al., 2002). 
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 Elevated tissue:blood ratios of estrogens have been observed in additional 
tissues. Estradiol concentrations in the hippocampus, cortex, and hypothalamus of 
female Sprague Dawley rats collected on postnatal day 10 were approximately 25, 125, 
and 833.3-fold higher than plasma concentrations (Konkle and McCarthy, 2011b). 
Aromatase activity measured in the hypothalamus was 10-fold higher than in the 
hippocampus and cortex (Konkle and McCarthy, 2011b). These studies suggest AI 
treatment could alter estrogen content in local tissues by reducing in situ aromatization, 
thereby reducing estrogens in peripheral tissue, including the blood. To understand the 
mechanism by which AIs alter the physiology of a cell secondary to a change in estrogen 
content of this tissue, it is important to determine the contribution of in situ synthesis by 
aromatase. 
 
Aromatase inhibitors 
 
Rationalization, discovery, and development of AIs as breast cancer therapies 
In a seminal paper published in 1896, Sir George Beatson, M.D. introduced 
ovariectomy (oophorectomy) of premenopausal women as therapy for breast cancer and 
identified manipulation of steroid hormones as an effective therapeutic strategy 
(Beatson, 1896). Others subsequently noticed reduced tumor burdens following surgical 
adrenalectomy and hypophysectomy (Santen et al., 2009). The recognition that surgical 
treatment of breast cancer may be effective as a result of estrogen suppression initiated 
a strong interest in the discovery of new endocrine therapies for breast cancer. 
Recognizing the therapeutic potential of targeting aromatase prompted a systematic 
search for selective aromatase inhibitors. Structure-function characterization of over 100 
compounds by Harry Brodie and Angela Brodie led to the identification of 1,4,6-
androstatrienedione (Schwarzel et al., 1973) and 4-hydroxy-androstenedione as the 
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 most promising candidate inhibitors with selectivity for aromatase (Brodie et al., 1977). 
The effectiveness of these compounds to treat breast cancer drove the development of 
additional aromatase inhibitors with increasing selectivity and potency (Geisler and 
Lonning, 2005b). 
 
Current generation AIs are used to treat early stage, locally advanced, and 
metastatic breast cancers in which the primary tumors express estrogen receptor alpha 
and/or the progesterone receptor (Schnitt, 2006). The clinical value of determining 
hormone-receptor positivity is to determine the likelihood that a patient will respond to 
endocrine therapy, such as AIs. As a result of improved detection of early stage breast 
cancers, AIs are most often used in adjuvant (after surgery) treatment regimens in 
postmenopausal women. Five years of AI therapy, either as monotherapy or following 
two to three years of tamoxifen, has been shown to reduce the risk of cancer recurrence 
relative to five years of tamoxifen therapy alone (Dowsett et al., 2010). Anastrozole and 
exemestane are currently being evaluated for their ability to reduce the development of 
invasive breast cancer in postmenopausal women at high risk for the disease (Lazzeroni 
and DeCensi, 2013).  
 
Pharmacology of third-generation AIs: exemestane and letrozole 
Exemestane (6-methylenandrosta-1,4-diene-3,17-dione) is an irreversible 
aromatase inhibitor. Pre-incubation studies using human placental microsomes as a 
source of aromatase enzyme show exemestane confers time-dependent aromatase 
inhibition, with a Ki of 26 nmol/L (Giudici et al., 1988). While bioavailability in humans 
was never determined due to the absence of a suitable formulation for intravenous 
delivery, approximately 5% of exemestane is bioavailable in rats following an oral dose 
of 30 mg/kg (U.S. Food and Drug Administration, 1998b). Rapid metabolism likely 
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 accounts for its low bioavailability, as less than 5% of the drug is excreted unchanged in 
rats (U.S. Food and Drug Administration, 1998b). The drug is also extensively 
metabolized in humans, as <1% of unchanged drug is recovered in urine and feces after 
a single oral dose of 25mg in humans (U.S. Food and Drug Administration, 1998a). In 
human liver microsomes, exemestane undergoes reduction of the 17-keto group by 
multiple cytochrome P450s to form the most abundant metabolite, 17-hydroexemestane 
(Kamdem et al., 2011). Although 17-hydroexemestane inhibits aromatase, it is 2.6-times 
less potent than the parent drug and plasma concentrations in humans are 
approximately ten percent of the parent, suggesting the metabolite does not substantially 
contribute to the in vivo pharmacologic activity of exemestane at therapeutic doses (U.S. 
Food and Drug Administration, 1998a). Daily oral dosing of 25mg exemestane in 
postmenopausal women suppresses aromatization of intravenously administered 3H-
androstenedione to 3H-estrone by 97.9%, corresponding to an average suppression of 
plasma concentrations of estradiol, estrone, and estrone sulfate by 92.2%, 94.5%, and 
93.2% respectively (Geisler et al., 1998).  
 
The ability of exemestane to inhibit aromatase in rats was estimated using adult 
female rats injected with pregnant mare's serum gonadotrophin (PMSG) (Giudici et al., 
1988). PMSG contains follicle-stimulating hormone and luteinizing hormone which 
stimulate the synthesis of enzymes mediating steroidogenesis in the ovaries, including a 
significant induction of estrogen synthesis by aromatase (Banks et al., 1991; Rowlands, 
1944). Twenty-four hours after administering exemestane (0, 0.3, 1, 3, or 10 mg/kg; s.c.) 
to PMSG-stimulated rats, aromatase activity was significantly inhibited in ovarian 
microsomes preparations, with the ED50 between 1 and 3 mg/kg. Aromatase activity in 
rats dosed with 10 mg/kg exemestane was 20% of the vehicle-treated controls, 
suggesting maximum effective doses had not been tested. Results of a similar study 
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 measuring aromatase activity in ovary microsomal preparations from PMSG-stimulated 
rats, showed aromatase activity was reduced to 43.6% of controls 6 hours after 
administration of 10 mg/kg exemestane (s.c.) (Zaccheo et al., 1991). In these rats, 
average plasma estradiol concentrations were reduced to 27.9% of the concentration 
measured in control animals (Zaccheo et al., 1991). 
 
In contrast to exemestane, letrozole (4-4′-(1H-1,2,4-triazol-1-yl-methylene)-bis-
benzonitrile) is a non-steroidal, competitive aromatase inhibitor. Letrozole inhibits 
aromatase activity in human placental microsomes with an IC50 of 11.5 nM and inhibits 
luteinizing hormone-stimulated production of estradiol in hamster ovaries in situ with an 
EC50 of approximately 10 nM, suggesting the drug is a potent aromatase inhibitor 
(Bhatnagar et al., 1990). In humans, letrozole is almost completely absorbed into 
circulation after oral dosing of the therapeutic dose of 2.5 mg (Sioufi et al., 1997). Once 
absorbed, letrozole clearance occurs primarily through cytochrome P450 (CYP) - 
mediated metabolism to an inactive carbinol (4,4′-methanol-bisbenzonitrile), which is 
excreted in the urine as a glucuronide conjugate (Pfister et al., 2001). Single doses of 
0.1, 0.5, and 2.5 mg letrozole reduce serum estrone and estradiol concentrations within 
two and eight hours of administration (Iveson et al., 1993). Twenty-four hours after a 
single dose of 2.5 mg, concentrations of estrone and estradiol are suppressed to at least 
10 and 3 pM and remain suppressed for up to fourteen days (Iveson et al., 1993). Daily 
oral dosing of 2.5mg letrozole in postmenopausal women suppresses aromatization of 
intravenously administered 3H-androstenedione to 3H-estrone by over 99.1%, and 
additionally suppresses plasma concentrations of estradiol, estrone, and estrone sulfate 
by an average of 84.3%, 87.8%, and 98.0%, respectively (Geisler et al., 2002). 
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 Letrozole pharmacokinetics in rats resembles those observed in humans. 
Letrozole dosed intravenously in female rats has a half-life of 34 to 37 hours (doses of 
0.1, 0.5, 1, and 2 mg/kg) and a volume of distribution of approximately 2 liters/kg (Tao et 
al., 2006). Letrozole readily crosses the blood brain barrier and accumulates in tissue, 
resulting in tissue concentrations several fold higher than those measured in plasma 
(Dave et al., 2013; Liu et al., 2000). Gender significantly influences letrozole 
pharmacokinetics in rats. Cumulative plasma drug exposure following oral dosing in 
males is between 10% and 60% that of females and can be attributed to a much shorter 
half-life in males (Liu et al., 2000; U.S. Food and Drug Administration, 1996; Wempe et 
al., 2007). Akin to metabolism observed in humans, 14C-letrozole administered 
intravenously to female rats is primarily excreted in urine as a glucuronide conjugate of 
the carbinol (4,4′-methanol-bisbenzonitrile) metabolite (U.S. Food and Drug 
Administration, 1996). Similar to exemestane, the in vivo potency of letrozole has been 
determined using several rat models that are sensitive to estrogen concentrations. The 
estimated ED50 for letrozole inhibition of androstenedione-induced uterine hypertrophy in 
immature female rats (an index of aromatase inhibition in vivo) is 1-3 ug/kg (Bhatnagar 
et al., 1990). Daily oral administration of letrozole to intact, cycling female rats for 14 
days results in a dose-dependent reduction in uterine wet weight (Bhatnagar et al., 
1990). Uterine weight reduction following administration of 1 mg/kg was equivalent to 
that observed after ovariectomy. 
 
Aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) 
 
Detection and measurement of AIMSS 
Early trials evaluating the efficacy of AIs for treatment of estrogen sensitive 
metastatic breast cancer showed arthralgia and joint pain were more frequently reported 
13 
 
 by patients receiving AIs than several other therapies (Bonneterre et al., 2000; 
Dombernowsky et al., 1998; Goss et al., 1999; Nabholtz et al., 2000). The first report to 
highlight the potential clinical importance of increased rates of arthralgia and joint pain 
during AI therapy was a letter to the editor in the Journal of Clinical Oncology written by 
Paul Donnellan and colleagues (Donnellan et al., 2001). He reported musculoskeletal 
symptoms in 77 post-menopausal patients receiving anastrozole who had previously 
failed on tamoxifen. Importantly, none of these patients had previous arthritis or 
arthralgia associated with menopause or prior chemotherapy. Within two months of 
initiating anastrozole, twelve patients (16%) reported new joint pain, primarily in the 
hands, knees, hips, lower back and shoulders. Early morning stiffness was a common 
side effect. Four of the 77 patients (5%) discontinued therapy due to arthralgia, which 
subsequently resolved. 
 
Despite these indications that musculoskeletal toxicity may be a significant side 
effect of AIs, early observations by oncologists suggested that these drugs were well-
tolerated. This view was reinforced by low rates of musculoskeletal adverse events 
reported in large randomized phase III clinical trials, which demonstrated the efficacy of 
AIs as adjuvant hormonal therapy for the treatment of early stage breast cancer (Baum 
et al., 2002; Coombes et al., 2004; Thurlimann et al., 2005; Whelan et al., 2005). In 
these studies, the incidence of musculoskeletal toxicity (disorder, pain, arthralgia, or 
aches) was 2-8% greater in subjects receiving an AI when compared to subjects 
receiving tamoxifen or placebo (Baum et al., 2002; Coombes et al., 2004; Thurlimann et 
al., 2005; Whelan et al., 2005). The increased rate of musculoskeletal toxicity in subjects 
receiving AIs represented significant, but relatively small changes, relative to rates in the 
comparator arm. Due to the immense size of these trials, which individually recruited 
several thousand study subjects, AIs were considered to be well tolerated and 
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 musculoskeletal toxicities were not expected to impact their clinical use. However, in 
retrospect, the evaluation of musculoskeletal adverse events was not sufficiently robust 
or consistent in these trials to detect the increased rate of joint symptoms among AI 
users. Instead, musculoskeletal toxicity reported in these trials was assessed by a 
number of different methods, including: case-report forms graded according to the 
Common Toxicity Criteria of the National Cancer Institute (version 2.0) (Thurlimann et 
al., 2005), Medical Outcomes Study 36-item Short Form Health Survey and the 
Menopause Specific Quality of Life Questionnaire (Whelan et al., 2005) or self-reporting 
by patients (Baum et al., 2002; Coombes et al., 2004). Consequently, it is possible that 
musculoskeletal toxicities were differentially and inadequately captured by these various 
methods for a number of reasons. For instance, the Common Toxicity Criteria of the 
National Cancer Institute (version 2.0) includes a section on musculoskeletal pain and 
stiffness (grade 0-5), but does not allow for reporting specific site or organ toxicity 
(National Cancer Institute, 1999). During investigator-initiated evaluation of adverse 
events, clinicians must attribute the adverse events to the drug intervention. Patients 
may also underreport toxicities in clinical trials of new cancer therapies. Finally, given the 
frequency of musculoskeletal pain in postmenopausal women, AI-induced 
musculoskeletal toxicities may have often been overlooked.  
 
In fact, the overall toxicity burden on breast cancer patients was unrecognized 
until AIs became widely used in common oncology practice. As shown in the following 
discussion, after musculoskeletal toxicity was recognized as a major side effect, smaller 
studies have more carefully collected patient reported musculoskeletal adverse events. 
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 Common symptoms, their severity and frequency 
In common clinical practice, the frequency of AIMSS after initiating AI therapy – 
either new joint pain or worsened pre-existing joint pain – is approximately 50% (Crew et 
al., 2007; Henry et al., 2007; Moxley, 2010). Of these patients, roughly one-half report 
new joint pain, and the remaining patients report exacerbations of pre-existing joint 
discomfort. Additionally, some patients with pre-existing joint pain report the involvement 
of additional joints after initiating an AI (Moxley, 2010). Irrespective of the method used 
to evaluate AIMSS, most patients develop joint symptoms within the first 2 to 6 months 
following treatment initiation (Castel et al., 2013; Henry et al., 2007; Kanematsu et al., 
2011; Sestak et al., 2008). 
 
Although there are significant differences in clinical presentation between 
patients, most patients describe symmetrical pain, with accompanying joint or muscle 
stiffness that frequently occurs in the morning (Burstein and Winer, 2007; Donnellan et 
al., 2001; Moxley, 2010). Of the many sites of discomfort reported by patients (includes 
the hands (fingers and wrists), arms, knees, feet, pelvic and hip bones, and back), the 
hands, knees and back (lower back and/or shoulders) seem the most affected (Crew et 
al., 2007; Donnellan et al., 2001). The number of painful joints is variable between 
patients, with reports ranging from 3 to 20 (Laroche et al., 2007). While the majority of 
patients describe joint pain, muscle pain of the forearms and arms has been reported, 
which is inconsistent with a distribution involving strictly the joints (Henry et al., 2007; 
Laroche et al., 2007). Despite many studies describing the severity of joint pains, there is 
little information describing the quality of this pain. Descriptions of pain or discomfort 
during AI therapy include: “aching in joints and muscles” (Moxley, 2010), “soreness” 
(Khan et al., 2010), “joint pain, achy and stiff joints, muscle pain, morning joint stiffness, 
tingling, numbness, joint swelling” (in descending frequency) (Henry et al., 2007). 
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 Variability in pain intensity mirrors the overall variability in clinical symptoms. In a study 
by Henry et al., patients referred to a rheumatologist for AIMSS after at least 6 months of 
therapy reported a median pain intensity of 51 on a 100 point scale (Henry et al., 2007). 
However, pain intensity ranged from 0 to 79 in these patients (Henry et al., 2007). In 
contrast, patients in this trial receiving AIs that were not referred to rheumatology for joint 
symptoms had a median pain rating of 2.5 with a range of 0 to 80 (Henry et al., 2007). 
Similarly, Crew et al. reported that 33% of patients reported mild symptoms (patient 
reported pain rating of 1-4 on a 10-point scale), while 67% of patients experienced 
moderate to severe symptoms (pain ratings of 5-10 on a 10-point scale) (Crew et al., 
2007). Thus, using the thresholds of Crew et al., at least 50% of patients in the studies 
conducted by Crew et al. and Henry et al. rated their pain as moderate to severe. 
Patients experiencing AIMSS have significantly increased physical disability, as 
measured by difficulty performing everyday tasks (e.g. walking, dressing, standing up, 
grasping small objects) that may be a consequence of increased pain or stiffness (Henry 
et al., 2007; Morales et al., 2007; Moxley, 2010). 
 
Objective evaluation of joints in patients receiving aromatase inhibitors 
Patient-reported complaints of arthralgia and joint stiffness during AI therapy 
merely describes the symptoms of an underlying pathophysiology, but does not indicate 
a specific pathological changes. Based on clinical evaluation, patients with AIMSS are 
diagnosed with a range of conditions, including: tendonitis or tenosynovitis, 
osteoarthritis, and carpal tunnel syndrome, with multiple rheumatologic conditions 
diagnosed in a significant fraction of patients (Henry et al., 2007; Morales et al., 2007; 
Moxley, 2010). Thus, it has been proposed that AI-induced musculoskeletal symptoms 
may be a result of new or worsened manifestations of common rheumatological 
conditions of the joints. To describe and identify structural changes that may contribute 
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 to joint symptoms in patients receiving AIs, rheumatologic examination of the hands and 
wrists has been conducted using magnetic resonance imaging and high-resolution 
ultrasonography (Dizdar et al., 2009; Henry et al., 2010a; Lintermans et al., 2012; 
Lintermans et al., 2011; Morales et al., 2008). These are complimentary methods that 
have been used to describe changes in other rheumatic conditions with associated 
arthralgia, such as osteoarthritis and rheumatoid arthritis (Braun and Gold, 2012; 
McGonagle et al., 2001). Magnetic resonance imaging is a sensitive method to visualize 
bony and soft tissue changes. Specifically, this method can identify areas of bone 
erosion, formation of soft tissue pannus, changes in tendon and tendon sheath structure, 
tissue swelling and edema, as well as small cartilage or bone fragments in the joint. 
Ultrasonography is well suited to visualize tenosynovial and articular cartilage structures. 
Results from these imaging studies suggest several common changes in breast cancer 
patients receiving AIs, including: enhancement of the synovium, increase in intra-
articular fluid, and tenosynovial changes manifested as swelling of the tendon sheath 
(Henry et al., 2010a; Morales et al., 2008). There are conflicting reports on abnormalities 
of the tendon itself during AI therapy. Henry et al. noted that tendon abnormalities were 
rare, however a second cross-sectional study observed increased tendon thickness in 
patients receiving AIs versus controls (Dizdar et al., 2009; Henry et al., 2010a). In 
addition to these cohort studies, tendinopathies have been reported in several case 
studies (Martens et al., 2007; Papadimitriou et al., 2012). As a whole, these studies 
show that not all patients develop new or worsening musculoskeletal abnormalities and 
findings are not uniform between patients, reflecting the heterogeneity of joint and 
muscle symptoms experienced by patients. If pain during AI therapy is a result of 
structural changes in the joints then we might expect pain and functional disability to be 
limited to those body regions most impacted by the diagnosed condition (e.g. pain 
limited to the wrists and arms in patients with a diagnosis limited to carpal tunnel 
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 syndrome). However, these correlations have not been delineated in the literature. One 
interesting finding of these studies was the high frequency (25% to 48%) of intra-articular 
fluid or tenosynovial abnormalities in patients prior to the initiation of AI therapy (Henry et 
al., 2010a; Morales et al., 2008), which may reflect common underlying rheumatic 
conditions in postmenopausal breast cancer patients (Moxley, 2010). Therefore, it is 
important that future studies should appropriately control for the underlying joint structure 
abnormalities in this patient population and further evaluate patients not treated with AIs 
to evaluate drug-induced effects. 
 
Importantly, musculoskeletal changes identified in patients receiving AIs do not 
resemble those that are characteristic of other rheumatologic conditions that are 
associated with significant arthralgia, such as rheumatoid arthritis and osteoarthritis. 
Rheumatoid arthritis (RA) involving the hands and wrists is often associated with soft 
tissue swelling and loss of bone mineralization centered about the joints (Aletaha et al., 
2010; Majithia and Geraci, 2007). RA involving the knees often results in progressive 
cartilage degeneration, leading to areas of joint narrowing, in addition to joint effusions, 
synovial thickening and inflammation (Aletaha et al., 2010). A prominent characteristic of 
RA that is also not observed in AIMSS is overtly swollen and warm or hot joints. The 
non-inflammatory clinical presentation of AIMSS further distinguishes it from a number of 
inflammatory arthropathies, which are readily detected by physical examination and 
imaging of the involved joints. Similar to rheumatoid arthritis, osteoarthritis presents with 
joint space narrowing secondary to localized cartilage loss (Altman et al., 1990; Lanyon 
et al., 1998). Additionally, progressive osteoarthritis is associated with the formation of 
osteophytes and the presence of osteochondral or cartilage fragments in the joint due to 
fragmentation (Lanyon et al., 1998). In fact, a significant number of breast cancer 
patients are diagnosed with osteoarthritis (71% (12 of 17 of patients) in the study by 
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 Morales et al. and 82% (23 of 28 patients) in the study by Lintermans et al.) or arthritis 
(36% (36 of 100 patients) in the study by Henry et al.) before initiating AI therapy (Henry 
et al., 2007; Lintermans et al., 2012; Morales et al., 2008). Consistent with the distinction 
between AIMSS and inflammatory or autoimmune joint disorders, blood concentrations 
of biomarkers that indicate an inflammatory or autoimmune response are not elevated 
during AI exposure (Dizdar et al., 2009; Henry et al., 2007; Henry et al., 2010b). 
Furthermore, therapeutic approaches that effectively alleviate inflammatory joint 
disorders, such as nonsteroidal anti-inflammatory drugs (NSAIDS) and acetaminophen, 
are used for symptom management by a majority of patients (Henry et al., 2007; Sestak 
et al., 2008). However, these treatments have been described as largely ineffective in 
alleviating AI-induced musculoskeletal pain (Martens et al., 2007; Morales et al., 2008). 
Also, in a retrospective cohort study of 29,967 patients’ prescription claims for AIs 
(anastrozole, exemestane, or letrozole), co-prescribing pain modifying medications 
(among them: NSAIDS, anti-depressants, opioids) along with an AI did not significantly 
increase persistence on AI therapy (Hashem et al., 2013). Taken as a whole, these 
observations suggest that AI-induced arthralgias do not arise from musculoskeletal 
abnormalities associated with other common rheumatic conditions, including those that 
arise from inflammatory processes or auto-immune reactions. 
 
AI-induced musculoskeletal symptoms reduce compliance 
While AIs are effective breast cancer drugs, many recent studies have shown 
that noncompliance with AI therapy is common (Neugut et al., 2011; Partridge et al., 
2008). Of the potential factors influencing patients’ inability to continue therapy, 
intolerable drug-induced musculoskeletal pain is a major contributor (Henry et al., 2012). 
Indeed, of the one-third of patients prescribed AIs who discontinue treatment 
prematurely, 60% are attributable to intolerable musculoskeletal pain (Henry et al., 
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 2012). Thus, approaches to alleviate these side effects are expected to improve 
tolerability of this class of drugs. 
 
Clinical predictors and factors associated with aromatase inhibitor-induced 
musculoskeletal symptoms 
Demographic and other clinical factors that influence risk of musculoskeletal toxicity 
AIs induce musculoskeletal pain in women who have a high baseline risk for 
musculoskeletal pain due to natural, surgical or chemotherapy-induced menopause 
(Cecil and Archer, 1925; Loprinzi et al., 1993). The effects of menopause and prior 
chemotherapy on joint and muscle symptoms, as well as physical, cognitive and 
behavioral co-morbidities associated with cancer, can obscure our ability to identify 
which patients are experiencing musculoskeletal pain as a result of AI use, and to 
specifically identify factors associated with AI-induced musculoskeletal toxicity in the 
population of breast cancer patients. Therefore, many studies intended to identify clinical 
factors associated with AIMSS have examined the impact of factors such as prior 
therapy and baseline pain scores. Additionally, a number of other covariates have been 
studied, including basic demographic factors (e.g. age and race) and factors with both 
strong (e.g. body mass index (BMI)) and weak (e.g. age and age from menopause) 
relationships with estrogen concentrations prior to a patient initiating AI therapy. Results 
of univariate analysis of six covariates common across five studies are shown in Table 1. 
Associations in these studies suggest age and BMI are not consistent predictors of 
AIMSS. Among these variables, prior taxane-based chemotherapy is the factor most 
consistently associated with the odds of developing AIMSS. In the study by Ingle et al., 
cases and controls were selected from a large randomized phase III trial and matched 
based on treatment (exemestane, anastrozole), prior adjuvant chemotherapy (yes, no), 
age at start of AI treatment (±5 years), celecoxib use (yes, no), and time on study, which 
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 eliminated the ability to analyze prior chemotherapy as a potential AIMSS risk factor 
(Goss et al., 2013; Ingle et al., 2010b).  
 
The association between prior taxane chemotherapy and risk of AIMSS raises a 
number of interesting hypotheses. Prior to the onset of neuropathy, paclitaxel use is 
associated with acute aches and pains, which has been referred to as paclitaxel-induced 
arthralgias and myalgias (Garrison et al., 2003; Loprinzi et al., 1993). Patients with 
severe aches and pains within the first week following their first dose of paclitaxel 
developed more severe peripheral sensory neuropathy symptoms during the entire 12-
week course of therapy (Loprinzi et al., 2011). The impact of taxanes on the joints or 
peripheral nervous system may sensitize these tissues to additional toxicity induced by 
AIs. Given this hypothesis, patients experiencing severe arthralgia or neuropathy during 
taxane therapy may be at greater risk for AIMSS. Additionally, there may be a 
relationship between time from completion of chemotherapy to endocrine therapy 
initiation and the risk of AIMSS. Alternatively, chemotherapy-induced amenorrhea, which 
is greatest among patients receiving taxane therapies, may increase the risk of 
developing AIMSS (Najafi et al., 2011). However, clinical studies have not adequately 
explored the relationship between chemotherapy and AI therapy to understand the effect 
on AIMSS risk and the mechanistic implications. 
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 Table 1. Summary of studies reporting an association between clinical predictors and musculoskeletal symptoms during aromatase 
inhibitor therapy for breast cancer. 
 Crew et al. 
J Clin Oncol 
2007 1 
Mao et al. 
Cancer 
2009 2 
Ingle et al. 
J Clin Oncol 
2010 3 
Henry et al. 
J Clin Oncol 
2012 4 
Sestak et al. 
Lancet Oncol 
2008 5 
Study 
description 
Cross-sectional study 
of 200 patients with 
early-stage breast 
cancer receiving 
adjuvant ANA, EXE, or 
LET.6 
Cross-sectional study 
of 300 patients with 
early-stage breast 
cancer receiving 
adjuvant ANA, EXE, or 
LET. 
Matched case-control 
study of 878 patients 
matched by: AI (ANA or 
EXE), any prior 
chemotherapy, age, prior 
celecoxib use, time on 
study. 
Prospective evaluation of 
500 patients with early-
stage breast cancer 
receiving adjuvant ANA, 
EXE, or LET 
Retrospective analysis of 
ATAC trial.7 
Patients with early-stage 
breast cancer receiving 
adjuvant ANA (N=2698) 
or TAM (N=2735).6 
Analysis did not stratify 
by therapy. 
Primary 
outcome 
Joint pain and 
joint stiffness 
Patient-reports that AIs 
are causing joint pain 
NCI CTCAE v3.0 
Grade 3 or 4 MS-AE 
(yes/no) 8 
Time to discontinuation 
of AI therapy due to 
patient-reported MSK 
symptoms 6 
Any patient reported 
arthralgia, arthrosis, 
arthritis, or 
joint disorder 
Endocrine 
therapy X
 10 X X X 
OR=1.25 9 
(ANA=35.2%, 
TAM=30.3%) 
Body mass 
index (kg/m2) 
Joint pain:    
   <25: 57% 
        25-30: 34% 
  >30: 54% 
Joint stiffness: not sig. 
X X X 
   <25: OR=1      (31%) 
25-30: OR=1.01 (31%) 
  >30:  OR=1.32 (37%) 
Age (years) X 
   <55: OR=1      (65%) 
55-65: OR=0.56 (47%) 
   >65: OR=0.31 (33%) 
─ HR=0.7 (<55 versus >55) X 
Prior 
chemotherapy X X ─ X 
OR=1.34 
(Yes=38%, No=31%) 
Prior  
taxane-based 
chemotherapy 
Pain: OR=2.14 
(Yes=62%, No=43%) 
Stiffness: OR=2.73 
(Yes=62%, No=37%) 
OR=1.94 
(Yes=50%, No=34%) ─ 
HR=1.9-2 
(Yes versus No) ─ 
Prior hormone 
replacement 
therapy 
─ X  X OR=1.72 (Yes=41%, No=28%) 
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 1. (Crew et al., 2007) 
2. (Mao et al., 2009) 
3. (Ingle et al., 2010b) 
4. (Henry et al., 2012) 
5. (Sestak et al., 2008) 
6. ANA – anastrozole, EXE – exemestane, LET – letrozole, TAM – tamoxifen, MSK – musculoskeletal 
 
7. ATAC - Arimidex, Tamoxifen Alone or in Combination (ATAC) study 
8. NCI CTCAE v3.0 Grade 3 or 4 MS-AE (yes/no) 
 
9. OR – odds ratio 
 
10. “X” – Association with primary endpoint was not significant at a type I error rate of 5%. 
 
11. “─”– Association with primary endpoint was not analyzed in the study. 
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 Germline genetic variation 
Studies determining whether germline genetic variation is associated with AIMSS 
have utilized both genome-wide and candidate gene approaches. Ingle et al. conducted 
a genome-wide association study of postmenopausal breast cancer patients with 
ER+/PR+ cancer (stages I to III) receiving anastrozole or exemestane (Ingle et al., 
2010b). Cases were required to either have at least grade 3 musculoskeletal toxicity, 
according to the NCI-CTCAE v3.0, or go off treatment due to a musculoskeletal adverse 
event within the first 2 years. This study identified genetic variants in 3′ region of TCLA1 
as having the strongest association with musculoskeletal toxicity. Several additional 
studies have also utilized case-control designs, however, genetic variation evaluated in 
these studies was focused on genes in three main pathways: sex steroid synthesis 
[aromatase (CYP19A1), steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)], estrogen 
signaling [estrogen receptor 1 (ESR1), estrogen receptor 2 (ESR2), and progesterone 
receptor (PGR)], and vitamin D metabolism and signaling [7-dehydrocholesterol 
reductase (DHCR7), vitamin D-binding protein (GC), vitamin D 25-hydroxylase 
(CYP2R1), 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1), vitamin D3 receptor 
(VDR), and 1,25-dihydroxyvitamin D 24-hydroxylase (CYP24A1)] (Garcia-Giralt et al., 
2013; Mao et al., 2011; Wang et al., 2013). An additional study in patients treated with 
letrozole or exemestane determined whether genetic variation in candidate genes 
related to estrogen metabolism, estrogen signaling, and AI metabolism were associated 
with time to treatment discontinuation because of AI-associated toxicity (Henry et al., 
2013). This study identified an intronic variant in ESR1 (rs9322336) that was associated 
with an increased risk of discontinuation of exemestane therapy. The ESR1 variant was 
not associated with discontinuation in patients receiving letrozole therapy, suggesting a 
drug-specific effect. Collectively, these studies support association between genetic 
variants in TCLA1, ESR1, CYP19A1, CYP27B1, CYP17A1 and VDR with AIMSS. Taken 
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 together, it is difficult to draw strong conclusions about the influence of genetic variation 
on AI-induced musculoskeletal toxicity due to differences in the genes and genetic 
variants studied between these trials. Only genetic variants in TCLA1, ESR1 and 
CYP19A1 have been genotyped in more than one study, of which only variation in ESR1 
has shown significant associations in more than one study. As will be discussed, 
interpretation of results across these studies is also limited by the lack of a standardized 
definition of AI-induced musculoskeletal toxicity. 
 
Inflammation 
The influence of estrogens on the innate and adaptive immune systems has 
been well documented. Inflammatory cytokines are suppressed by high blood estrogen 
concentrations, while lower estrogen concentrations can augment inflammatory cytokine 
production (Islander et al., 2011). Additionally, estrogens modulate the adaptive immune 
system by inhibiting lymphopoesis and increasing the contribution of T helper type 2 
relative to T helper type 1-mediated immune processes (Straub, 2007). The question of 
whether changes in plasma concentrations of inflammatory cytokines are associated 
with AIMSS has been evaluated by Henry et al. (Henry et al., 2010b). This study found 
that before initiation of AI therapy, subjects who would subsequently develop AIMSS had 
higher baseline serum concentrations of six cytokines and growth factors relative to 
those subjects that would not develop AIMSS (fibroblast growth factor-basic, interleukin-
12 p40, interleukin-1 receptor alpha, macrophage inflammatory protein-1, interleukin-1 
beta, and interleukin-17). However, no changes in serum concentrations of 36 factors 
assayed relative to pre-treatment were observed between cases and controls during AI 
therapy, suggesting AIMSS is not a consequence of systemic inflammatory response to 
AIs. Additionally, rheumatologic evaluation of subjects with AIMSS does not support 
inflammation of affected joints and studies to identify blood biomarkers have shown no 
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 association with biochemical markers of inflammation (e.g. C-reactive protein), muscle 
injury (e.g. creatinine kinase), or autoimmunity (e.g. rheumatoid factor and anti-nuclear 
antibody) (Briot et al., 2010; Henry et al., 2007; Henry et al., 2010b). 
 
Reduced bone mineral density 
AIs accelerate the loss of bone mineral density of the lumbar spine and hip in 
post-menopausal breast cancer patients, presumably due to reduced estrogen 
concentrations. While it has been suggested that AIMSS may be secondary to loss of 
bone mineral density, to date, no prospective study has directly addressed whether the 
onset or severity of AIMSS correlates with changes in bone mineral density or 
biochemical markers of bone turnover (Henry et al., 2008). In several randomized trials, 
bisphosphonates have effectively prevented or reduced bone loss in women receiving 
AIs (Brufsky et al., 2007; Gnant et al., 2009; Van Poznak et al., 2010). Therefore, if bone 
loss leads to AIMSS, bisphosphonates may be effective agents to inhibit or reverse 
musculoskeletal pain. However, Brufsky et al. showed no difference in the frequency of 
arthralgia, myalgia, pain in extremities, or back pain, between patients who received 
zolendronic acid upfront and those who received a delayed treatment (Brufsky et al., 
2007). The mean time to initiation of zoledronic acid in the delayed group was 8.8 
months (range, 0.03 to 24.15 months), and given that many patients develop symptoms 
within six months of initiating an AI, a majority of patients would have developed 
musculoskeletal pain before initiating the bisphosphonate. Furthermore, the rate of 
arthralgia in the upfront group was similar to that reported in other studies in which 
patients only received an AI. These data are consistent with an additional study that 
showed that discontinuation of anastrozole therapy due to arthralgia or arthritis 
symptoms was not different in postmenopausal patients randomized to receive a 
bisphosphonate (risedronate) versus placebo (Van Poznak et al., 2010). In another 
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 study, arthralgia adverse events were more frequent in premenopausal breast cancer 
patients receiving zolendronic acid in addition to anastrozole and goserelin (for ovarian 
suppression) (150 of 450; 33.3%) than those not receiving zolendronic acid (112 of 453; 
24.7%) (Gnant et al., 2009). Collectively, these results do not support the hypothesis that 
enhanced bone loss represents an important causal factor mediating pain during AI 
therapy. 
 
Estrogen depletion 
As has been hypothesized, AI-associated pain may be initiated by estrogen 
depletion, as measured by reduction in concentrations of plasma or tissue estrogens 
(Felson and Cummings, 2005; Henry et al., 2008). Indeed, numerous clinical 
observations support the association between reduced blood estrogens and 
musculoskeletal pain: development and intensification of osteoarticular pain is strongly 
associated with transition into menopause (Berecki-Gisolf et al., 2009; Cecil and Archer, 
1925; Dugan et al., 2006; Meriggiola et al., 2012), joint symptoms worsen following 
discontinuation of hormone therapy (Brunner et al., 2010; Ockene et al., 2005), 
arthralgia is common during gonadotropin-releasing hormone antagonist treatment 
(Friedman et al., 1993; Spitz et al., 2012), and myalgias and arthralgias develop 
following cyclophosphamide-induced ovarian suppression (Loprinzi et al., 1993). 
Conversely, menopause-associated joint pain and stiffness is relieved by estrogen plus 
progestin therapy (Chlebowski et al., 2013). 
 
A pair of studies have addressed whether AIMSS is associated with estrogen 
concentrations during AI therapy. One study reported that serum estradiol 
concentrations less than 5 pg/mL are associated with a higher incidence of AIMSS 
(Honda et al., 2011), whereas the second study found no association between serum 
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 concentrations of estradiol or estrone when concentrations were stratified by the 
analytical lower limit of their detection (1.5 and 1.7 pg/mL respectively) (Mao et al., 
2011). Although these studies support seemingly opposite conclusions, several 
limitations reduce our ability to make strong conclusions based on these findings. First, 
neither study was sufficiently powered to test this association. Secondly, it is unclear 
whether the analytical methods utilized to measure serum estrogens were sufficiently 
sensitive and specific for measuring serum estradiol during AI therapy. Lastly, the 
estrogen concentration thresholds used have no physiologic basis and no attempt was 
made in either study to explore a concentration-dependent effect of serum estrogens. 
Therefore, further clinical studies are needed to fully address this hypothesis. 
 
A retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination 
(ATAC) study revealed a correlation between symptoms related to endocrine therapy 
and risk of breast cancer recurrence (Cuzick et al., 2008). Specifically, women 
experiencing joint pains within the first three months of therapy had significantly reduced 
risk of recurrent disease. This study was adequately powered to address this question, 
using 1967 and 1997 women randomized to anastrozole and tamoxifen who were 
monitored over 9 years. These data support a unifying hypothesis, suggesting the AI-
induced estrogen suppression is associated with both aromatase inhibitor efficacy and 
toxicity. Correlation of drug-induced side-effects with response to treatment has been 
noted in a few other situations, notably neurotoxicity with increasing exposure to agents 
such as vincristine or platinum agents, graft-versus-host disease for allogeneic bone-
marrow transplantation, and skin rash for antibodies directed at the EGFR or tyrosine-
kinase inhibitors. The inferred relationship between AI potency, as measured by 
estrogen depletion, and outcomes has not been directly tested and the underlying 
mechanism remains speculative. 
29 
 
 Summary 
Many clinical studies have been conducted to identify clinical factors and other 
biomarkers associated with the incidence or severity of AI-induced musculoskeletal 
symptoms. Factors showing strong association with these side effects could be used in a 
number of ways, including providing insight into potential mechanisms, guiding 
interventional strategies, identifying patients at high risk for toxicity, and therapy 
selection. However, to date, there are no consistent risk factors to predict which patients 
will develop AI-associated musculoskeletal symptoms. While comparisons among 
studies are limited by variable trial design and covariates analyzed, a significant 
limitation is the lack of diagnostic criteria and no accepted definition of what constitutes 
AI-induced musculoskeletal toxicity. As a result of ambiguity in defining the syndrome, 
studies have evaluated patients using a variety of quality of life questionnaires and 
patient self-reporting. Several studies have used rheumatologic questionnaires that are 
validated for the longitudinal assessment of arthritis, such as the Health Assessment 
Questionnaire-Disability Index (Henry et al., 2007). However, it has been suggested that 
AI-induced musculoskeletal pain is not associated with inflammation resembling that 
found in rheumatoid arthritis, calling into questions the use of instruments designed to 
measure inflammatory disease (Henry et al., 2007). Additionally, the toxicity may 
represent a cluster of symptoms, potentially each having a unique mechanistic basis. 
Thus, better measures of AI-induced musculoskeletal toxicity that are based on a 
mechanistic understanding of the toxic effects of these drugs are needed. 
 
Many of the the clinical association studies presented here are based on rational 
assumptions as to the mechanisms (e.g. bone turnover), cells (e.g. immune cells), or 
organs (e.g. bone) contributing to AI-induced pain. In addition, it has been proposed that 
changes in pain transmission, specifically reduced inhibitory mechanisms in the CNS, 
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 are altered during AI therapy (Felson and Cummings, 2005). Undoubtably, the nervous 
system plays a critical role in the perception, transmission, and processing of noxious 
events in patients with musculoskeleltal pain during AI therapy. As discussed below, 
altering systemic and tissue estrogen concentrations is known to significantly alter 
animal models of pain, forming the basis of the hypothesis that estrogen-mediated CNS 
or PNS changes during AI therapy may result in AI-induced pain (Felson and Cummings, 
2005). Additionally, the expression of aromatase in the peripheral nervous system 
suggests that one effect of AIs may be to alter nociception by directly acting on the 
peripheral nervous system. On the other hand, AIs may also alter nociception through 
mechanisms unrelated to their ability to reduce aromatase activity and both potential 
mechanisms may contribute to pain during AI therapy. 
 
Estrogen deficiency and animal models of pain 
 
Humans with pain may experience dysesthesia, hyperalgesia, or allodynia as a 
result of altered sensory recognition of a stimulus. In chronic pain states, many human 
subjects also experience dysesthesia in the absence of an apparent external stimulus. In 
psychophysical terms, the state of pain is associated with a leftward shift that occurs in 
the relationship between stimulus intensity (no stimulus in the case of spontaneous pain) 
and the affected sensations and pain perception. It is likely that animals experience pain-
like sensations that may mirror those experienced by humans, however, our inability to 
communicate with animals restricts our understanding of their perception of a stimulus 
and relating this experience to what humans might consider painful. Thus, the inability to 
communicate between animals and humans is the greatest obstacle in generating 
meaningful animal models of pain. In absence of a clear translation between animal and 
human recognition of pain, a series of behavior models have been developed that 
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 equate a stimulus or substances known to elicit pain in man and the behavior after 
introducing the stimulus or substance into animals. While these models are limited in 
their interpretation, the study of animal behavior in reaction to a stimulus that would be 
algogenic in humans provides the only indicator of what may be disagreeable to the 
animal. This cannot be reliably determined using any other types of methods or 
measures (e.g. electrophysiological parameters). 
 
The ovariectomized (OVX) rat 
The in vivo effects of reduced estrogen concentrations in animal models of pain 
are often studied by determining behavioral changes in OVX animals. Two weeks after 
female rats are ovariectomized, serum estrogen concentrations are significantly depleted 
(Pfaff, 2002). Mean serum concentrations of estradiol in OVX rats have been estimated 
to be between 1.83 and 3.9 pg/mL when measured by radioimmunoassay without 
organic extraction (Kuba et al., 2006; Strom et al., 2008b). These concentrations are 
near those measured in male rats using radioimmunoassay without organic extraction (3 
± 1 pg/mL) (Toung et al., 1998). Organic extraction prior to analytical measurement of 
steroids is the gold-standard approach for measuring low steroid concentrations and 
results in much lower estimated concentrations, presumably due to the elimination of 
conjugated steroids (Strom et al., 2008a). In a study measuring serum estradiol from 
male rats that incorporated a diethylether extraction step prior to assaying estradiol by 
radioimmunoassay, estradiol concentrations were 1.06 ± 0.23 pg/mL (Erben et al., 
2000). Furthermore, plasma estradiol concentrations in post-menopausal women and 
women receiving AI therapy are consistently lower when measured by gas 
chromatography/tandem mass spectrometry assay than those determined by RIA, 
presumably due to increased selectivity following chromatography of the steroids 
(Santen et al., 2007). Thus, serum estradiol concentrations in OVX and male rats are 
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 likely much lower than concentrations reported in many studies using 
radioimmunoassays. 
 
In the course of several weeks following surgery, ovariectomized female rats and 
mice develop enhanced sensitivity to mechanical stimulation of the hind paws (Chen et 
al., 2012; Dina et al., 2001; Ma et al., 2011; Sanoja and Cervero, 2005). These effects 
are attributed to reduced estrogens following ovariectomy, as estrogen replacement was 
shown to prevent (Ma et al., 2011; Sanoja and Cervero, 2005) or reverse (Sanoja and 
Cervero, 2008) OVX-induced mechanical allodynia. As will be discussed, the 
development of mechanical allodynia in OVX rats has been proposed to be mediated by 
enhanced sensitivity to endogenous inflammatory mediators in nociceptive sensory 
neurons (Chen et al., 2012; Ma et al., 2011). In contrast, the effect of estrogen loss 
modeled by ovariectomy on thermal hypernociception is variable. Some studies have 
shown that OVX animals respond more rapidly to a noxious thermal stimulus than intact 
or sham operated animals (Sanoja and Cervero, 2008), others have shown the opposite 
effect of OVX on thermal hypernociception (Terner et al., 2005), and yet additional 
studies have demonstrated no effect of ovariectomy or estrogen add-back (Mannino et 
al., 2007; Sanoja and Cervero, 2005). 
 
The influence of OVX and hormone replacement on hypernociception in 
response to inflammation has been thoroughly reviewed (Craft, 2007; Fillingim and 
Ness, 2000). The effect of altering systemic estrogens in inflammatory pain models are 
complex, and OVX can produce hypernociception or anti-nociception depending on the 
inflammatory model, the site of inflammation, and the nociceptive behavior measured. 
One inflammatory mediator whose effects on nociceptive behaviors are altered by 
estrogens or estrogen depletion is ATP. For example, when compared to sham-operated 
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 controls, overt nociceptive response to intraplantar administration of ATP into the rat 
hindpaw is augmented in OVX rats (Ma et al., 2011). Augmentation of nociceptive 
behavior produced by ATP was inhibited by coadministration of an antagonist of P2X1 / 
P2X3-ATP receptors (2′,3′-O-(2,4,6-trinitrophenyl) adenosine-5′-triphosphate, TNP-ATP), 
suggesting a change in the activity of these channels. These behavioral changes 
correlated with increased expression of P2X3 in dorsal root ganglia (DRG) in OVX 
animals. Conversely, administration of 17β-estradiol (daily subcutaneous injection of 30 
μg/kg/day) to OVX rats for five weeks attenuated the enhanced nociceptive response to 
ATP and reduced P2X3 expression in DRGs (Ma et al., 2011). Interestingly, TNP-ATP 
administration additionally reversed mechanical sensitivity to von Frey filaments that 
developed follow ovariectomy, implicating P2X receptor activity in the maintenance of 
mechanical hypersensitivity following OVX (Ma et al., 2011). Estradiol similarly 
attenuated overt nociception induced by the P2X1 / P2X3 –selective agonist, α,β-meATP, 
in female and OVX female rats when the compounds were co-administered in the paw 
(Lu et al., 2013). This effect was mimicked by co-administration of selective agonists for 
the estrogen receptors ERα and G protein-coupled estrogen receptor 1 / G protein-
coupled receptor 30 (GPER / GPR30), suggesting that the activation of estrogen 
receptors modulates ATP-evoked behavior when sufficient local concentrations of the 
steroid are achieved (Lu et al., 2013). 
 
The diverse, and often contradicting, effects of ovariectomy on nociceptive 
behavior may be explained by the pleiotropic roles of estrogens in the initiation, 
processing, and response to nociceptive stimuli (Craft, 2007). On the other hand, there 
may be other contributing factors. Ovariectomy induces hyperphagia that, in turn, results 
in substantial weight gain and adiposity (Gale and Sclafani, 1977). Adipose tissue can 
act as an endocrine organ and secretes a number of inflammatory factors (Lyon et al., 
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 2003). Accelerated bone and cartilage turnover and erosion following OVX in rodents 
has been used to study mechanisms underlying postmenopausal osteopenia and 
osteoarthritis (Hoegh-Andersen et al., 2004; Weitzmann and Pacifici, 2006). 
Upregulation of inflammatory mediators in the joints and in the circulation are expected 
to alter nociceptive responses to specific stimuli and may augment or oppose the 
specific actions of reduced estrogen concentrations (Abu-Taha et al., 2009). Thus, 
interpreting OVX-mediated behavioral changes as a consequence of estrogen depletion 
in the nervous system is perilous given the additional adaptive and physiological 
changes that occur in this model. 
 
Although the major source of endogenous estrogen in females is the ovaries, it is 
well established that males and females synthesize estrogens in other tissues including 
the adipose, spinal cord, DRGs, and select brain regions. For instance, estradiol content 
in the rat brain varies widely between brain regions, and while region-specific content 
does not show a clear correlation with blood estradiol concentrations, regions with 
relatively high levels of aromatase activity correspond to high estradiol content (Konkle 
and McCarthy, 2011a). Therefore, the amount of estrogen in aromatase-expressing 
tissues may be asynchronous with blood estrogen concentrations. For example, 
aromatase activity in adipose tissue is unchanged following ovariectomy in rats (Zhao et 
al., 2004). However, OVX rats gain considerable amounts of adipose tissue, suggesting 
non-gonadal aromatase activity contributes little to blood estrogen concentrations in rats 
(Gale and Sclafani, 1977). In aromatase-expressing tissues, mechanisms may exist to 
rapidly modulate the bioavailability of estrogen in a space-, concentration-, and time-
dependent manner, details that could not be well controlled with estrogens derived from 
the circulation. Based on these observations, the use of OVX animals to model the effect 
of tissue estrogen depletion on pain may be most appropriate for tissues with estrogens 
35 
 
 supplied primarily by the blood. Tissues expressing aromatase, with the ability to 
synthesize local estrogens on demand may be less influenced by ovariectomy. Despite 
this, estrogen exposure is expected to be reduced in most tissues in OVX animals and 
changes in nociceptive behaviors in OVX rats may be helpful in guiding studies of AI 
effects on nociception, particularly those influenced by aromatase inhibition. 
 
Aromatase inhibitor treatment 
Despite the clinical significance of AI-induced arthralgia, few studies have 
attempted to determine the effects of AIs in animal models of nociception. Naïve and 
ovariectomized female rats treated systemically with letrozole exhibited augmented 
hypernociceptive behaviors following intraplantar administration of formalin (Moradi-
Azani et al., 2011). More specifically, letrozole augmented the second phase of formalin-
induced behavior, which is mediated by an inflammatory response at the site of formalin 
administration and altered integration of peripheral afferent activity by second order 
neurons in the spinal cord dorsal horn (Tjolsen et al., 1992). The effect of letrozole to 
augment nociceptive behavior is consistent with previous reports suggesting that OVX 
rats have augmented formalin-induced nociception, which is attenuated by systemic 
estrogen replacement (Ceccarelli et al., 2003; Fischer et al., 2008; Kuba et al., 2006; 
Mannino et al., 2007). The ability of AIs to alter inflammatory nociceptive behavior in 
OVX rats suggests that estrogen synthesis in non-ovarian tissues may play an additional 
role in mediating the integrated nociceptive response to formalin. Aromatase knockout 
mice also display increased grooming during interphase and phase II following formalin 
injections in the lip, suggesting an ability of AIs to augment the response to formalin is 
mediated by altered aromatase activity (Multon et al., 2005). In comparison, studies in 
the male Japanese quail showed systemic and intrathecal administration of the AI, 
vorozole, either increased or had no effect on withdrawal latency following immersion of 
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 the birds’ feet in hot water, depending on the birds’ hormonal status (Evrard and 
Balthazart, 2004a, b). Collectively, these studies suggest that AIs alter behavior 
responses to nociceptive stimuli, although there may be differences depending on the 
stimulus, route of administration and the model organism. However, the effects of AIs in 
these models have not been sufficiently studied to draw strong conclusions as to their 
potential effects and mechanisms.  
 
It is clear from studies using OVX rats and estrogen replacement that nociceptive 
behaviors to a variety of stimuli are modulated by altering systemic and local 
concentrations of estrogens. Studies using isolated sensory neurons have also shown 
that estrogen can alter several features that contribute to their function, suggesting that 
their effects in vivo may be attributed, in part, to their actions at the level of the 
nociceptor. For instance, a microarray analysis of trigeminal ganglia from OVX rats 
identified 21 genes whose expression was significantly altered by systemic estradiol 
treatment (Diogenes et al., 2006). As will be discussed below, in sensory neuron 
cultures, estradiol exposure has been shown to alter the expression of 
neurotransmitters, as well as, as the expression and activity of several ion channels. 
These molecular changes could be expressed as altered neuronal function in vivo. Since 
AIs induce musculoskeletal pain in humans, and preliminary studies in animals suggest 
AIs also alter nociceptive behaviors, these drugs may directly or indirectly alter the 
response of the peripheral nervous system to a variety of stimuli. As will be discussed, 
the recent observation of aromatase expression in DRG neurons suggests that local 
estrogen synthesis may regulate the function of estrogen-sensitive sensory neurons. 
Moreover, one mechanism by which AIs may alter sensory neuron function may be 
secondary to aromatase inhibition in these cells. 
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 Sensory neurons 
 
General anatomy and physiology 
Sensory neurons are neurons that detect stimuli external to the organism and 
encode the stimulus in the form of action potentials. Sensory neurons are therefore 
distinct from neurons of the central nervous system (CNS), which receive stimuli from 
other neurons and from glia. The cell bodies, or soma, of primary sensory neurons are 
clustered in DRGs, ganglia that lie laterally along the spinal column. Primary sensory 
neurons are morphologically pseudo-unipolar, in that the axon is bifurcated; one branch 
projects to form synapses on second-order sensory neurons of the spinal cord and the 
other branch innervates peripheral tissue. When sensory fibers resident in peripheral 
tissues are subjected to a sufficient external stimulus, they transmit the stimulus in the 
form of action potentials toward the CNS. Due to a vast heterogeneity in stimuli that are 
encoded by these specialized cells, they collectively relay a continuum of information to 
the CNS, contributing to proprioception (awareness of body position), kinesthesia 
(awareness of body movement), discriminative touch, vibration, itch, temperature 
gradations (cool to cold and warm to hot), and mechanical gradations. The summation of 
these sensory transmissions to the CNS allows the brain to “perceive” the organism’s 
environment.  
 
A body of work has related the excitation of a subset of ‘noci-receptive’ sensory 
fibers, termed ‘nociceptors’, and the perception of pain, which are of principally important 
to this body of work (Sherrington, 1906). Nociceptors are specialized primary afferent 
sensory neurons that are functionally defined by their distinct stimulation thresholds. 
Under physiological conditions, nociceptors generate action potentials in response to 
stimulus intensities just below that which would generate tissue damage. Conversely, 
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 under resting conditions, nociceptors respond weakly or not at all to innocuous stimuli. 
When nociceptors are subjected to an injury within their receptive field, they may be 
physically damaged or exposed to inflammatory mediators released at the site of injury. 
Under these conditions, they often develop a lowered threshold for generating action 
potentials and display an enhanced response to suprathreshold stimuli. Therefore, the 
implied physiologic function of nociceptors is two-fold: to notify the CNS when stimuli 
approach intensities that may result in damage to the organism and to discern and adapt 
to an ongoing injury. In parallel with these changes in sensory neuron function, the 
individual may perceive pain at the site of injury (primary hyperalgesia) or pain in the 
surrounding skin or tissue (secondary hyperalgesia). 
 
Nociceptors can detect and react to several stimulus modalities, including: 
temperature (thermoreceptors), mechanical force (mechanoreceptors), and many 
endogenous and exogenous chemicals (chemoreceptors). As described by Bessou and 
Perl using cats as a model, unmyelinated cutaneous sensory neurons elicit action 
potentials in response to one or more of these stimuli delivered over a range of 
intensities, yielding a response pattern that can be grouped into several categories 
(Bessou and Perl, 1969; Perl, 1996b). Among C-fibers, the most common nociceptors 
are ‘polymodal’ (30 per cent of neurons); these cells are excited by strong mechanical 
stimulation (needle pricks and von Frey hairs), by noxious heat, and by irritant chemicals 
(a drop of 0.1N hydrochloric acid applied to the skin). Another fourteen percent of the C-
fibers are activated by strong mechanical stimulation, but are unresponsive to noxious 
heat (60°C) and cooling the skin to abnormal temperature (10°C), and thus could be 
considered as selective mechanoreceptors. The remaining neurons surveyed could be 
described by neuronal discharge in response to gentle mechanical stimuli (von Frey 
hairs of 0.01 to 0.045 grams) and cooling, small innocuous temperature changes, or no 
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 response to skin stimulation. Thus, approximately 44% of the slowly conducting C-fibers 
innervating the skin are excited by noxious stimuli and are therefore, by definition, 
nociceptors. A similar survey of lightly myelinated sensory neurons innervating the cat 
hind limb (classified as Aδ-fibers by conduction velocities from 6 to 51 meters per 
second), suggested this class of sensory neurons is unresponsive to noxious heat (> 
50°C) and cooling to 20°C or acid applied to the skin (Burgess and Perl, 1967). Rather, 
they found that 14% of Aδ-fibers responded to one or more forms of noxious mechanical 
stimulation, while the remaining neurons were excited by innocuous mechanical forces 
or completely insensitive to all stimulus modalities (Burgess and Perl, 1967). Cutaneous 
nociceptors in other species, including the rat and mouse, have been identified with 
similar properties, although the relative proportion of receptor types within C- and Aδ-
fibers are dependent on the species and innervated tissue (Koltzenburg et al., 1997; 
Leem et al., 1993). These classifications are not comprehensive and several excellent 
articles describe the functional classification of nociceptive fibers, including further 
subdivision based on additional stimuli, under physiological, pathological, and 
inflammatory conditions (Dubin and Patapoutian, 2010; Kumazawa et al., 1996). 
Importantly, a feature of many polymodal C-fibers and myelinated mechanoreceptors is 
enhancement of responsiveness after exposure to an initial noxious stimulus or 
inflammatory mediators (Bessou and Perl, 1969; Perl, 1996a). This adaptable property, 
termed ‘sensitization’, is manifest by an increase of discharge for a given stimulus and a 
lowering of the threshold to evoke neuronal discharge. 
 
Molecular classification 
Estrogen receptors 
The physiological effects of estrogens are mediated by a family of intracellular 
ligand binding proteins called the estrogen receptors (ERs) that orchestrate both 
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 transcriptional and ′non-genomic′ functions secondary to ligand binding. Due to their 
lipophilicity, unconjugated estrogens (e.g. predicted logP of estradiol is 3.75) diffuse 
freely through lipid bilayers to bind ERs. When estrogens bind the classical ERs (ERα 
and/or ERβ), these receptor complex(es) translocate to the cell nucleus and bind DNA at 
estrogen response elements to either induce or repress gene expression (Lin et al., 
2007). The binding and activity of ER-interacting proteins confer distinct ER functionality, 
and therefore, the pleiotropic and tissue-specific actions of estrogens result from the 
differential expression and interaction between the ERs and their coactivators and 
corepressors (Moggs and Orphanides, 2001). In L6 and S1 DRG of adult female rats, 
roughly 40% of small and medium diameter neurons are immunoreactive for ERα or 
ERβ, and only 5% of neurons display immunoreactivity to both ERs (Papka and Storey-
Workley, 2002). However, the expression level or distribution of ERs in DRG neurons 
may be dependent on the ganglion level (Taleghany et al., 1999).  
 
In addition to the classic ERs, the seven-transmembrane spanning G-protein-
coupled estrogen receptor GPR30 is also expressed in DRG neurons (Takanami et al., 
2010). GPR30 is a Gαs-coupled receptor that was identified based on the ability of 
estrogens to activate adenylyl cyclase in cells that lack ERα and ERβ (Filardo and 
Thomas, 2005). Although estradiol is an agonist at GRP30, the receptor has 
pharmacology distinct from ERα and ERβ and can be activated by partial and pure 
antagonists of ERα and ERβ (Aronica et al., 1994). GPR30 is expressed in small (< 30 
µm), medium (≥ 30, ≤ 40 µm), and large (> 40 µm) diameter neurons in the lumbar DRG, 
with roughly 40% of small diameter neurons and 20% of larger diameter neurons 
displaying immunoreactivity (Takanami et al., 2010).  
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 Transient receptor potential cation channel subfamily V member 1 (TRPV1) 
Cell surface receptors expressed in peripheral nerve terminals conduct stimuli 
impinging upon the receptive field(s) of sensory neurons. For a given stimulus, activation 
of one or more of a diversity of protein families, including ion channels, G-protein 
coupled receptors, and tyrosine kinase receptors initiate nociceptor excitation (Lumpkin 
and Caterina, 2007). Among these many receptors, the temperature-activated, transient 
receptor potential (TRP) family of cation channels mediate thermosensation. While 
sensory neurons are activated by a wide range of temperatures, individual TRP 
channels conduct cations in response to a limited range of temperatures. For instance, 
TRPM8 is activated by cooling from normal skin temperatures (approximately 30°C) to 
temperatures below 30°C (Peier et al., 2002). Conversely, temperatures of 43°C and 
52°C activate TRPV1 and TRPV2, respectively (Caterina et al., 1999; Tominaga et al., 
1998). Like many TRP channels, TRPV1 is polymodally activated: additional stimuli 
include non-selective physiologic molecules (such as low pH or protons and 
eicosanoids) and selective xenobiotic agonists (such as capsaicin and resiniferatoxin). 
Experiments with mice lacking several transmembrane regions of TRPV1 (TRPV1 KO) 
support the role of this ion channel in encoding noxious heat and as a vanilloid receptor. 
When compared to wild-type mice, TRPV1 KO mice exhibit marked thermal hypoalgesia 
when placed on a hot plate at temperatures ≥ 52.5°C and have reduced flinching and 
licking responses to intradermally administered TRPV1 agonists (Caterina et al., 2000). 
In sensory neurons of the rat DRG, TRPV1 is predominantly expressed in small 
diameter sensory neurons (< 35 µm) that also express neuropeptides: approximately 
35% of TRPV1-expressing neurons also express substance P and 50% co-express 
calcitonin gene-related peptide (CGRP) (Price and Flores, 2007). 
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 The activity of TRPV1 and nociceptive behaviors generated by TRPV1 agonists 
is both enhanced and diminished by estrogens through several mechanisms. For 
example, exposing DRG neurons to estradiol for 24 hours inhibits capsaicin-stimulated 
TRPV1 currents (Xu et al., 2008). In neuronal cultures from trigeminal ganglia, estradiol 
upregulates the prolactin receptor, which confers the ability of prolactin to sensitize 
capsaicin-stimulated TRPV1 currents (Diogenes et al., 2006). In vivo, intraplantar co-
injection of estradiol with capsaicin potentiates capsaicin-induced nocifensive response 
in male rats (Lu et al., 2009). Using an alternative behavioral model to study activation of 
TRPV1-expressing nociceptors, ten days of systemic estradiol administration (20 μg/d) 
did not alter nocifensive behavior elicited by capsaicin applied to the eyes. However, 
estradiol treatment did augment the effect of prolactin to augment this behavior 
(Diogenes et al., 2006). These studies suggest that the response of sensory neurons to 
TRPV1 activation may be sensitive to changes in estrogen concentrations during AI 
treatment. 
 
Calcitonin gene-related peptide (CGRP) 
CGRPα is a 37 amino acid peptide that is produced by alternative splicing of the 
calcitonin messenger RNA, transcribed from Calca (Amara et al., 1982; Rosenfeld et al., 
1992). Another gene (Calcb) encodes another CGRP isoform, CGRPβ, which differs 
from CGRPα by one amino acid (Amara et al., 1985). In DRG neurons, CGRPα is the 
predominant isoform due to higher expression of Calca than Calcb (Schutz et al., 2004). 
CGRP and substance P immunoreactivity in sensory neurons has been used to 
demarcate the “peptidergic” class of nociceptors, though the expression of these 
peptides is not limited to nociceptive neurons (Lawson et al., 2002). The neuropeptides 
CGRP and substance P are upregulated by estradiol. Estradiol increases mRNA and 
content of CGRP and substance P in a concentration and time-dependent manner in 
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 vitro and in vivo (Gangula et al., 2000; Mowa et al., 2003a; Mowa et al., 2003b). 
Estrogens may upregulate the expression of these neuropeptides by ER-initiated 
transcription of the target genes or upregulation of the NGF receptors, p75NGFR and 
trkA, that mediate NGF-induced expression of both neuropeptides (Sohrabji et al., 1994). 
 
CGRP is implicated in the underlying pathology of several painful joint disorders, 
including temporomandibular joint disorder and rheumatoid arthritis. In rats, CGRP-
immunoreactive DRG neurons innervate many tissues of the lower hind limbs, including 
glabrous skin, the knee joint, as well as gastrocnemius and tibialis anterior muscles 
(Fernihough et al., 2005; McCoy et al., 2013; O'Brien et al., 1989). CGRP expression is 
particularly prominent in sensory neurons innervating the rat knee, where approximately 
70% of joint afferent soma display CGRP immunoreactivity (Fernihough et al., 2005; 
O'Brien et al., 1989). Interestingly, experimentally-induced inflammation of the rat knee 
(by intra-articular injection of iodoacetate or complete Freund’s adjuvant) results in 
increased expression of CGRP and TRPV1 in DRG neurons (Fernihough et al., 2005; 
Staton et al., 2007) and enhanced capsaicin-stimulated CGRP release in spinal cord 
dorsal horn slices (Nanayama et al., 1989). However, this phenomenon is not limited to 
inflammation originating in the articular space, as subcutaneous inflammation elicits a 
similar enhancement of basal or capsaicin-stimulated release of the neuropeptide 
(Fehrenbacher et al., 2003; Garry and Hargreaves, 1992; Vasko, 1995). Microinjection of 
the CGRP receptor antagonist CGRP(8-37) close to dorsal horn neurons with joint input 
inhibits inflammation-evoked hyperexcitability, as well as responses to noxious pressure 
onto the knee (Bullock et al., 2014; Kumazawa, 1996). These data suggest CGRP 
expressing neurons play a role in the expression of pain behaviors, including mechanical 
sensitivity, secondary to inflammation that is in part due to the release of CGRP by the 
central terminals of primary afferent nociceptors. Additionally, CGRP may contribute to 
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 neurogenic inflammation in the joint by increasing blood flow, recruiting immune cells, 
and activating resident sensory neuron fibers. Given the ability of estradiol to regulate 
CGRP and its role in experimental joint pain models, CGRP expressing neurons may 
contribute to AI-induced pain. However the expression of CGRP or release of CGRP 
from sensory neurons has not been investigated in animals or cells treated with AIs. 
 
Purinergic receptors 
All living cells utilize adenosine 5′-triphosphate (ATP) for numerous cellular 
processes and intracellular concentrations are estimated between 1 and 10 mM, while 
concentrations in synaptic vesicles in neurons can achieve 100 mM (Beis and 
Newsholme, 1975; Burnstock, 2007). Early observations of pain and hyperalgesia 
induced by ATP applied to blister bases and injected intracutaneously suggested ATP 
activates or sensitizes peripheral sensory neuron fibers (Bleehen and Keele, 1977; 
Coutts et al., 1981). The potential release of large amounts of ATP into the extracellular 
space following tissue damage has prompted speculation that ATP is an important 
chemical mediator of pain during inflammation. Experimental evidence for this 
phenomenon has been shown in sensory neuron cultures, where damage to neighboring 
cells or focal application of cell lysates resulted in excitation of DRG neurons and 
generated inward currents that were inhibited by pre-treatment with purinergic receptors 
antagonists (Cook and McCleskey, 2002). Subsequent findings that dissociated sensory 
neurons are depolarized and generate action potentials in response to ATP suggest that 
the ability of ATP to act as an algogen is a result of direct actions on the neurons (Jahr 
and Jessell, 1983). 
 
Once released, ATP is subject to rapid degradation by membrane-bound and 
soluble nucleotideases, generating adenosine 5′-diphosphate, adenosine 5′-
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 monophosphate, and adenosine, all of which have receptor-mediated activities 
(Burnstock, 2007). The effects of these compounds on cells are mediated by the 
purinergic receptor superfamily that preferentially bind purine nucleosides (e.g. 
adenosine; P1 receptors) and purine nucleotides (e.g. ATP; P2 receptors). In turn, this 
superfamily of receptors can be subdivided into those that are G-protein coupled 
receptors (P1 and P2Y receptors) and those that are of the ligand-gated ion channel-
type (P2X receptors) (Burnstock, 2007; North, 2002).  
 
P2X receptors are ligand-gated, nonselective cation channels that mediate 
transmembrane transport of Ca2+, Na+ and K+ (Evans et al., 1996). In humans, rats, and 
mice, there are seven genes encoding P2X receptor subunits (P2X1 to P2X7), of which 
six are expressed in primary sensory neurons (subunits 1 through 6) (North, 2002). 
When individually expressed in various expression systems, all P2X subunits form 
functional homodimers. Additionally, functional heterodimers are also formed when two 
P2X subunits are expressed together, forming an array of P2X channels in cells 
expressing a few P2X genes. The selective expression of P2X3 homodimers and P2X2/3 
heterodimers in nociceptors has attracted much attention on the role of these channels 
in pain (Collo et al., 1996; Lewis et al., 1995; Vulchanova et al., 1997; Xiang et al., 
1998). While P2X3 expression is largely believed to be a marker for non-peptidergic 
sensory neurons, approximately 20% of P2X3-immunoreactive neurons also express 
CGRP (Bradbury et al., 1998). The presence of P2X3 and P2X1 channels can be 
pharmacologically identified using α,β-meATP, a P2X1/P2X3 - selective ATP analog that 
is resistant to enzymatic degradation (Khakh et al., 2001). ATP and α,β-meATP 
exposure generates inward cation currents and a transient burst of action potentials, 
whose duration mirrors the inactivation of the P2X channels (Molliver et al., 2002). 
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 Eight mammalian P2Y receptors have been cloned (P2Y1,2,4,6,11,12,13,14) that are 
differentially activated by endogenous purine nucleotides ligands (ATP and ADP) and 
also by pyrimidine nucleotides (UTP and UDP) (Donnelly-Roberts et al., 2008). In DRG 
neurons from adult rats, P2Y1, P2Y2, P2Y4, and P2Y6 mRNA have been detected 
(Sanada et al., 2002). ATP and UTP-mediated activation of P2Y2 receptors has been 
shown to induce a slow-onset and sustained excitation and sensitize capsaicin-
stimulated CGRP release in DRG neuron cultures (Huang et al., 2003; Molliver et al., 
2002).  
 
In addition to the ability of ATP to induce pain in humans, activation of G-protein-
coupled P2Y and ionotropic P2X nucleotide receptors contributes to inflammatory and 
neuropathic pain behaviors in rodents and may be an important mediator of enhanced 
mechanosensory transduction in these models (Chen et al., 2005; Cockayne et al., 
2000; McGaraughty et al., 2003; Souslova et al., 2000; Tsuda et al., 1999; Xu and 
Huang, 2002). For example, mice lacking the P2X3 gene have significantly decreased 
flinching behavior in response to 5% formalin (Cockayne et al., 2000; Souslova et al., 
2000). Pharmacological activation of purinergic receptors by ATP or α,β-meATP in the 
dermis rapidly induces nocifensive behavioral responses and reduces hindpaw 
withdrawal thresholds to von Frey hair stimulation, which is also induced by intrathecal 
administration of either agent (Bland-Ward and Humphrey, 1997; Nakagawa et al., 2007; 
Tsuda et al., 2000). As discussed, nociceptive behavior produced by ATP or α,β-meATP 
injections is significantly augmented in OVX rats and attenuated by systemic 
administration of estradiol and co-administration of estradiol. In cultures of dissociated 
rat DRG neurons, estradiol and the estrogen receptor agonists PPT (ERα-selective) and 
G-1 (GPR30-selective) attenuate α,β-meATP-induced currents, suggesting the 
hypernociceptive behaviors to purinergic receptor activation in OVX rats may be 
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 attributed to changes at the level of the sensory neuron (Lu et al., 2013). In addition, 
estradiol has also been shown to inhibit increases in intracellular Ca2+ following 
stimulation with ATP in DRG cultures from rats and mice (Chaban et al., 2003; Chaban 
and Micevych, 2005). Since activation of P2X and P2Y receptors increases intracellular 
Ca2+, estradiol may inhibit either pathway. Given the importance of intracellular Ca2+ to 
the release of neurotransmitters, changes in estradiol exposure in sensory neurons may 
alter neurotransmitter release following ATP exposure. 
 
Aromatase 
While it is clear that estrogens have diverse roles in modulation of pain or 
nociception, the potential contribution of local estradiol synthesis has been relatively 
unexplored. The capacity for de novo synthesis of estrogens and other steroids in the 
vertebrate nervous system is well established. In situ hybridization studies have 
localized CYP19 (aromatase) mRNA to the preoptic area, hypothalamus, amygdala, and 
hippocampus (Wagner and Morrell, 1996, 1997). In these brain regions, aromatase 
immunoreactivity is located in neuronal cell bodies, presynaptic boutons and 
postsynaptic neurons and in glia (Hojo et al., 2004; Naftolin et al., 1996; Peterson et al., 
2005; Schlinger et al., 1994). It has been shown that testosterone that diffuses into the 
preoptic area of the male neonatal rat is locally aromatized to estradiol. Exposure to 
estradiol during this developmental period confers the ability of adult sex-specific 
hormones to activate male-specific reproductive behaviors (McCarthy, 2008; Naftolin et 
al., 1975). The significant effects of aromatase in the preoptic area are believed to be 
mediated by estradiol-induced changes in the expression of numerous genes and the 
ability of estradiol  to alter the number and pattern of dendritic spines, resulting in a sex-
specific neuronal organization (McCarthy, 2008). Thus, tissue-specific aromatase activity 
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 can alter neuronal behavior as a result of altered molecular phenotypes and the 
formation of altered synaptic patterning. 
 
In the songbird, aromatase activity in the caudomedial nidopallium (NCM), the 
bird auditory cortex, is rapidly upregulated during 30 minutes of social interaction, 
mimicked by audio playback of bird songs (Remage-Healey et al., 2008). Intracerebral 
microinjections of an aromatase inhibitor (1,4,6-androstatrien-3,17-dione) in the NCM 
suppressed auditory-stimulated neuronal firing rates of NCM neurons, whereas estradiol 
microinjections increased the mean firing rate, providing evidence that estradiol formed 
locally in the NCM modulates the processing of sensory information (Tremere et al., 
2009). These observations demonstrate that brain-derived estrogens influence 
integrated behaviors by eliciting organizational effects during development that manifest 
in adult behaviors and can alter the processing of sensory information.  
 
As compared to the central nervous system, little is known about the expression, 
activity, and potential role of aromatase in the peripheral nervous system. As discussed, 
Evrard and Balthazart have demonstrated that intrathecal delivery of an AI alters 
nociceptive behaviors in the Japanese quail (Evrard and Balthazart, 2004a, b). In the 
spinal cord of these birds, aromatase immunoreactivity has been localized to the 
superficial dorsal horn, in proximity to substance P immunoreactive terminals (Evrard et 
al., 2000). Thus, as suggested by Evrard and colleagues, aromatase activity may 
influence or be influenced by sensory transduction from the peripheral nervous system 
(Evrard et al., 2000; Evrard et al., 2003). In contrast, aromatase activity was not detected 
in rat spinal cord homogenates in two separate studies. It is unclear whether 
experimental differences contribute to these differences or whether these results indicate 
significant species differences in the localization and contribution of aromatase activity in 
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 the spinal cord (MacLusky et al., 1987; MacLusky et al., 1994). However, aromatase 
immunoreactivity and synthesis of 3H-estradiol from the steroid precursor 3H-
pregnenolone was shown in lumbosacral DRGs from rats (Schaeffer et al., 2010). The 
capacity of a neural center to synthesize steroids requires the expression and activity of 
key steroidogenic enzymes and the presence of the requisite steroid precursors. It is 
expected that aromatase substrates could be effectively delivered to aromatase 
expressed in DRG cells by the circulatory system given the high density of blood 
capillaries in ganglion tissue (Jimenez-Andrade et al., 2008). Alternatively, aromatase 
substrates may be formed by metabolism, as testosterone and androstanediol are 
known to be formed from progesterone within the DRG (Schaeffer et al., 2010). 
Furthermore, if locally produced steroids impart biological activity in an autocrine or 
paracrine fashion, in turn regulating a neurobiological process, formation of the terminal 
steroid product should occur within the involved neural circuit, in the proximity of steroid 
receptors. Expression of aromatase and estrogen receptors in DRG neurons raises the 
interesting possibility that, in addition to exposure to blood supplied estrogens, estrogen 
synthesis within sensory neurons may alter their physiology via intracrine or paracrine 
signaling (Schaeffer et al., 2010).  
 
Sensory neuron cultures from the dorsal root ganglia 
Psychophysical studies have demonstrated that a number of endogenous and 
exogenous substances applied within the receptive field of sensory neuron fibers can 
induce pain or sensitize the response to numerous stimuli. One approach to studying the 
underlying mechanisms has been to use behavioral animal models, which allow further 
manipulations than those which would be acceptable in human studies. However, 
responses measured in humans and animal models are the summation of an integrated 
response of a substance acting on multiple potential cellular targets. Therefore, using in 
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 vivo models, it is difficult to interpret whether the measured response results from direct 
action of a substance on neurons, and further, differentiate between peripheral and 
central mechanisms. 
 
One approach to study the role of peripheral sensory neurons is to utilize isolated 
sensory neuron preparations. These cellular models have been used by many 
investigators to study basic properties of sensory neurons, including the composition and 
pharmacology of ion channels and other receptors that control the generation of action 
potentials and neurotransmitter release. These preparations have also been extensively 
used to study the action of xenobiotics known to cause pain in humans on sensory 
neurons. In this context, an advantage of the isolated sensory neuron model is the ability 
to precisely control drug exposure (concentration x time) in the cell preparation. While 
drug exposure can be manipulated in vivo by altering the dose, route of administration, 
or frequency of administration, the effects of these changes are often only understood in 
the context of drug concentrations in the blood while dynamic effects in tissues, such as 
the DRG are not examined. Therefore, concentration – response relationships can be 
more easily determined using isolated cells. The use of sensory neuron cultures to study 
the effects of AIs also removes circulating sources of endogenous sex steroids or other 
potential inflammatory mediators that may be altered following administration of AIs to 
animals or humans and which could otherwise cloud interpretation of the data. Thus, this 
in-vitro model is useful to study whether AIs directly alter the function of sensory 
neurons. 
 
Neuronal cell bodies (soma) from dissociated DRGs express many of the same 
receptors and signaling molecules that are expressed in the central terminals, peripheral 
terminals, and axons of nociceptors (Basbaum et al., 2009). As a result, sensory neuron 
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 cultures reproduce the broad diversity of neuron types and physiological properties 
observed in less reductionist models (e.g. skin nerve preparations) and in vivo. Since 
many neurotransmitters are released from both central terminals as well as receptive 
endings, investigating the release of neurotransmitters from sensory neuron cultures can 
be used as an indicator of overall neuronal function. As is the case with any in vitro 
preparation that seeks to be relevant to in vivo physiology, these preparations also have 
some limitations. The use of dissociated DRG cells clearly disrupts sensory neuronal 
interactions with other neurons and non-neuronal components that may play important 
roles in vivo. For instance, spinal transmission from first order to second order sensory 
neurons is a regulated process, recruiting facilitory and inhibitory modulation by 
interneurons, glia, and descending pathways. Thus, the physiological relevance of 
changes in neuronal excitability or neurotransmitter release from neuronal cultures must 
be viewed in the context of loss of these interactions and carefully interpreted. 
Furthermore, DRG cultures are often supplemented with growth factors that play pivotal 
roles in the maintenance of neuronal phenotypes and excitability. For example, NGF 
regulates the expression of many ion channels (for example, TRPV1: (Winter et al., 
1988); TRPM8, a cold-sensitive channel: (Babes et al., 2004); and ASIC3, an acid-
sensing ion channel: (Mamet et al., 2002)) and neuropeptides (Lindsay et al., 1989). 
Also, neurotrophic factors have been shown to directly sensitize nociceptors in vitro (Shu 
and Mendell, 1999). Thus, supplementing culture medium with neurotrophic factors, in 
combination with other factors, such as serum, may alter the detection of many stimulus 
modalities and the subsequent response. 
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 Summary and Research Aims 
 
Although AI-induced pain is thought to be a consequence of aromatase inhibition 
and estrogen deprivation, alleviating symptoms with estrogenic treatments cannot be 
ethically tested in the clinical setting. Thus, alternative methods are needed to establish 
the pathophysiology and mechanisms linking AI treatment to musculoskeletal pain. 
Given that AIs are used to treat breast cancer in postmenopausal women, the question 
remains whether AI-induced pain syndromes are secondary to a reduction in the already 
low concentrations of circulating estrogens, or caused by other potential mechanisms, 
including inhibition of the local production of estrogens. Additionally, the specific 
tissue(s) or cell type(s) relevant to pain during AI therapy are unknown, although 
changes in bone (Muslimani et al., 2009), tendon (Morales et al., 2007), nerve (Felson 
and Cummings, 2005), and the immune system (Laroche et al., 2007) have been 
proposed. However, the expression of aromatase and estrogen receptors in DRGs and 
the spinal cord raises the interesting possibility that aromatase activity in pain-
transduction pathways may modulate the processing of afferent sensory information via 
autocrine or paracrine signaling.  
 
My central hypothesis is that aromatase inhibitors sensitize nociceptors resulting 
in hypersensitivity during AI treatment. Studies outlined in this dissertation test this 
hypothesis through the following specific aims: 
 
 Specific aim 1. To develop an animal model of AI-induced hypernociception. 
 Specific aim 2. To determine if AIs sensitize sensory neurons. 
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 MATERIALS AND METHODS 
 
Animals 
 
Experiments were performed using adult male and female Sprague Dawley rats 
(150-200 grams; Harlan Laboratories, Indianapolis, IN), housed two to three per cage 
under a 12-hour dark-light cycle (facility was illuminated from 7:00 A.M. to 7:00 P.M.). 
Ovariectomies were performed by the supplier. Briefly per Harlan’s procedures, the 
female rat was anesthetized and the dorsal mid-lumber area was shaved and disinfected 
with iodine and alcohol. A 2-3 cm dorsal midline skin incision was made midway 
between the caudal edge of the ribcage and the tail base. To gain access to the ovaries, 
incisions of 5.5-10 cm were made into the muscle wall on both sides of the animal, 
approximately one-third of the distance between the spinal cord and the ventral midline. 
The ovaries and oviducts were externalized and removed with single cuts through the 
oviducts proximal to the ovary. Remaining tissue was replaced into the peritoneal cavity 
and a sterile wound clip was applied to close the skin incisions. Animals were closely 
examined for incision repair and infection for 72 hours post-surgery and wound clips 
were removed 10 days post-surgery, as recommended by the supplier. Male rats were 
housed for at least one week, while ovariectomized rats were housed for at least two 
weeks, before beginning experiments. Food and water were available ad libitum. All 
experiments were performed in accordance with the ethical guidelines for investigations 
of experimental pain in conscious animals and the guidelines of the Indiana University 
School of Medicine Institutional Animal Care and Use Committee (Zimmermann, 1983). 
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 Chemicals and other materials 
 
Letrozole and exemestane were obtained from United States Pharmacopeia 
(Rockville, MD). Prostaglandin E2 (PGE2) was obtained from Cayman Chemical (Ann 
Arbor, MI). Adenosine 5′-triphosphate disodium salt (ATP), alpha, beta-
methyleneadenosine 5'-triphosphate lithium salt (α,β-meATP), 2-hydroxypropyl-β-
cyclodextrin (HPβCD), capsaicin, desmethyldiazepam (DMD), 1-methyl-2-pyrrolidinone 
(MPL), methanol (MeOH), Phe-Ala, bacitracin, L-Ascorbic acid, collagenase type IA, 
poly-D-lysine, laminin, 5-fluoro-2′-deoxyuridine, uridine, tyrosine phosphatase inhibitor 
cocktail #2, serine/threonine phosphatase inhibitor cocktail #3, 0.01M phosphate 
buffered saline (PBS, pH 7.4), methanol, β-mercaptoethanol, RNAseZAP, and 
phenylmethanesulfonyl fluoride were obtained from Sigma Chemical Company (St. 
Louis, MO). CGRP (rat) was obtained from Tocris (1161; Bristol, United Kingdom) and 
[Tyr27]-CGRP27-37 peptide (canine, mouse, rat) for iodination was obtained from 
BACHEM (H-5504; Torrance, CA). HEPES buffer (25mM HEPES, 135mM NaCl, 3.5 mM 
KCl, 3.3 mM CaCl2, 1.1 mM MgCl2, 3.7 mM D-glucose, and 0.1% (w/v) bovine serum 
albumin (pH 7.4)) was prepared with chemicals from Sigma Chemical Company. 
Protease inhibitor cocktail III and radioimmunoprecipitation assay buffer (RIPA) were 
obtained from EMD Millipore (Billerica, MA). Nerve growth factor (NGF) was obtained 
from Harlan (Indianapolis, IN). Cell culture plates were obtained from BD Biosciences 
(San Jose, CA) or Thermo Scientific (Waltham, MA). All other cell culture supplies were 
obtained from Life Technologies (Carlsbad, CA). iScript cDNA synthesis kit, Bio-Rad 
Protein Assay Dye Reagent, a Coomassie® Brilliant Blue G-250 based-dye, Bovine 
plasma gamma globulin, and anti-mouse horseradish peroxidase-conjugated (HRP) 
secondary antibody were purchased from Bio-Rad (170-6516; Hercules, CA). 
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 Western blots were run using the NuPAGE® sodium dodecyl sulphate – 
polyacrylamide gel electrophoresis gel system using a Mini-Cell electrophoresis 
chamber: NuPAGE® pre-cast Bis-Tris gels, 2-(N-morpholino) ethanesulfonic acid SDS 
running buffer (20x), antioxidant, transfer buffer (20X), sample reducing agent containing 
500mM dithiothreitol (10X), lithium dodecyl sulfate sample buffer (4X), SeeBlue Plus2 
Prestained Standard, Invitrolon polyvinylidene difluoride (PVDF) membranes, and filter 
paper were obtained from Invitrogen (Carlsbad, CA). The mouse anti-human aromatase 
monoclonal antibody was obtained from Serotec (MCA2077S; Oxford, UK) and its 
selectivity has been previously characterized (Turner et al., 2002). The mouse anti-actin 
monoclonal antibody that reacts with all six known vertebrate isoforms of actin and two 
cytoplasmic actins (β, γ) was obtained from Thermo Scientific (MS-1295-P1ABX) and 
the polyclonal rabbit anti-human hypoxanthine phosphoribosyltransferase 1 (HPRT) 
antibody was obtained from Santa Cruz (sc-20975; Dallas, TX). The goat anti-rabbit 
HRP-conjugated secondary antibody was purchased from Jackson ImmunoResearch 
Laboratories (111-035-046; West Grove, PA). SuperSignal® West Femto Maximum 
Sensitivity Substrate was obtained from Thermo Scientific and Western Lightning® Plus-
ECL Substrate was obtained from Perkin Elmer (Santa Clara, CA). USB PrepEase RNA 
Spin Kit for RNA isolation was obtained from the USB Corporation (Cleveland, OH). 
Materials and reagents for quantitative real-time polymerase chain reaction (RT-PCR) 
were obtained from Applied Biosystems (Foster City, CA): TaqMan® Universal PCR 
master mix, MicroAmp® 96-well plates, MicroAmp® optical adhesive film, as well as, 
TaqMan® probe and primer sets for relative quantification of CYP19a1 
(Rn00567222_m1), Esr1 (Rn01430445_m1), Esr2 (Rn00562610_m1), Gper 
(Rn00592091_s1), and GAPDH (4352338E). The rabbit anti-rat CGRP antiserum was a 
gift from Dr. Michael Iadorola and its selectivity has been previously characterized 
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 (Vasko et al., 1994). ddiH2O was produced by a EMD Millipore Milli-Q water purification 
system (Billerica, MA). 
 
Drug administration  
 
In behavioral experiments, on the day of drug injection, letrozole and 
exemestane powders were dissolved in a 2.5 to 30 percent solution of HPβCD in sterile 
normal saline. AIs were administered as single or multiple intraperitoneal (i.p.) injections 
(1 to 30 mg/kg) using a 26G needle. In all experiments, percent solutions and/or 
volumes of vehicle and saline injections administered to control animals were the same 
as those administered to animals in the experimental group. ATP was prepared in ice-
cold sterile PBS and kept on ice until injection. Prior to injection, ATP and PBS vehicle 
solutions were drawn into a syringe and warmed to room temperature. Injections in the 
paw were administered intradermally in the mid-plantar footpad using a 31G needle (50 
µL injection volume).   With the exception of experiments determining the effect of acute 
AI exposure, if systemic drug injections and behavioral evaluation occurred on the same 
day, behavior was measured prior to drug administration. 
 
Behavioral testing 
 
Experiments were performed between 7 am and 3 pm during the animals’ light 
cycle. After a minimum of one week in the animal care facility, animals were acclimated 
to the testing environment on multiple days for one week preceding any behavioral 
measurement or drug administration. Prior to each measurement session, animals were 
acclimated in the testing apparatus for approximately 30 minutes or until grooming or 
57 
 
 exploratory behavioral ceased. In all experiments, the observer was blinded to treatment 
and data analysis was completed at the conclusion of the experiment. 
 
For repeated measures experiments evaluating sensitivity to mechanical and 
thermal stimuli, baseline responses were obtained by exposing animals to stimuli two to 
three times on separate days prior to drug administration. The measurement 
immediately prior to the first drug injection, however, was used as the baseline 
response. In preliminary experiments with OVX rats, I observed variability in baseline 
withdrawal thresholds to von Frey filaments. In order to minimize the potential 
confounding effect of baseline response on drug-induced changes in these longitudinal 
experiments, male and OVX rats with baseline paw withdrawal thresholds greater than 
15 grams, or less than 4 grams, were excluded from the study. To normalize baseline 
response between treatment groups, animals were rank ordered according to baseline 
paw withdrawal thresholds and block randomized into treatment groups. 
 
To ascertain mechanical sensitivity (von Frey filament test), rats were placed in 
an elevated cage with a wire mesh bottom that allowed for stimulation of hind paws. Paw 
withdrawal response to mechanical stimulation was evaluated with calibrated Semmes 
and Weinstein monofilaments, using a modification of the “up-down method” (0.4 - 26 
grams, the lower and upper limit of the test; Stoelting, Wood Dale, IL) (Chaplan et al., 
1994). Filaments were applied to the mid-plantar surface of each hind paw. Trials were 
started with the four gram filament. A trial consisted of three applications of a filament for 
approximately five seconds, with at least five seconds separating successive stimulation. 
A positive response was defined as sharp paw withdrawal when the stimulus was 
applied, or paw withdrawal immediately upon removal of the filament. The paw 
withdrawal threshold (PWT) was the stimulus/filament evoking a consistent paw 
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 withdrawal response. PWT was measured for both hind paws and averaged to generate 
final withdrawal threshold at the specified time point. 
 
To assess thermal sensitivity (Hargreaves test), rats were placed in a ventilated 
acrylic cage atop a flat glass surface. Paw withdrawal latency (PWL) to noxious radiant 
heat was assessed using an infra-red heat source (Ugo Basile, Italy) applied to the mid-
plantar surface of each hind paw (Hargreaves et al., 1988). Upon initiating the thermal 
stimulus, an electronic timer was activated. A paw withdrawal (flinching or lifting the paw) 
was detected by a photocell, which switched off the infra-red source and timer, yielding 
the PWL. The heat source intensity was chosen to yield baseline paw withdrawal 
latencies of 10 seconds in the rats. A cut-off of 30 seconds was used to avoid tissue 
damage to the paw. At least 30 seconds separated successive trials in the same animal. 
PWL from each hind paw was measured three times and all six measurements were 
averaged to generate the final latency at the specified time point. 
 
Overt nociceptive behavior in response to ATP was made by observing 
unrestrained animals on a glass surface covered by an inverted and ventilated four liter 
plastic beaker. Mirrors were positioned below and behind the beaker to assist behavioral 
assessment, regardless of animal orientation. Once acclimated to the testing 
environment, animals were removed, lightly restrained, and administered an intradermal 
injection in the left hind paw. Animals were immediately returned to the testing apparatus 
and behavior was observed. As a measure of overt, spontaneous nocifensive behavior, 
flinching or shaking of the injected paw or hindquarters was recorded (McGaraughty et 
al., 2003; Wheeler-Aceto and Cowan, 1991). Each observed behavior was recorded as 
one flinch and behavioral responses were tallied in one minute intervals for 10 or 15 
minutes following the injection. 
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 Harvest of rat spinal cord and DRG neurons 
 
Sensory neuron cultures were prepared using a modification of our previously 
published protocol (Burkey et al., 2004). Briefly, rats were sacrificed by rendering them 
unconscious by exposure to CO2 and then decapitating them with a guillotine. The dorsal 
skin was disinfected with 70% ethanol prior to cutting away fur and skin from the spinal 
column using scissors sterilized in ethanol. The spinal column was isolated with a 
transverse cut across the spinal column near the pelvic girdle, followed by dissection 
along parasagittal and coronal incisions along the long axis of the spinal column. 
 
For experiments utilizing the spinal cord, a sterilized 10 mL syringe fitted with a 
blunt end needle was inserted into the caudal end of the vertebral canal. Using sufficient 
pressure, the spinal cord was ejected from the spinal column into ice-cold Hank’s 
balanced salt solution (171 mM NaCl, 6.7 mM KCl, 1.6 mM NaHPO4, 0.46 mM KH2PO4, 
and 6.1 mM D-glucose; pH 7.4). This procedure often required a small amount of the 
cranial spinal column to be removed because the cranial vertebral canal orifice was too 
constricted to eject the cord. 
 
To isolate spinal ganglia, residual fur and blood were removed by quickly rinsing 
the column in running hot tap water and the tissue was subsequently placed in a 50 mL 
conical tube filled with ice-cold Hank’s solution. Excess muscle was trimmed away 
before the vertebral column was bisected by making cuts through vertebrae along the 
rostral-caudal axis on the dorsal and ventral sides, yielding two halves of the vertebral 
column with the spinal cord and spinal ganglia exposed. The bisected column was 
returned to ice-cold Hank’s solution. Dorsal root ganglia of adult male rats were 
dissected into ice-cold Hank’s solution and their axons were trimmed. For experiments 
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 quantifying mRNA, detecting protein immunoreactivity, or quantifying drug 
concentrations from DRGs, excess Hank’s solution was removed and the intact ganglion 
were either frozen in liquid nitrogen or further processed in lysis buffers, as discussed 
later. Wet tissue weight of ganglia used for quantifying drug concentrations was 
recorded. Additional experiments utilized cultured cells from dissociated DRGs that were 
generated using the following procedure. 
 
Cell culture of rat DRG neurons 
 
Cell culture plates and dishes were prepared prior to DRG harvest; culture 
surfaces were first coated with poly-D-Lysine overnight at 37°C (3% CO2) and then 
coated with laminin overnight at 37°C (3% CO2). Ganglia were digested in collagenase 
for one hour at 37°C (3% CO2) and single-cell suspensions were produced by 
mechanical agitation using a sterile fire polished Pasteur pipette. Approximately 30,000 
cells per well were plated into 12-well Falcon culture plates (3.8 cm2 surface area; 
approximately 7900 cells per cm2), whereas 60,000 cells were plated into 6-well Falcon 
culture plates (35 mm well diameter) or individual 35 mm culture dishes (8.8 cm2 surface 
area; approximately 6800 cells per cm2). Cells were grown in 3% CO2 in F12 media or 
phenol red-free DMEM/F12 media supplemented with 3 mM glutamine, 50 units/mL 
penicillin, 50 µg/mL streptomycin, 30 µM 5-fluoro-2′-deoxyuridine, 75 µM uridine, and 
10% (v/v) heat-inactivated horse serum. Unless specified otherwise, media was 
supplemented with 30 ng/mL NGF prior to its additional to cells. Cultures were typically 
grown in F12 media for 12 days and DMEM/F12 media for 9 days, with media changed 
the day after harvest and every other day until an experiment. For experiments testing 
the effect of drug exposure on cells in culture, water insoluble drugs (e.g. letrozole and 
PGE2) were initially dissolved in 1-methyl-2-pyrrolidinone and then diluted to appropriate 
61 
 
 concentrations in culture media. In these experiments, biological controls were treated 
with the solvent(s) at the same dilution. 
 
Isolation and storage of other rat tissues 
 
Isolation of DRGs and spinal cord was carried out as described above. Rat 
tissues isolated to quantify mRNA, protein, or drug concentrations were harvested using 
sterilized surgical tools using the following general procedure. Following sacrifice of the 
animal, trunk blood was captured in a 15 mL plastic conical tube by inverting the animal. 
To isolate serum, blood samples were placed in ice for 15 to 30 minutes to allow 
sufficient coagulation, followed by centrifugation at 2500 rpm (approximately 1400 g). 
Plantar foot pads were dissected using a sterile 6mm biopsy punch (Miltex, York, PA). 
Other solid tissues were isolated within minutes of the animal’s sacrifice, immersed in 
Hank’s solution, and trimmed of adipose and connective tissue using a scalpel. After 
excess Hank’s solution was removed and tissue wet weight was recorded, the tissues 
were placed in 1.5 mL Eppendorf tubes or plastic conical tubes and snap frozen in liquid 
nitrogen. Tissues to be used for RNA quantification were stored in RNAse-free tubes. All 
tissues were stored at -80°C. 
 
Measuring CGRP by radioimmunoassay 
 
Immunoreactive calcitonin gene-related peptide (iCGRP) release from sensory 
neurons was measured as previously described (Vasko et al., 1994). CGRP released 
into HEPES buffer from sensory neurons in culture and perfused spinal cord slices was 
quantified using a standard curve of 0 – 250 fmol CGRP, prepared in duplicate in 
HEPES buffer. Standards were prepared in an equivalent volume to the unknowns being 
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 measured in a given experiment. To each unknown and standard, 25 µL of a 1:13 
dilution of rabbit anti-rat CGRP antiserum stock (final titer = 1:910,000) were added. 
Antiserum was not added to two additional blank standards that contained no CGRP 
(NSB, non-specific binding). Following a 12 – 18 hour incubation at 4°C, a volume of 125I-
[0Tyr]-CGRP27-37 containing 2000 – 2500 CPMs (typically 25 µL of freshly iodinated 
peptide) was added to all samples. The same volume of 125I-[0Tyr]-CGRP27-37 was added 
to two additional tubes to represent total counts of the radiolabeled peptide (totals). The 
samples were incubated at 4°C for 12 – 18 hours and 0.5 mL of an activated charcoal 
suspension (0.1 M NaH2PO4, 50 mM NaCl, 0.1% BSA, and 1% Norite charcoal (pH 
7.4)) was added to all tubes except the ′totals′ containing only the radioactive peptide. 
Samples were equilibrated for 10 minutes to allow unbound peptide to be bound by the 
charcoal and then centrifuged at 3000 x g for 20 minutes (4°C) to pellet the charcoal. 
Supernatants were decanted to a new tube and radioactivity in the samples was 
measured using a Wallac Automatic Gamma Counter (model 2470) (Perkin Elmer, 
Waltham, Massachusetts). A calibration curve was constructed by four-parameter log-
logistic curve fitting of the signal (partial binding or y = (CPM standard - CPM NSB) / (CPM 
totals - CPM NSB)) versus log10-transformed amount of standards (x) (Perkin Elmer Workout 
software, v2.5). The amount of iCGRP in experimental samples was estimated by 
interpolation of the fitted line. 
 
Release of iCGRP from sensory neurons in culture 
 
iCGRP release was measured from sensory neurons grown in culture for 7 to 12 
days, as previously described (Vasko et al., 1994). Release of iCGRP was measured 
from sequential 10-minute incubations of neuronal cultures in 400 µL HEPES buffer 
maintained at 37°C. Basal iCGRP release was determined by incubating cells in HEPES 
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 buffer alone. Subsequently, cells were exposed to drugs diluted in HEPES to determine 
their effect on basal release. The effect of drugs on evoked release was determined by 
re-exposing cells to drugs in the presence of 10 or 30 nM capsaicin or 30 mM KCl 
(substituted for equimolar sodium chloride). Lastly, cells were re-exposed to HEPES 
buffer alone to demonstrate basal release could be re-established. Buffer (300 µL) was 
collected following each incubation and transferred to plastic 5 mL tubes. Finally, to 
measure remaining iCGRP content, cells were lysed in 0.1 N HCl.  Cell lysates were 
serially diluted in HEPES buffer (typically a 24x dilution) and 300 µL were assayed along 
with the collected fractions for iCGRP using radioimmunoassay, as described. In all 
experiments, three wells of cells from at least 3 independent harvests were exposed to 
each experimental condition. Water insoluble compounds (e.g. capsaicin, letrozole, and 
PGE2) were initially dissolved in MPL, and then diluted to appropriate concentrations in 
HEPES buffer. ATP and α,β-meATP were initially dissolved in CaCl2-free and MgCl2-free 
0.01 M phosphate buffered saline (PBS, pH 7.4), and then diluted in HEPES buffer. 
Biological controls were treated with the solvent(s) at the same dilution. Previous studies 
in Dr. Vasko’s lab have established that iCGRP content, nor basal or stimulated release 
of iCGRP, are affected by MPL at dilutions used in these experiments. 
 
Release of iCGRP from spinal cord tissue 
 
Spinal cord slices were prepared as previously described (Chen et al., 1996). 
After rats were anesthetized and sacrificed using CO2 asphyxiation and decapitation, a 1 
cm segment of the lumbar enlargement was dissected and chopped transversely and 
parasagitally into 0.3 x 0.3 mm sections. Tissue from each animal was placed into an 
individual cylindrical perfusion chamber and is reported as one experimental sample. 
Slices were perfused at a flow rate of 0.5 mL/min with HEPES buffer (pH 7.4) 
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 supplemented with 200 µM ascorbic acid, 100 µM Phe-Ala, 20 µM bacitracin, and 10 µM 
phenylmethanesulfonyl fluoride, aerated with 95% O2–5% CO2, and maintained at 37°C. 
After perfusing slices for 20 minutes to equilibrate the tissue, perfusate was collected in 
3 minute intervals throughout the experiment (1.5 mL/fraction) using an automatic 
fraction collector. Baseline release was established by perfusing tissue with HEPES for 
18 minutes (6 fractions), with the last 3 fractions considered as ‘basal’ release. 
Subsequently, potassium-stimulated release was determined by perfusing tissue for an 
additional 9 minutes (3 fractions) with HEPES buffer containing 30 mM KCl (substituted 
for equimolar NaCl). Lastly, slices were perfused with HEPES buffer for 21 minutes (7 
fractions) to re-establish basal release. In experiments determining the effect of acute 
PGE2 exposure, slices were perfused with HEPES buffer containing vehicle (1:2000 
dilution MPL) or 30 µM PGE2 for 9 minutes (3 fractions) prior to, and throughout 
stimulation with 30 mM KCl. Following tissue perfusion, spinal cord tissue was collected 
and homogenized in 2 mL of 0.1 N HCl. Homogenate was centrifuged at 3,000 rpm for 
20 minutes at 4°C. The supernatant was serially diluted with HEPES buffer and assayed 
for iCGRP along with perfusate fractions by radioimmunoassay. The total iCGRP content 
in each tissue slice was calculated as the content measured in all perfusate fractions 
plus the tissue homogenate. 
 
Western blotting for aromatase immunoreactivity 
 
Total protein isolation from sensory neuron cultures and rat tissues 
Sensory neurons in culture were washed, then scraped in ice-cold PBS, 
supplemented with 1 mM EDTA, 1 mM EGTA, 1X protease inhibitor cocktail and 1X 
tyrosine and serine/threonine phosphatase inhibitor cocktails. Cells were pelleted at 
18,500 g for 4 minutes at 4°C. The supernatant was discarded and the pellet was re-
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 suspended in RIPA buffer supplemented with protease and phosphatase inhibitors. 
DRG, spinal cord, plantar foot pads, and ovaries were dissected into ice-cold Hank’s 
solution and DRG axons were trimmed. After removing residual Hank’s solution with a 
glass pipette, the tissues were snap-frozen in liquid nitrogen and stored at -80°C. 
Tissues were re-suspended in 1X RIPA buffer supplemented with protease and 
phosphatase inhibitors. Fibrous tissues (ovaries and skin) were first mechanically 
homogenized on ice with a Janke and Kunkel Ultra-Turrax rotor-stator homogenizer 
fitted with a 8 mm turret (three times 5-seconds) (IKA, Breisgau, Germany). Tissues 
were disrupted using ultrasonicatic homogenization with a Fisher Scientific Sonic 
Dismembrator 550 (Waltham, MA) fitted with microtip probe (three 5-second pulses at 30 
percent intensity).  Samples were centrifuged at 18,500 g for 4 minutes (4°C) and the 
resulting supernatant was transferred to a new tube. Total protein concentrations of the 
resulting lysates were measured with the Bio-Rad Protein Assay using Bovine plasma 
gamma globulin standards (50 – 500 µg/mL). 
 
Western blot 
Each protein sample was diluted in 10 µL of NuPAGE lithium dodecyl sulfate 
sample buffer, 4 µL of NuPAGE reducing agent, and ddiH2O to a final volume of 40 µL. 
Samples were heated at 70°C for 10 minutes and then loaded in a NuPAGE Novex Bis-
Tris gel (4-12%) immersed in 2-(N-morpholino) ethanesulfonic acid SDS buffer (diluted 
in ddiH2O to 1X, containing NuPAGE antioxidant diluted to 1X), along with 10 µL of a 
pre-stained protein standard. Proteins were separated for 1.5 hours at 200V and then 
transferred at 15V to a PVDF membrane overnight at 4°C in NuPAGE Transfer Buffer 
(diluted to 1X in ddiH2O, containing 10% MeOH and NuPAGE antioxidant diluted to 1X). 
The membrane was subsequently blocked for two hours in 5% milk (w/v) diluted in Tris-
buffered saline containing 0.1% Tween 20 (v/v) (TBST). Aromatase immunoreactivity in 
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 DRGs and ovaries was detected by incubating the membrane in mouse anti-aromatase 
antibody overnight at 4°C (1:250 dilution in blocking buffer). Following three washes in 
TBST, the membrane was incubated with a HRP-conjugated anti-mouse secondary 
antibody (1:2,000 to 1:20,000 dilutions in blocking buffer were utilized) for two hours at 
4°C. Membrane was washed and incubated in Western Lightning® Plus-ECL substrate. 
 
Detecting aromatase expression in sensory neuron cultures required a modified 
protocol that utilized an ultra-sensitive chemiluminescent substrate system 
(SuperSignal® West Femto Maximum Sensitivity Substrate) that enables detection of 
low femtogram amounts of antigen bound by horseradish peroxidase (HRP)-conjugated 
antibodies. Due to the intense chemiluminescence generated using this substrate, 
manufacturer’s suggestions were used to minimize background chemiluminescence 
while probing for aromatase immunoreactivity. Specifically, following incubations in a 
more dilute mouse anti-aromatase antibody (1:1,000 dilution in blocking buffer), the 
membrane was vigorously washed in a large volume of TBST (10 mL) for 10 minutes on 
a rotary shaker. Membranes were then incubated with the secondary anti-mouse 
antibody, diluted in TBST (0.1% tween) and pre-filtered through a 0.45um Steri-flip filter 
(Millipore) ((1:100,000 final dilution) for 1 hour at room temperature. Membranes were 
then vigorously washed in TBST, replaced 5 times over 10 minutes, using a rotary 
shaker, followed by incubation in the SuperSignal® West Femto Maximum Sensitivity 
Substrate.  
 
Actin and HPRT immunoreactivity were determined by incubating membranes 
with a mouse anti-actin antibody (1:10,000 in 5% milk) or a rabbit anti-HPRT antibody 
(1:500 in 5% milk) overnight at 4°C. Following three washes in TBST, the membranes 
were incubated with a HRP-conjugated anti-mouse secondary antibody (1:20,000 in 5% 
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 milk in TBST) or HRP-conjugated anti-rabbit secondary antibody (1:5000 in 5% milk in 
TBST) for two hours at 4°C. The membranes were washed three times in TBST and 
incubated in the Western Lightning® Plus-ECL substrate. 
 
Protein immunoreactivity on the immunoblots was visualized by 
chemiluminescence. Membranes were overlaid with X-ray film in a film cassette in a 
darkroom. Following exposure, the film was processed in an X-ray film developer. 
 
Gene expression analysis using real-time PCR 
 
Total RNA isolation from sensory neuron cultures 
Each sample corresponds to RNA isolated from DRG neurons cultured from a 
single male Sprague Dawley rat.  DRGs were cultured in 35 mm dishes or 6-well plates 
at a density of 60,000 cells/well.  Cultures were maintained in F12 media with the 
addition of 30ng/mL NGF for 12 days. Cells were lysed for RNA extraction using the 
following steps: media was aspirated, cells were washed 2X with PBS, and cells were 
disrupted in 300uL of RA1 buffer (USB PrepEase RNA Spin Kit) and 3 µL β-
mercaptoethanol by aspirating and pipetting the cells five times with a pipetteman. Lysis 
solution from wells with similar treatments were pooled in a 1.5mL eppendorf tube and 
stored at -80°C. 
 
Total RNA isolation from ovaries and dorsal root ganglia 
Ovary tissue was thawed in 300 µL of RA1 buffer + 3 µL β-mercaptoethanol and 
samples were re-frozen for 15 minutes at -80°C.  Samples were then thawed and 
disrupted with a rotor stator homogenizer (three time 5-seconds). To reduce RNA 
degradation, the rotor was treated with RNAseZAP, rinsed 2X with ddiH2O, spun in a 
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 tube of ddiH2O, and patted dry with a Kim Wipe before, between, and after samples. 
Samples were placed on ice and sonicated (30% intensity) for 10 sec, three times. 
 
Dissected DRGs were transferred to 300 µL of RA1 and 3 µL of β-
mercaptoethanol in a 1.5mL RNAse-free tissue homogenization tube (Kimble Chase, 
Vineland, NJ). DRGs were immediately transferred to -80°C freezer and stored for at 
least 1 hour prior to homogenization. DRGs were thawed, pelleted and the RA1 buffer 
was transferred to an RNAse-free 1.5mL eppendorf tube. DRGs were then homogenized 
in the small volume of remaining lysis buffer using the 1.5mL tube using the 
corresponding pestle (Kimble Chase, Vineland, NJ). Cell lysate was transferred to the 
same 1.5 mL tube and an additional 200 µL of RA1 buffer was homogenized to collect 
any residual RNA from tube and pestle.  
 
RNA was isolated using the USB PrepEase RNA Spin Kit per manufacturer’s 
instructions and eluted in 50 µL of nuclease-free water. Total RNA content was 
measured using a Nanodrop 1000 UV-Vis Spectrophotometer (Thermo Scientific). RNA 
was immediately stored at -80°C or used to synthesize complimentary deoxyribonucleic 
acid (cDNA). 
 
cDNA synthesis and RT-PCR 
Isolated total RNA was converted to cDNA via a reverse transcriptase (RT) 
reaction using random hexamer primers (iScript cDNA synthesis kit). cDNA synthesis 
from each sample was performed in duplicate 40 µL reactions (consisting of: 500 ng total 
RNA, buffer containing primers and salts, RT enzyme, and nuclease-free water) and 
incubated at 25°C for 5 minutes, 42°C for 30 minutes, then at 85°C for 5 minutes, and 
4°C until the reaction tubes were recovered. Duplicate RT reactions were pooled to 
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 generate 1000 ng in 80 µL total volume, yielding a final cDNA concentration of 12.5 
ng/µL, assuming complete reaction efficiency. 
 
RT-PCR amplification of each cDNA was performed in triplicate in 20 µL 
reactions containing: 8 µL cDNA (100 ng), 10 µL master mix, 1 µL primer mix, and 1 µL 
nuclease-free water. Quantification of target and reference (endogenous control) genes 
in each cDNA was performed in separate wells (single-plex reactions). Reactions were 
prepared in 96-well reaction plates and RT-PCR was performed using an Applied 
Biosystems StepOnePlus system. 
 
Measuring letrozole concentrations in serum and tissue 
 
A quantitative assay to measure letrozole concentrations in rat serum and tissue 
was utilized based on a validated assay to measure letrozole in human plasma (Desta et 
al., 2011). The assay utilizes high pressure liquid chromatography (HPLC) with 
fluorescence detection for letrozole (excitation: 230 nm; emission: 295 nm) and UV-VIS 
detection of the internal standard DMD (234 nm; 0.1 absorbance units full scale 
(AUFS)). HPLC analysis was carried out on a Waters System (Milford, MA) consisting of 
a Waters 717 plus autosampler, Waters 600S pump and controller, Waters 486 
absorbance detector, and a Hewlett Packard 1046A fluorescence detector (Palo Alto, 
CA), controlled by Waters Empower software. Analytes were separated on a Zorbax SB-
C18 column (3.5 μm particle size, 150 × 4.6 mm; Agilent, Santa Clara, CA), a Nova-Pak 
C18 guard column (Waters, Milford, MA) (4-μm particle size) using isocratic elution at 
flow rate of 1 mL/min. Under the above conditions, letrozole eluted at approximately 17 
minutes and DMD eluted at 27 minutes. Previously validated using human plasma 
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 samples, the assay has a limit of quantification of 7 ng/mL, with interday and intraday 
coefficients of variation of <6.5% and <10%, respectively (Desta et al., 2011). 
 
Tissues isolated for HPLC analysis were thawed on ice and mechanically 
homogenized in 1000 to 5000 µL PBS with a Janke and Kunkel Ultra-Turrax rotor-stator 
homogenizer fitted with a 8 mm turret (two times 5-seconds). Tissue homogenate (100 
µL of DRG homogenate or 300 µL brain homogenate) was transferred to 1.5 mL 
Eppendorf tubes and frozen at -20°C until assayed. Frozen serum or tissue homogenate 
was thawed on ice and vortex-mixed before use. Serum (100 µL), brain homogenate 
(300 µL) or DRG homogenate (100 µL) produced from letrozole or vehicle-treated rats 
was spiked with 25 µL MeOH and 50 µL of 1 µg/mL DMD (internal standard) dissolved in 
methanol. Standard curves were generated by spiking equivalent volumes of serum or 
tissue isolated from naïve animals with 25 µL of letrozole (0 to 100 µg/mL) and 50 µL of 
1 µg/mL DMD. The samples were vortex-mixed for 15 seconds and centrifuged at 
18,500 g for two minutes. The resulting supernatant was transferred to a glass culture 
tube and extracted with 0.5 mL of 1M NaOH/1M glycine buffer (pH 11.3) and 6 mL of 
ethyl acetate. Samples were vigorously vortex-mixed and centrifuged at 3600 rpm for 15 
minutes. The organic phase was removed, transferred to a clean glass culture tube, and 
evaporated in a SpeedVac Concentrator (Thermo Scientific; Waltham, MA) for 
approximately two hours to dryness. The residue was reconstituted in 150 µL of mobile 
phase (35% acetonitrile, 65% 10 mM KH2PO4 titrated to pH 6.5 with 5M KOH) and 
transferred to an injection vial containing a 200 µL polyethylene insert and 50 µL was 
injected onto the analytical column. For a single analytical run, technical duplicates of 
experimental samples and calibration standards were prepared, extracted together and 
assayed in sequence via HPLC. Method evaluation using rat tissues was performed 
using tissue obtained from naïve rats.  
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 Area under the curve (AUC) for letrozole and DMD peaks were automatically 
integrated by the Empower software and manually confirmed and adjusted if necessary. 
For each sample, the ratio of the letrozole peak area to the internal standard peak area 
(AUC LET / AUC DMD) was calculated and averaged over the technical replicates. A 
calibration curve was constructed by weighted least-squares linear regression of the 
AUC ratios (y) versus known concentrations of the standards (x) in each analytical run, 
with a weighting factor of 1/x2. Letrozole concentrations in experimental samples were 
estimated by interpolation of the least-squares line. 
 
Data analysis 
 
Data analysis software 
Data manipulation and analysis was performed using GraphPad Prism versions 
5.04 and 6.01 (GraphPad Software Inc., La Jolla, CA), Excel 2010 (Microsoft, Redmond, 
WA) and R v2.7.1 (R Foundation for Statistical Computing, Vienna, Austria). Analysis 
and visualization of raw RT-PCR data was performed using StepOne Software v2.2 
(Applied Biosystems). Protein sequence alignments were performed using ClustalW 
implemented in CLC Sequence Viewer v6.9 (CLC bio, Cambridge, MA). 
 
Behavioral studies 
Repeated measures studies evaluating treatment effects on PWT and PWL were 
analyzed using two-way analysis of variance with repeated measures (two-way RM-
ANOVA), followed by post hoc two-sample t-tests. One-way RM-ANOVA was used to 
evaluate whether PWT and PWL change during behavioral testing. PWT data are 
reported in grams (mean ± S.E.M.). Due to logarithmic intervals in pressure exerted by 
sequential filaments, log10-transformed thresholds were used for data analysis. PWL 
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 data are reported as the observed latency in seconds (mean ± S.E.M.) and analysis was 
performed using this metric. To compare treatment effects on PWT and PWL between 
studies, we normalized baseline responses by calculating percent change from baseline 
for each rat.  In experiments evaluating overt nociceptive behavior, numbers of flinches 
observed in one-minute intervals are reported as mean ± S.E.M. flinches and compared 
between treatment groups using the Mann-Whitney U test. Cumulative ATP-induced 
nociceptive behavior is reported as median (25th percentile, 75th percentile) and was 
compared between treatment groups using the Mann-Whitney U test. Boxplots depict 
overt nociceptive behavior as five-number summaries with horizontal lines representing 
(from top to bottom): 75th percentile + (1.5 x interquartile range) (upper whisker), 75th 
percentile, median, 25th percentile, 25th percentile - (1.5 x interquartile range) (lower 
whisker). 
 
Release of iCGRP from sensory neurons in culture 
Release of iCGRP is presented as the mean ± S.E.M. of the amount of peptide 
released in ten minute incubations as percent of the total peptide content in each well. 
Treatment effects on basal and evoked iCGRP release were evaluated using t-tests, 
while treatment effects on total content of iCGRP was determined using one-way 
analysis of variance.  Statistical significance for each comparison was assessed using a 
Type I error rate of 5%.  
 
Release of iCGRP from spinal cord slices 
iCGRP released in spinal cord perfusate is expressed as the mean ± S.E.M. of 
peptide measured per minute in each fraction, divided by the total iCGRP content for 
that spinal cord sample (percent of total content per minute). Treatment effects were 
compared by determining the fractional release of peptide (percent of total content per 
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 minute) during the three basal and three stimulated fractions. The difference between 
iCGRP released during exposure to high potassium (stimulated) and iCGRP released 
during drug or vehicle exposure prior to high potassium stimulation (basal) is termed 
evoked release. Treatment effects on basal, stimulated, and evoked iCGRP release 
were evaluated using t-tests. Total iCGRP content measured in spinal cord slices is 
normalized to the wet weight of tissue placed in perfusion chambers (fmol/mg) and 
presented as mean ± S.E.M. Treatment effects on total iCGRP content were evaluated 
using two-sample t-tests. Statistical significance for each comparison was assessed 
using a Type I error rate of 5%. 
 
RT-PCR 
The threshold cycle (CT) for each RT-PCR reaction was determined by StepOne 
Software. For each RT-PCR reaction, the amount of target cDNA was normalized the 
endogenous reference by calculating ∆CT (∆CT = CT target – CT reference) (Livak and 
Schmittgen, 2001). The standard deviation of ∆CT was calculated from the standard 
deviations of the target and reference genes as follows: 𝑆𝑆𝑆𝑆∆𝐶𝐶𝑇𝑇 =
��𝑆𝑆𝑆𝑆𝐶𝐶𝑇𝑇,𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡�2 + �𝑆𝑆𝑆𝑆𝐶𝐶𝑇𝑇,𝑡𝑡𝑡𝑡𝑟𝑟𝑡𝑡𝑡𝑡𝑡𝑡𝑟𝑟𝑟𝑟𝑡𝑡�22  (Livak and Schmittgen, 2001).  
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 RESULTS 
 
Effect of aromatase inhibitor administration on experimental pain models in rats 
 
Letrozole induces mechanical hypersensitivity in ovariectomized female rats 
I first examined whether AIs alter basal and evoked responses in OVX rats by 
measuring changes in PWT and PWL following treatment with a single dose of 1 mg/kg 
or 5 mg/kg letrozole (Figure 3A); these doses that have been shown previously to 
effectively inhibit aromatase in rats (Schieweck et al., 1993). Administration of 1 mg/kg 
letrozole (n = 11) significantly reduced the response threshold to a mechanical stimulus 
compared to vehicle-treated controls (100 mg/kg HPβCD; n = 9) (two-way RM-ANOVA, 
P < 0.05; Figure 3B). Post-hoc analysis demonstrated a significant reduction in PWTs in 
animals treated with 1 mg/kg letrozole at 5, 10, and 30 days following drug 
administration compared to vehicle-treated rats. Baseline PWT was not different 
between treatment groups. In a similar manner, a single injection of 5 mg/kg letrozole (n 
= 5) produced mechanical hypersensitivity after 3 days compared to vehicle treatment 
(750 mg/kg HPβCD; n = 5), and this effect was maintained for 30 days after drug 
administration (Figure 3C). Baseline PWT was not different between treatment groups. 
Comparing baseline-normalized PWT between letrozole doses did not reveal a 
significant effect of dose, suggesting PWT was maximally reduced by 1 mg/kg letrozole. 
 
In contrast to letrozole-induced mechanical hypersensitivity, response latency to 
noxious thermal stimulation was not altered at any time points examined after 
administration of 1 mg/kg or 5 mg/kg letrozole (Figure 3D and Figure 3E). Additionally, 
no significant changes in PWL in vehicle treated animals were observed during 30 days 
of evaluation. 
75 
 
  
Figure 3. A single dose of letrozole induces sustained mechanical, but not thermal 
hypernociception in OVX rats. 
A: Depiction of the experimental design. Each point represents the mean ± S.E.M. of (B, 
C) paw withdrawal threshold (PWT) in grams or (D, E) paw withdrawal latency (PWL) in 
seconds. Letrozole (1 mg/kg: B, D or 5 mg/kg: C, E) or vehicle was administered in a 
single dose on day 0. An asterisk represents significant differences in PWT following 
treatment with 1 mg/kg letrozole versus vehicle, whereas a cross represents significant 
differences in PWT following treatment with 5mg/kg letrozole versus vehicle using two-
way RM-ANOVA followed by post-hoc two-sample t-tests. 
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 Analysis of all vehicle-treated animals evaluating time and vehicle dose showed 
PWTs were significantly reduced over the course of the experiment (two-way RM-
ANOVA, P < 0.05). Consequently, we determined whether this reduction was caused by 
injection of vehicle or secondary to OVX by measuring PWT in OVX rats treated with a 
single injection of 750 mg/kg HPβCD (n = 5) or saline (n = 5) (Figure 4A). PWTs were 
significantly reduced over 30 days in all rats independent of vehicle or saline injection, 
suggesting enhanced mechanical sensitivity following ovariectomy is not directly 
attributable to vehicle administration (Figure 4B). A post-hoc analysis of the combined 
animals showed PWTs were significantly reduced from baseline during the experiment 
and mechanical hypersensitivity developed after 5 days of evaluation (RM-ANOVA 
followed by post-hot t-tests, P < 0.05; data not shown). 
 
While letrozole significantly reduces PWTs in OVX rats, ovariectomy results in a 
steady decline in PWTs for at least 30 days following recovery from surgery (Figure 3B, 
Figure 3C, Figure 4B). While letrozole treatment reduces PWTs during this time, it is 
unclear whether this effect is a result of augmenting the development of OVX-induced 
hypersensitivity or whether letrozole treatment might further reduce PWTs of OVX rats 
once they reached their minimum. To address whether PWTs in OVX rats reach a 
steady state beyond 30 days of evaluation, PWTs were measured in untreated rats for 
52 days (approximately 7 weeks) following ovariectomy (Figure 5A). In this experiment, 
rats with baseline PWTs considered to be outliers (> 15 g or < 4 g) were not excluded 
during the initial 7 week evaluation period. As shown in Figure 5B, PWTs declined 
following ovariectomy and were significantly lower by 23 days after behavioral testing 
was initiated (Figure 5B). PWTs had reached a minimum by this timepoint, as changes 
in the average PWT were not observed beyond 23 days (Figure 5B). Administration of 5 
mg/kg letrozole (n = 8) did not alter response thresholds to a mechanical stimulus 
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 compared to vehicle-treated controls, suggesting that AI-induced mechanical 
hypersensitivity cannot be reliably detected in OVX rats once their PWTs have stabilized 
(750 mg/kg HPβCD; n = 7) (two-way RM-ANOVA, P > 0.05; Figure 5C).  
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Figure 4. Vehicle administration does not alter mechanical hypersensitivity in 
OVX rats. 
A: Depiction of the experimental design. B: Each point represents the mean ± S.E.M. 
of paw withdrawal threshold (PWT) in grams. Vehicle or saline was administered in a 
single dose on day 0. 
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Figure 5. A single dose of letrozole does not alter mechanical hypersensitivity 
after long-term ovariectomy. 
A: Depiction of the experimental design. B and C: Each point represents the mean ± 
S.E.M. of paw withdrawal threshold (PWT) in grams. B: PWT of female rats was 
measured for approximately 7 weeks following ovariectomy. Rats were then randomized 
to letrozole (5 mg/kg) or vehicle treatment. An asterisk represents significant differences 
in PWT from baseline using RM-ANOVA followed by post-hoc paired t-tests. C: PWT 
measurements immediately prior to drug injections (day -1 in (B)), was used as the 
baseline response. Letrozole (5 mg/kg) or vehicle was administered in a single dose on 
day 0. 
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 Letrozole induces mechanical hypersensitivity in male rats 
The effect of letrozole to reduce PWTs in OVX rats suggests the observed 
behavioral change may not attributed to changes in circulating estrogens. If letrozole-
induced mechanical hypersensitivity is secondary to a reduction in tissue estrogen 
concentrations, we should observed the effects in other animals with very low circulating 
estrogen concentrations. For this reason, we determined whether AIs also augment 
nociception in males. To test this, male rats were treated with 5mg/kg letrozole (n = 8) or 
vehicle (750 mg/kg HPβCD; n = 8) daily for 15 days and PWT and PWL were measured 
(Figure 6A). We chose to use chronic dosing in males since previous pharmacokinetic 
estimates of cyclodextrin-complexed letrozole in male and female rats suggest male rats 
have approximately 5-fold greater clearance of the drug following intravenous delivery 
(Wempe et al., 2007).  When evaluating the main treatment effect, daily dosing with 5 
mg/kg letrozole significantly reduced the PWT compared to vehicle treated controls (two-
way RM-ANOVA, P < 0.05; Figure 6B). Post-hoc analysis showed letrozole-treated 
animals had reduced PWTs five days after initiating drug administration and at days 10 
and 15 during treatment (n = 8; Figure 6B). For example, at 5 days of treatment PWT 
was 5.3 ± 0.5 g in vehicle-treated rats and 1.6 ± 0.4 g in letrozole-treated animals. In 
contrast to reduced PWTs observed in vehicle-treated OVX females, PWT in vehicle-
treated male rats did not significantly change during the treatment period (one-way RM-
ANOVA). After discontinuing drug administration, animals remained hypersensitive to 
mechanical stimulation for at least 72 hours. However, no significant difference in PWT 
between treatment groups was detected 7 days after stopping treatment (experiment 
day 21), suggesting the effect of letrozole was reversible (Figure 6B). As we observed in 
OVX rats, treating male rats with letrozole did not significantly alter the PWL when 
compared to vehicle treated rats (two-way RM-ANOVA; Figure 6B). 
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Figure 6. Daily dosing of 5 mg/kg letrozole induces mechanical, but not thermal 
hypernociception in male rats. 
A: Depiction of the experimental design. B and C: Each point represents the mean ± 
S.E.M. of (B) paw withdrawal threshold (PWT) in grams or (C) paw withdrawal latency 
(PWL) in seconds. Letrozole or vehicle was administered daily on days 0 through 14 (15 
total doses) during which behavior was measured (solid lines). PWT continued to be 
measured following drug discontinuation (dashed lines in (B)). An asterisk represents 
significant differences in PWT between treatment groups using two-way RM-ANOVA 
followed by post hot two-sample t-tests. 
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 Intraplantar ATP administration induces dose-dependent flinching of the injected 
paw 
 
Intradermal injection of purinergic receptor agonists induces dose-dependent 
overt nociceptive behavior in rats, as measured by hind paw lifting and licking activity 
[Bland-Ward Br J Pharmacol 1997]. Interestingly, estrogens have been shown to alter 
overt nociceptive responses to ATP [Ma Purinergic Signal 2011]. By depleting estradiol 
from blood and tissues, aromatase inhibitors may also be altering excitability of sensory 
neurons through similar mechanisms. To address this intriguing possibility, I first 
determined whether the findings of Ma et al. 2011 could be replicated. Specifically, I 
asked whether ovariectomy increases overt nociception following intraplantar injection of 
ATP. To evaluate the dose-dependency of ATP-induced overt nociception as measured 
by flinching, and effect of ovariectomy, OVX and intact female rats were administered 
100, 1,000 or 10,000 nmol ATP in an intradermal injection in the mid-plantar left hind 
paw. Following the injection, flinching of the injected paw was observed and counted 
during 1 minute intervals for 15 minutes. 
 
In response to intradermal administration of 100 nmol ATP, rats exhibited a small 
amount of flinching behavior that subsided by 10 minutes following the injections (Figure 
7A). Of the 7 animals administered 100 nmol ATP, the distribution of the total number of 
flinches was as follows: 0 (1 OVX, 1 intact), 1 (1 OVX), 2-3 (1 OVX, 1 intact), >3 (1 OVX, 
1 intact) (Figure 7D). These data suggested there was a small and variable effect on 
nociceptive responses to ATP at this dose. In comparison, intradermal administration of 
10,000 nmol ATP rapidly elicited a large number of flinches within the first minute 
following injection of the algogen. All animals injected responded with flinching behavior 
throughout the observation period that did not appear to diminish by 15 minutes (Figure 
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 7C). The two OVX rats tested responded with 75 and 81 cumulative flinches, whereas 
the intact females responded with 50 and 75 flinches (Figure 7D). Due to the large 
amount of nociceptive behavior induced by 10,000 nmol ATP, no more animals were 
evaluated at this dose. Due to limited observations in OVX and intact females at the 100 
and 10,000 nmol doses, cumulative nociceptive responses were not formally compared 
between these groups. 
 
Intradermal administration of 1000 nmol ATP rapidly elicited flinching behavior 
within the first minute following injection in 13 of 16 animals (Figure 7B). The 3 rats that 
did not immediately response to this dose were intact female rats. In 12 of the 16 rats, 
the flinching rate (flinches per minute) of the injected paw was maximal during the first 
two minutes following ATP injection. In OVX and intact female rats, flinching behavior 
declined during the observation period and subsided by 10 minutes (Figure 7B). 
Compared to intact females, OVX rats exhibited significantly more flinches 1 and 8 
minutes after ATP injection (Figure 7B). Furthermore, OVX rats exhibited greater 
cumulative nociceptive response to 1000 nmol ATP than intact females (Figure 7D). 
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Figure 7. ATP-evoked flinching is augmented in OVX rats. 
A, B and C: Each point represents the mean ± S.E.M. of flinches observed in one 
minute intervals after injection of 100 (A), 1,000 (B) or 10,000 nmol ATP (C) in OVX and 
intact female rats. An asterisk represents significant differences in the number of flinches 
observed in one-minute intervals between these groups using Mann-Whitney U tests. D: 
Cumulative hind paw flinches observed for ten minutes following ATP injections are 
presented as box plots for each ATP dose, with cumulative responses for each animal 
shown. The pound symbol indicates significantly different ATP-induced cumulative 
flinches between the groups using Mann-Whitney U tests. 
 
 
 
 
85 
 
 Aromatase inhibitors augment ATP-induced overt nociception 
 
Effects of chronic dosing of AIs on ATP-induced flinching 
To determine if AIs alter nociceptive behavior produced by intraplantar ATP 
injection, male rats were administered AIs or vehicle (HPβCD) daily for five days (i.p.), a 
time when letrozole-treated rats in our previous experiments had significantly lowered 
PWTs. The day following the last injection, we measured flinching in response to 1000 
nmol ATP injected in the rat hind paw (Figure 8A). In vehicle (750 mg/kg HPβCD; n = 
13) and letrozole-treated (5 mg/kg; n = 10) rats, flinching of the injected paw was 
observed within one minute following ATP injection (Figure 8B). The flinching rate 
(flinches per minute) in 19 of 23 rats was maximal during the first two minutes following 
ATP injection and declined rapidly during the observation period. In letrozole treated 
rats, significantly more flinches were observed 2, 4, 7, 8, and 10 minutes after ATP 
injection when compared to vehicle injected animals (Figure 8B). The letrozole treatment 
significantly augmented the cumulative ATP-induced flinches observed for 10 min after 
intraplantar injection of the nucleotide (Figure 8C). In a series of control experiments, 
male rats administered saline (n = 8) versus vehicle (750 mg/kg HPβCD; n = 13) daily for 
five days did not have different flinching behavior after injection of 1000 nmol ATP: The 
median (25th percentile, 75th percentile) of cumulative flinches measured for 10 minutes 
after ATP injection was 17 (9, 24) in saline treated animals versus 14 (6.5, 22) in vehicle 
treated animals (Figure 8C). In addition, flinching behavior in response to intraplantar 
PBS, the vehicle for intraplantar injections, was measured in male rats following 
administration of saline (n = 5), vehicle (750 mg/kg HPβCD; n = 5), or 5 mg/kg letrozole 
(n = 5) for five days. Cumulative flinching behavior measured for 10 min after PBS 
injection was not significantly different between these treatment groups (saline: 1 (0, 
4.5), vehicle: 1 (0, 3), and 5 mg/kg letrozole: 2 (0, 3)) (Figure 8C). 
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 In an analogous series of experiments, I evaluated whether a mechanism-based 
inhibitor of aromatase, exemestane could enhance ATP-induced nocifensive behavior 
(Giudici et al., 1988). Male rats were administered vehicle (1000 mg/kg HPβCD; n = 9) 
or 30 mg/kg exemestane (n = 7) daily for five days (i.p.). This dose was chosen because 
it likely produces substantial aromatase inhibition in rats [Giudici J Steroid Biochem. 
1988, Zaccheo Cancer Chemother Pharmacol. 1989] Twenty-four hours following the 
last injection, nociceptive behavior in response to an intraplantar injection of 1000 nmol 
ATP was measured (Figure 8A). The maximal flinching rate of all rats occurred within the 
first minute of observation and diminished during the 10-minute observation period. 
Flinching behavior in exemestane-treated rats (n=7) was greater than in those receiving 
vehicle (n=9) at 8, 9 and 10 minutes following ATP injection (Figure 8D). Cumulative 
flinching over the 10 min after intraplantar injection of 1000 nmol ATP was significantly 
greater in exemestane-treated rats when compared to vehicle treated animals (Figure 
8E).  
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 Figure 8. ATP-induced nocifensive behavior in male rats is augmented following 
five days of treatment with aromatase inhibitors. 
A: Depiction of the experimental design. B and D: Each point represents the mean ± 
S.E.M. of flinches observed in one minute intervals after injection of 1000 nmol ATP in 
rats treated for five days with letrozole, exemestane, vehicle, or saline as indicated. An 
asterisk represents significant differences in the number of flinches observed in one-
minute intervals between rats treated with AIs versus vehicle using Mann-Whitney U 
tests. C and E: Cumulative hind paw flinches observed for ten minutes following ATP 
injections are presented as box plots for each treatment group. Star symbols indicate 
significantly different cumulative flinches following intraplantar injections of 1000 nmol 
ATP versus PBS (0 nmol ATP), comparing rats administered the same systemic 
treatment (saline, vehicle, or letrozole; Mann-Whitney U tests). The pound symbol 
indicates significantly different ATP-induced cumulative flinches in vehicle-treated 
controls versus (C) letrozole and (E) exemestane-treated rats using the Mann-Whitney U 
test. 
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 A single dose of 5 mg/kg letrozole augments ATP-induced flinching 
My results demonstrate that the nociceptive response to intraplantar ATP in male 
rats is enhanced with repeated administration of aromatase inhibitors. I also examined 
the effect of a single dose of letrozole on ATP-induced flinching behavior. Male rats were 
treated with a single i.p. dose of vehicle (750 mg/kg HPβCD; n = 7) or 5 mg/kg letrozole 
(n = 6) and 3 hours following drug administration, flinching behavior in response to 
intraplantar injection of 1000 nmol ATP was observed for 10 minutes (Figure 9A). 
Flinching evoked by intraplantar ATP was significantly greater in letrozole-treated rats at 
1, 2, and 3 minutes after injection of the nucleotide (Figure 9B). Unlike the chronic 
dosing with letrozole, the ATP-induced flinching behavior returned to the level of those 
seen in the vehicle by 4 min.  A single dose of letrozole significantly augmented the 
cumulative number of ATP-induced flinches over 10 min compared to animals treated 
systemically with the vehicle (Figure 9C). 
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Figure 9. ATP-induced nocifensive behavior in male rats is augmented by a single 
dose of 5 mg/kg letrozole. 
A: Depiction of the experimental design. B: Each point represents the mean ± S.E.M. of 
flinches observed in one minute intervals after injection of 1000 nmol ATP, which was 
administered three hours after letrozole or vehicle treatment. An asterisk represents 
significant differences in the number of flinches observed in one-minute intervals 
between treatment groups using Mann-Whitney U tests. C: Cumulative hind paw flinches 
observed for ten minutes following ATP injections are presented as box plots for each 
treatment group. The pound symbol indicates significantly different ATP-induced 
cumulative flinches in rats treated with vehicle versus letrozole using the Mann-Whitney 
U test. 
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 Extracting and quantifying letrozole in rat tissues 
Any effect of letrozole to alter nociceptive responses in male and female rats may 
be a consequence of altered aromatase activity in tissues mediating pain transduction or 
perception, but whether letrozole distributes to cells comprising the peripheral and 
central nervous systems has not been described. Pharmacokinetic studies conducted by 
CIBA Geigy using 14C-labeled letrozole showed higher radioactivity in tissues (e.g. 
adrenals - 7.1 µg/g and liver – 2.2 µg/g) compared with plasma (0.6 µg/mL) five minutes 
after intravenous administration of 1 mg/kg to female rats (U.S. Food and Drug 
Administration, 1996). A separate study of letrozole pharmacokinetics in female Sprague 
Dawley rats showed initial plasma concentrations following intravenous administration of 
1 mg/kg were approximately 1 µg/mL (Tao et al., 2006). Tao et al. dissolved letrozole in 
hydroxypropyl-β-cyclodextrin, the same formulation I used for in vivo studies. Any 
influence of the vehicle on letrozole disposition would be represented in 
pharmacokinetics determined by Tao et al. An assay to measure letrozole 
concentrations in blood and tissues following a single dose of 1 mg/kg would optimally 
measure concentrations in this range. To determine whether letrozole could be 
quantified from rat serum and tissue (brain and DRGs) using a method validated in 
human plasma, standard curves were generated by spiking known concentrations of the 
drug into samples obtained from naïve male rats. Linearity of the extracted standard 
curves was compared with direct injection of these letrozole standards. Standards for 
direct injection were generated by evaporating solvent from 25 µL of letrozole (0 to 100 
µg/mL) and 50 µL of 1 µg/mL DMD added to Eppendorf tubes and reconstituting the 
compounds in 150 µL mobile phase. 
 
Figure 10 demonstrates representative chromatograms of letrozole and DMD 
following direct injection and extraction of the compounds from rat tissues. Direct 
92 
 
 injection of 208 ng letrozole (25 µg/mL standard) and 17 ng DMD on column resulted in 
two peaks in the chromatogram, with letrozole eluting at 17.5 minutes and DMD eluting 
at 27.5 minutes (Figure 10A). Note that while letrozole was also detected by absorbance 
(as seen at 17.5 minutes in the absorbance spectra in Figure 10A), however this method 
utilized fluorescence detection for letrozole quantification due to better signal-to-noise 
properties. Peaks corresponding to these compounds were also observed at the same 
retention times following extraction of the same amounts of letrozole and DMD from rat 
serum and DRGs (Figure 10B). Letrozole fluorescence from the 0.05 µg/mL standard 
(0.42 ng on column) was distinguishable from noise following direct injection and 
extraction from serum, however letrozole was less reliably detected at this concentration 
extracted from brain. The lowest standard extracted from DRGs was 0.1 µg/mL (0.83 ng 
on column), which gave a strong signal. Coefficients of variation (CV%) of AUC LET / AUC 
DMD less than 15% were obtained from direct injection and extraction from serum, brain, 
and DRGs from the 0.05, 0.05, 0.25, and 0.1 µg/mL standards, respectively, suggesting 
these may be lowest effective concentrations for future quantification. Peak integration 
ratios of letrozole to the internal standard (AUC LET / AUC DMD) resulting from direct 
injections and extraction from tissues increased linearly with increasing amounts of 
letrozole (Figure 11). Letrozole and DMD extraction efficiencies from serum, calculated 
as the percent of peak area observed in extracted tissue relative to direct injection at a 
given concentration, averaged 64% and 61% over the concentration range, resulting in a 
similar slope. Letrozole and DMD extraction efficiencies were higher in DRGs, averaging 
94% and 80%, also resulting in a similar slope. However, DMD was not as efficiently 
extracted from brain (average = 32%), resulting in larger AUC LET / AUC DMD ratios and a 
greater slope (Figure 11). R2 values of 0.99 obtained from least-squares linear 
regression suggest highly linear relationship between letrozole concentrations and 
detector response. 
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Figure 10. Chromatograms of letrozole and internal standard following direct 
injection and extraction from rat tissues. 
Typical chromatograms of letrozole and the assay internal standard 
(desmethyldiazepam; DMD) following HPLC separation and fluorescence detection for 
letrozole (excitation: 230 nm; emission: 295 nm) and UV-VIS detection of DMD (234 
nm; 0.1 AUFS). A: Fluorescence (mV) and UV-VIS (AUFS) detector response after 
direct injection of letrozole (25 µg/mL standard – 208 ng on column) and DMD (1 
µg/mL standard – 17 ng on column). B: Comparing fluorescence chromatograms for 
letrozole quantification from serum and DRGs harvested from two OVX rats three 
hours following intraperitoneal administration of either 1 mg / kg letrozole or vehicle 
(HPβCD). 
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Figure 11. Comparison of calibration curves for letrozole by direct injection and 
extraction from rat tissues. 
The relationship between peak integration ratios of letrozole to the internal standard 
(AUCLET / AUCDMD) determined by HPLC analysis is compared to letrozole 
concentrations achieved by spiking increased amounts of letrozole in HPLC buffer 
(direct injection), serum, and tissue homogenates. Each point represents the mean ± 
standard deviation of triplicate measurements. 
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 Letrozole concentrations in the serum, brain and dorsal root ganglia following 
intraperitoneal administration to ovariectomized and intact female rats 
 
To determine letrozole concentrations achieved in the brain and DRGs of rats 
following i.p. administration of the drug, intact and OVX rats were administered either 1 
mg/kg letrozole (N = 4 per group) or vehicle (N = 2 per group). Using a dense sampling 
strategy within 5 hours of an oral dose of 0.5 mg/kg letrozole, Tao et al. observed that 
maximum plasma concentrations of the drug (Cmax) were achieved 1.5 hours after 
dosing. Thus, serum, brain, and DRGs were isolated at 0.5 hours or 3 hours following 
drug administration. To understand the terminal elimination characteristics of the drug 
from the circulation, another group of OVX rats (N = 9) were administered 1 mg/kg 
letrozole and serum was isolated 3, 4, and 21 days following drug administration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
  
 
Figure 12. Letrozole concentrations in serum, brain, and DRGs following drug 
administration to OVX and intact female rats. 
Following administration of 1 mg/kg letrozole to OVX and intact female rats, animals 
were sacrificed 0.5, 3, 72, or 96 hours post-dose and tissue samples were collected. A, 
B, and C: Letrozole concentrations measured in serum (A), brain homogenate (B) and 
DRG homogenate (C) samples from each animal are shown, along with the median 
concentration at each time point. D: Correlation between serum and tissue 
concentrations of letrozole. Coefficients of determination (r2) were calculated using 
letrozole concentrations measured in serum and tissue from OVX and intact female rats. 
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 Letrozole was observed in serum within 30 minutes of i.p. administration, 
suggesting rapid absorption of the drug into the bloodstream from the intraperitoneal 
cavity. When compared to intact females, serum concentrations achieved at 30 minutes 
and 3 hours in OVX females appeared higher, although the mean difference could not 
be reliably determined given the small number of samples in each group (Figure 12a). In 
both groups, concentrations at 30 minutes and 3 hours were comparable, which is 
consistent with Cmax occurring between these two time points or potentially little change 
in serum concentrations during this time. While sparse sampling time points were not 
sufficient for precise characterization of serum elimination, concentrations measured 3 
and 4 days (72 and 96 hours) following letrozole administration are consistent with slow 
clearance of the drug (Figure 12a). At 21 days following administration of letrozole to 
OVX rats, letrozole was undetectable in the serum. Using serum letrozole concentrations 
from only the OVX rats, the elimination half-life was estimated to be 26 hours, based on 
the slope obtained from a least-squares linear regression of natural log transformed 
concentrations versus time. 
 
Letrozole concentrations measured in the brain and DRGs of intact and OVX 
females followed a similar concentration-time profile as serum concentrations, however 
brain concentrations were higher than serum concentrations (Figure 12b,c). Assuming 
the density of brain and DRGs in rodents is approximately 1 g/mL (Leithner et al., 2010), 
the ratio of median brain concentrations to median serum concentrations measured at 
0.5 and 3 hours was 1.4 and 1.2 in OVX rats and 1.1 at both time points in intact rats. 
This ratio rose to 2.6 in OVX rats 96 hours after letrozole administration. Thus, letrozole 
concentrations achieved in the brain exceed serum concentrations throughout its 
duration in the body following an i.p. dose. Additionally, there was a strong correlation 
between serum and brain concentrations of letrozole, suggesting rapid equilibrium is 
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 reached between these tissues and the brain’s capacity to bind the drug is not saturated 
at these concentrations (Figure 12d). In contrast, the ratio of median DRG 
concentrations to median serum concentrations measured at 0.5 and 3 hours was 0.4 
and 0.5 in OVX rats and 0.5 and 0.7 in intact rats. The correlation between letrozole 
concentrations in the serum and DRGs was weak, suggesting that the binding capacity 
of DRG tissue has been reached at the observed concentrations (Figure 12d). These 
data suggest differential distribution of the AI to these tissues. 
 
CYP19A1 mRNA transcripts and aromatase protein are expressed in DRG neurons 
in culture 
 
Validating conditions for the relative quantification of target and control genes 
using Applied Biosystems TaqMan® gene expression assays 
Utilizing the comparative CT method (also known as the ∆∆CT method) for 
quantifying the relative expression of two genes in a biological sample requires two 
method validation steps. The first validation step is to empirically determine the range of 
input mass RNA in the reverse transcription (RT) reaction that results in a linear 
amplification of target and reference genes during RT-PCR, also known as the dynamic 
range of RT. If there are no factors altering the efficiency of the RT reaction for both 
mRNA targets, a plot of log10(input RNA amount) versus ΔCT (CT,target – CT,reference) has a 
slope of approximately zero. Non-linear relationships may occur with large amounts of 
input RNA due to interference of agents used in RNA purification and inhibitory 
compounds native to biological samples. To determine the dynamic range of RT, I 
generated RNA dilution curves by varying amounts of input RNA in the RT reaction. 
Total RNA pools were generated by extracting and pooling equal amounts of RNA from 
tissues isolated from three rats: rat ovaries obtained from intact female rats, freshly 
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 dissected DRGs isolated from male rats, and DRG cells from male rats maintained in 
culture for 12 days (supplemented with 30 ng/mL NGF). Equal amounts (ng) of RNA 
from samples comprising each pool were combined and diluted to a final concentration 
of 100 ng/µL. Serial dilutions of 100, 50, 25, 12.5 and 6.25 ng/µL were prepared and 10 
µL of each dilution was used as input in a 20 µL RT reaction. Final cDNA pools were 
made by adding 70 µL of nuclease-free water (11.1, 5.55, 2.78, 1.39, and 0.694 ng/µL) 
and RT- PCR of CYP19A1 and GAPDH (reference gene) was performed using 9 µL of 
each cDNA pool in 20 µL reactions (in triplicate). Figure 13 demonstrates there is little 
variation in ∆CT (CT,CYP19A1 – CT,GAPDH) with increasing amounts of total RNA input into the 
RT reaction. These results suggest the reverse transcription and PCR amplification of 
the two mRNA transcript targets are not differentially affected by impurities present in up 
to 100 ng RNA and support using this amount of total RNA for RT-PCR analysis. 
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Figure 13. Determining the dynamic range of reverse transcription. 
Total RNA isolated from DRGs, DRGs in culture, and ovaries were serially diluted, 
converted to cDNA, and used in real-time PCR of CYP19A1 and GAPDH. ∆CT 
(CT,CYP19A1 - CT,GAPDH) was calculated at each RNA dilution using the mean CT from 
triplicate reactions. For each tissue, the slope was determined using linear least-
squares regression analysis. 
 
 
 
 
 
 
 
101 
 
 For the comparative C
T 
method of relative quantitation to be valid, the 
amplification efficiency of the target and reference genes must be approximately equal. 
For this experiment, the expression level of the target and reference genes (CT) is 
determined from serially diluted cDNA, ideally over 5 logs (i.e. 100 ng to 10 pg). If the 
efficiencies of the two PCR reactions are equal, a plot of log10(input RNA amount) versus 
ΔCT has a slope of approximately zero. As shown in Figure 13, CYP19A1 CT values in 
DRGs (33.85 ± 0.30; mean ± S.D.) and DRG cultures (30.36 ± 0.15) measured with 100 
ng of input cDNA suggest low expression levels in these tissues. Therefore, RT-PCR of 
CYP19A1 and GAPDH were performed using 100 to 1 ng of cDNA prepared by serial 
dilution. Using mRNA isolated from freshly dissected DRGs isolated from male rats, 
differences in amplification efficiency between the two targets were noted at cDNA input 
less than 30 ng, as indicated by a deviation in ∆CT (CT,CYP19A1 – CT,GAPDH). CYP19A1 was 
undetectable in 1 ng of cDNA template from DRGs (as indicated by the lack of ∆CT data 
at 1 ng in Figure 14a), suggesting the lower limit of detection of CYP19A1 mRNA had 
been reached. However, amplification of GAPDH in DRGs was highly efficient across 
this range of input cDNA, with calculated efficiencies of 82 – 86% (efficiency = 10(-1/slope) 
– 1) (Figure 14c). Similarly, differences in amplification efficiency between the two 
targets were also observed using less than 30 ng of cDNA produced from DRGs 
maintained in culture for 12 days (supplemented with 30 ng/mL NGF) (Figure 14b). 
Amplification of GAPDH in DRGs maintained in cultures was highly efficient across this 
range of input cDNA (Figure 14d. Given the low expression of CYP19A1 relative to 
GAPDH in these tissues, these results suggest the highest amount of input RNA should 
be used in any experiments utilizing the ∆∆CT method to estimate fold-differences in 
CYP19A1 mRNA expression between samples. Furthermore, accurate quantification of 
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 reduced CYP19A1 mRNA expression may be not be feasible in these tissues without 
prior targeted amplification. 
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Figure 14. Determining the efficiency of real-time PCR amplification of CYP19A1 
and GAPDH. 
Serial dilutions of cDNA synthesized from DRGs and DRGs in culture was used in real-
time PCR of CYP19A1 and GAPDH. A and B: Each point represents the mean ± S.D. of 
∆CT (CT,CYP19A1 - CT,GAPDH) calculated from triplicate reactions at each cDNA dilution. C 
and D: Each point represents the mean CT for GAPDH at each cDNA dilution. For each 
sample, the slope and r2 was determined using linear least-squares regression analysis. 
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 Aromatase expression in dorsal root ganglia persists in sensory neuron cultures 
 
To address whether sensitization of primary sensory neurons by AIs may 
contribute to AI-induced hypernociception, I determined if aromatase is expressed in 
DRGs or the spinal cord and whether aromatase expression is maintained in sensory 
neuron cultures. Specifically, aromatase immunoreactivity and beta-actin 
immunoreactivity was determined in total protein lysates from pooled cranial, thoracic, 
lumbar, and sacral DRGs isolated from independent male rats (75 µg total protein), 
independent cultures of male rat DRGs maintained in F12 media (supplemented with 30 
ng/mL NGF and 10% horse serum) for 12 days (63 to 75 µg total protein), and ovaries 
isolated from two different female rats (25 µg total protein). Aromatase immunoreactivity 
and beta-actin immunoreactivity was additionally determined in total protein lysates from 
spinal cords isolated during DRG harvests from the male rats in the combined 
experiment (150 µg total protein), plantar foot pads isolated with sterile 6mm biopsy 
punch (150 µg total protein), and independent ovary samples (25 µg total protein). 
 
Proteins lysates were separated in NuPAGE Bis-Tris (4-12%) gels and proteins 
were transferred to a PVDF membrane overnight at 4°C. After blocking the membrane in 
5% milk, aromatase immunoreactivity was determined by incubating the membranes in 
mouse anti-aromatase antibody overnight at 4°C (1:250 dilution in blocking buffer). The 
membrane was washed and then incubated with a HRP-conjugated anti-mouse 
secondary antibody (1:5,000 in blocking buffer) for one hour at room temperature. After 
washing the membrane again, immunoreactivity detected using Western Lightning® 
Plus-ECL substrate.  
 
105 
 
 An immunoreactive band at approximately 55kDa, corresponding to the expected 
molecular weight of aromatase was evident in DRG lysates from all male rats (Figure 
15A). In contrast, no immunoreactive bands were observed in lysates from sensory 
neuron cultures, suggesting aromatase expression in cells composing the DRG is 
downregulated when dissociated and grown in culture (Figure 15a). As a positive 
control, immunoreactive bands of similar molecular weights were detected in total 
protein lysates from independent rat ovaries, however the molecular weight of 
aromatase in the second ovarian sample appeared slightly larger (Figure 15A, lane 9). 
The difference did not appear to be due to differences in the gel between these lanes, as 
actin immunoreactive bands were identical between samples. Despite the relatively large 
amount of tissue lysates used in the experiment, aromatase immunoreactivity was not 
observed in lumbar spinal cord lysate or plantar skin of the foot pad under these 
conditions (Figure 15B). 
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Figure 15. Aromatase is differentially expressed in DRGs, spinal cord, glabrous 
hind paw skin and ovaries from male and female rats. 
A: Immunoblot of total protein isolated from DRGs of three male rats, sensory neuron 
cultures from three male rats maintained for 12 days, and rat ovaries (100 µg of total 
protein was loaded for DRG and sensory culture lysates, whereas 50 µg of total 
protein was loaded for ovary lysate). B: Immunoblot of total protein isolated from 
spinal cords and glabrous hind paw skin lysates from three male rats and ovary 
lysates used in (A). 150 µg of total protein was loaded from spinal cord and hindpaw 
skin lysates, whereas 50 µg of total protein was loaded for ovary lysates. Membranes 
were probed with anti-aromatase and anti-actin antibodies. 
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 The lack of observable aromatase immunoreactivity in sensory neuron cultures 
may be due to very low expression levels of the enzyme. To enable the detection of 
potentially low levels of aromatase protein in sensory neuron cultures, aromatase 
immunoreactivity was determined using the western procedure optimized for an ultra-
sensitive chemiluminescent substrate. Aromatase immunoreactivity was again compared 
between lysates of pooled DRGs (cranial, thoracic, lumbar and sacral) isolated from 
independent male rats (100 µg total protein), independent cultures of male rat DRGs 
(100 µg total protein), and ovaries isolated from two different female rats (50 µg total 
protein). Using the enhanced ECL solution, aromatase was detected in all tissue lysates 
(Figure 16), suggesting low levels of aromatase expression in DRG neurons in culture. 
Furthermore, aromatase immunoreactivity was observed in all three cultures at similar 
expression levels. This expression pattern resembled consistent aromatase expression 
among DRG lysates from different rats (Figure 15A and Figure 16). Interestingly, 
aromatase immunoreactive bands in the sensory neuron cultures appeared at slightly 
higher molecular weight than in the whole DRG lysates. These differences in aromatase 
molecular weight were also observed in the two ovarian lysates, suggesting the higher 
molecular weight isoform is expressed after placing cells of the DRGs in culture. 
Furthermore, these two isoforms may be expressed in a single tissue, such as the 
ovaries. 
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Figure 16. Aromatase expression in DRGs persists in dissociated DRG cultures. 
Immunoblot of total protein isolated from DRGs of male rats, sensory neuron cultures 
from male rats maintained for 9 days, and rat ovaries (100 µg of total protein was 
loaded for DRG and sensory culture lysates, whereas 50 µg of total protein was 
loaded for ovary lysate). Sensory neurons in culture were isolated from cranial, 
thoracic, lumbar, and sacral DRGs; acutely isolated DRGs were also taken from these 
ganglia. Protein samples were isolated from independent rats or DRG cultures. 
Membrane was probed with anti-aromatase and anti-actin antibodies. 
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 To determine whether aromatase expression is maintained throughout the time 
DRG cells are in culture, aromatase immunoreactivity was compared between acutely 
dissociated DRG cells and DRG cells maintained in culture for 1, 4, 7, and 12 days. 
DRGs from two male rats were harvested, triturated, and re-suspended in F12 media 
supplemented with 10% horse serum and 30ng/mL NGF. Cells were plated in five 35 
mm culture dishes at a density of 60,000 cells per well, with cells from each rat cultured 
independently. Following 1, 4, 7 and 12 days in culture, cells from one culture dish from 
each animal were collected and processed as described in the methods, and stored at -
80°C. Using the modified western blot procedure for detecting aromatase 
immunoreactivity in sensory neuron cultures, immunoreactive bands corresponding to 
the molecular weight of aromatase were observed in 50 µg of total protein lysate from all 
samples (Figure 17A). This suggests that aromatase expression is maintained at low 
levels in culture and its expression level is relatively consistent throughout. Normalizing 
aromatase immunoreactivity to that of two internal controls, actin and HPRT, suggested 
some variability in aromatase expression between cultures. Sources of variability may be 
technical variability between cultures or inter-animal variability in expression of the 
proteins examined.  Normalized aromatase expression in sensory neuron culture one 
decreased with length in culture, while normalized expression in the second culture 
suggested an increase over time (Figure 17B). 
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Figure 17. Aromatase is expressed throughout the duration of DRG cultures. 
A: Immunoblot of total protein isolated from independent sensory neuron cultures 
derived from male rats and ovary lysates (50 and 25µg total protein loaded for culture 
and ovary lysates, respectively). Total protein was isolated from neuronal cultures 
after 1, 4, 7, or 12 days in culture. Membrane was probed with anti-aromatase, anti-
actin, and anti-HPRT antibodies. B: Data represent the density ratios of aromatase 
and actin or HPRT immunoreactive bands observed in (A), quantified by densitometry 
analysis.  
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 The presence of aromatase in the immunoreactivity in lysates from DRGs 
isolated from all levels of the spinal column does not demonstrate whether aromatase is 
selectively expressed in one or more of these structures. Therefore, to determine 
whether aromatase is expressed in DRGs containing sensory neurons that innervate the 
rat hind limbs, aromatase immunoreactivity was determined in lumbar 4, 5, and 6 (L4-6) 
DRGs. Furthermore, to determine whether aromatase is also expressed in DRGs from 
OVX females, total protein lysates of L4-6 DRGs (isolated bilaterally) isolated from three 
male rats and three OVX female rats (100 µg total protein) were separated in a 
polyacrylamide gel, along with ovaries isolated from two different female rats (25 µg total 
protein). Following overnight transfer to a PVDF membrane (at 4°C), the membrane was 
blocked and aromatase immunoreactivity was determined by incubating the membranes 
in mouse anti-aromatase antibody overnight at 4°C (1:250 dilution in blocking buffer). 
The membrane was washed and then incubated with a HRP-conjugated anti-mouse 
secondary antibody (1:5,000 in blocking buffer) for one hour at room temperature. After 
washing the membrane again, immunoreactivity detected using Western Lightning® 
Plus-ECL substrate. As seen in Figure 18, immunoreactive bands were observed in L4-6 
DRGs isolated from both male and female rats. When normalized to actin, aromatase 
immunoreactivity was several fold higher in OVX females when compared to males. 
Immunoreactive bands appearing in the male DRGs appeared to be of slightly higher 
molecular weight than those appearing in DRGs from OVX females, suggesting there 
may be several aromatase isoforms.  
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Figure 18. Aromatase is expressed in L4-6 DRGs from OVX female and male 
rats. 
Immunoblot of total protein isolated from L4-6 DRGs from three OVX female rats and 
three male rats, in addition to ovary lysates (100 and 50 µg total protein was loaded 
for DRG and ovary lysates, respectively). Membrane was probed with anti-aromatase 
and anti-actin antibodies. 
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 Effect of the aromatase inhibitor letrozole on release of the calcitonin gene-related 
peptide from sensory neurons in culture 
 
In sensory neuron cultures from OVX rats, capsaicin-stimulated iCGRP release is 
not sensitized by long-term letrozole exposure (10 pM to 1 µM) 
One mechanism that could mediate AI-induced hypersensitivity is the ability of 
the drugs to augment transmitter release from small diameter sensory neurons that 
conduct noxious information. Consequently, I conducted a series of studies examining 
whether acute or long-term exposure to letrozole would increase the basal or stimulated 
release of CGRP from sensory neurons in culture. For my initial studies, cells were 
stimulated with the TRPV1 agonist, capsaicin. In rat DRG cultures, capsaicin activates 
an inward current carried predominately by sodium and calcium ions and stimulates the 
release of CGRP in a concentration-dependent manner (Dymshitz and Vasko, 1994; 
Hingtgen and Vasko, 1994). Given the pattern of TRPV1 in rat DRGs and DRG cultures, 
CGRP released from DRG cultures following capsaicin exposure originates from the 
approximately 50% of TRPV1-expressing small diameter sensory neurons that also 
express CGRP (Price and Flores, 2007). 
 
Neuronal cultures were prepared from DRGs isolated from OVX female rats and 
maintained in F12 media for 12 days, supplemented with 30 ng/mL NGF. To determine 
whether letrozole might sensitize sensory neurons to capsaicin stimulation in a 
concentration-dependent manner, cells were treated with letrozole (10 pM to 1 µM) or 
vehicle (1:10,000 dilution of MPL) daily for the last five days in culture and then release 
experiments were performed. The cultures were washed in HEPES buffer for 10 minutes 
and then re-exposed to the drug or vehicle for 10 minutes prior to and throughout 
exposure to 30 nM capsaicin. Basal release of iCGRP was not altered by letrozole 
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 concentrations up to 1 µM (Figure 19A). Although exposing sensory neuron cultures to 
30 nM capsaicin resulted in over 15-fold increase in peptide release over release in 
HEPES buffer alone (Figure 19A, vehicle control), treatment with letrozole did not alter 
stimulated iCGRP release (Figure 19A). The content of iCGRP in sensory neuron 
cultures exposed to letrozole for five days was not significantly different from vehicle-
treated cultures (Figure 19B). 
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Figure 19. Release of iCGRP is not altered in sensory neurons from OVX rats after 
five days of letrozole exposure. 
A: The ordinate represent the mean ± S.E.M. release of iCGRP as percent of total 
content per well. Cells were treated with vehicle, 10 pM, 1nM, 100nM or 1 µM letrozole 
for five days prior to measuring iCGRP release then were exposed to vehicle or the 
same concentration of letrozole in the absence (Basal) or presence of 30 nM capsaicin. 
Within each treatment group, a cross indicates a significant difference in capsaicin-
stimulated release from basal release. B: Total iCGRP content measured from each 
treatment group. 
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 10µM letrozole sensitizes capsaicin-stimulated iCGRP release from sensory 
neuron cultures isolated from OVX rats, but not cultures from intact female or 
male rats 
When administered letrozole, OVX female rats and male rats developed 
mechanical hypersensitivity to stimulation with von Frey filaments. While basal or 
capsaicin-stimulated iCGRP release from DRG cultures from OVX rats was not altered 
by letrozole concentrations up to 1 µM, the average letrozole concentration achieved in 
DRG neurons following a single dose of 1 mg/kg to OVX females was approximately 
1000 pg/mL (3.5 µM) (Figure 12). Drug concentrations were measured at 0.5 and 3 
hours following drug administration and it is therefore unclear whether the observed 
concentrations approximate the maximum concentrations achieved in this tissue. In fact, 
following letrozole administration to female rats, the time at which maximum 
concentrations are achieved in the brain have been shown to lag behind maximum 
concentrations measured in plasma (Liu et al., 2000).  
 
Neuronal cultures were prepared from DRGs isolated from OVX, intact female, 
and male rats and maintained in F12 media for 12 days, supplemented with 30 ng/mL 
NGF. Basal and capsaicin-stimulated iCGRP release was compared between cultures 
prepared from ovariectomized versus intact female rats to determine whether there are 
differences in sensitivity to either stimulus following ovariectomy. To mimic the effect of 
higher tissue letrozole concentrations, neuronal cultures were treated with 10 µM 
letrozole or vehicle (1:10,000 dilution of MPL) daily for five days and then release 
experiments were performed. The effect of acute letrozole exposure was determined 
using cells treated for five days with vehicle (1:10,000 dilution of MPL). The cultures 
were washed and then treated with vehicle (1:10,000 dilution of MPL) or 10 μM letrozole 
for 10 min to prior to and throughout exposure to 30 nM capsaicin.   
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 In cultures derived from male, female, and OVX female rats, basal release of 
iCGRP was not altered following acute (10 min) or long-term (5 days) exposure to 10 µM 
letrozole (Table 2). There were no differences in basal peptide release among the 
different culture types, irrespective of treatment. Exposing sensory neuron cultures to 30 
nM capsaicin resulted in a significant increase in iCGRP release from baseline in all 
culture types (difference of 6.1% to 9.4% from baseline; Table 2). In cultures from OVX 
rats exposed to letrozole, capsaicin-stimulated iCGRP release (as percent of total 
iCGRP) was significantly increased by 2.6 percentage points (vehicle: 9.9% ± 0.0%, 10 
µM letrozole: 12.5% ± 0.0%; Table 2). Five days of letrozole exposure similarly 
increased iCGRP release in response to capsaicin, with an absolute difference of 1.6% 
relative to cells exposed to vehicle for five days (Table 2). Capsaicin-stimulated iCGRP 
release was also enhanced by acute letrozole treatment in cultures from male rats, with 
an absolute difference of 0.8% from vehicle-treated cells (Table 2). In contrast to OVX 
cultures, long-term exposure to letrozole did not enhance capsaicin-stimulated peptide 
release in male cultures. 
 
A secondary analysis of capsaicin-stimulated release between the culture types 
treated with vehicle showed capsaicin-stimulated release was significantly higher in OVX 
cultures compared to cultures derived from intact female and male rats (one-way 
ANOVA followed by two-sample t-tests; Table 2). Total iCGRP content in vehicle-treated 
cultures from intact females were significantly higher than OVX and male cultures (one-
way ANOVA followed by two-sample t-tests; Table 2), which may account for differences 
when data are presented as percent of total content. However, capsaicin-stimulated 
release from OVX cultures was significantly higher when femtomoles of iCGRP released 
were compared (mean ± S.E.M: OVX: 193 fmol ± 7, Intact: 169 fmol ± 7, Male: 142 fmol 
± 6). Capsaicin-stimulated iCGRP release was also higher in OVX cultures than intact 
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 female or male cultures treated with letrozole (acute or long-term) (Table 2). Additionally, 
total iCGRP content was significantly higher in cultures from intact female rats compared 
to the other culture types irrespective of vehicle or letrozole treatment (Table 2). 
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 Table 2. Comparing the effect of letrozole on basal and capsaicin-stimulated 
release of iCGRP from rat sensory neuron cultures isolated from male, OVX 
female, and intact female rats. 
 
 5 days  pre-treatment: Vehicle Vehicle 10 µM letrozole 
 Acute treatment: Vehicle 10 µM letrozole 10 µM letrozole 
Basal 
iCGRP 
release 
OVX female 0.5 ± 0.0 0.6 ± 0.1 0.6 ± 0.1 
Intact female 0.3 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 
Male 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 
iCGRP release 
stimulated by 
30 nM capsaicin 
OVX female 9.9 ± 0.0 † 12.5 ± 0.0 †,* 11.5 ± 0.0 †,* 
Intact female 6.4 ± 0.2 † 6.8 ± 0.4 † 6.9 ± 0.2 † 
Male 6.8 ± 0.2 † 7.6 ± 0.3 †,* 7.4 ± 0.6 † 
Total iCGRP 
content (fmol) 
OVX female 1979 ± 79 1895 ± 95 1999 ± 95 
Intact female 2667 ± 163 2479 ± 191 2451 ± 107 
Male 2082 ± 82 2117 ± 78 1946 ± 109 
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 Cells were treated for 5 days prior to measuring iCGRP release (pre-treatment) 
and additionally treated during the experiment to measure basal and stimulated iCGRP 
release (acute treatment). iCGRP release was measured from sequential 10-minute 
incubations during which cells were exposed to HEPES buffer in the presence of the 
indicated acute treatment (basal release), then 30nM capsaicin in the presence of the 
indicated acute treatment (stimulated release). Basal and stimulated iCGRP release are 
presented as the mean ± S.E.M. of iCGRP released as percent of total content per well 
(N=6-12 per condition). Total iCGRP content is the sum of iCGRP released during the 
experiment and remaining iCGRP measured from cells lysed with 0.1N HCl. Total 
iCGRP content is represented as mean ± S.E.M. femtomoles (fmol) of iCGRP per well 
(N=6-12 per condition). Crosses indicate enhanced iCGRP release stimulated by 30 nM 
capsaicin relative to basal release. Asterisks indicate significant difference in capsaicin-
stimulated iCGRP release in the presence of the indicated treatment versus vehicle-
treated controls. 
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 Letrozole does not sensitize iCGRP release from sensory neuron cultures isolated 
from OVX rats following serum deprivation 
While 10 µM letrozole sensitized DRG cultures derived from OVX rats, this effect 
was generally not observed in the other cultures (intact female and male) and there was 
no apparent concentration-dependent effect. Sensory neuron cultures used for 
experiments described in Figure 19 and Table 2 were maintained in F12 media, 
supplemented with 30 ng/mL NGF and 10% horse serum. Steroids present in the horse 
serum (collected from a donor herd, per manufacturer’s specifications) may include 
estrogens or high concentrations of androgens that could be metabolized to estrogens 
by aromatase, thereby masking our ability to detect changes in iCGRP release 
secondary to aromatase inhibition. To evaluate whether the effect of letrozole could be 
determined using DRG cultures maintained in serum-free conditions, I first evaluated the 
effect of serum deprivation on basal and capsaicin-stimulated iCGRP release, as well as 
total iCGRP content. Cells were maintained in 12-well plates in F12 media 
(supplemented with 30 ng/mL NGF and 10% horse serum) that was changed the day 
following DRG harvest (day 1) and every other day. On culture day 9, media in 3 wells 
was exchanged for F12 media, supplemented with only 30 ng/mL NGF, while the other 9 
wells received F12 media, supplemented with 30 ng/mL NGF and 10% horse serum. On 
culture days 10 and 11, media was changed for all wells and an additional 3 wells 
received F12 media, supplemented with only 30 ng/mL NGF. Cells receiving media 
without serum were maintained in serum-free conditions until the release experiment.  
 
Maintaining DRG cultures in serum-free conditions for 48 and 72 hours resulted 
in a significant increase in basal and capsaicin-stimulated iCGRP release when 
compared to cells maintained in 10% serum (Figure 20A). Capsaicin-stimulated iCGRP 
release was also augmented by 24 hours of serum-free conditions, however, basal 
122 
 
 release was not different from controls (Figure 20A). Additionally, iCGRP content in DRG 
cultures was sensitive to serum deprivation. As shown in Figure 20B, serum deprivation 
significantly reduced the total iCGRP content in cultured sensory neurons, with 
significant reductions in cells grown in serum-free conditions for 48 and 72 hours.  
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Figure 20. Capsaicin-stimulated release of iCGRP is augmented and iCGRP 
content is reduced in sensory neuron cultures maintained in the absence of 
serum 
A: The ordinate represent the mean ± S.E.M. release of iCGRP as percent of total 
content per well. Cells were maintained in serum free media for 0, 24, 48, or 72 hours 
prior to measuring iCGRP release (indicated above the bar graphs) in the absence 
(Basal; open columns) or presence of 30 nM capsaicin (hatched columns). Within each 
treatment group, a cross indicates a significant difference in capsaicin-stimulated release 
from basal release. An asterisk indicates a significant difference in basal release, 
whereas and double asterisks indicate a significant difference in capsaicin-stimulated 
release in serum-deprived cells compared to controls. B: Total iCGRP content measured 
from each treatment group following the release experiment. An asterisk indicates a 
significant difference in total content in serum-deprived cells compared to controls. 
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 To evaluate whether 10µM letrozole alters iCGRP release from sensory neurons 
in serum-free conditions, cells were initially maintained in F12 media, supplemented with 
30 ng/mL NGF and 10% horse serum. On culture day 11, media was exchanged for F12 
media, supplemented with only 30 ng/mL NGF, and treated with 10 µM letrozole or 
vehicle (1:10,000 dilution of MPL). After 24 hours in culture, basal and capsaicin-
stimulated iCGRP release was measured with letrozole or vehicle treatments maintained 
during the release experiment. As shown in Figure 21, iCGRP release stimulated by 30 
nM capsaicin was not sensitized by 10 µM letrozole in neuronal cultures maintained in 
the absence of serum, suggesting horse serum may not significantly influence the effect 
of letrozole on this endpoint. 
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Figure 21. Letrozole does not alter basal or capsaicin-stimulated iCGRP release 
from sensory neuron cultures maintained for 24 hours in serum-free media 
Sensory neurons were maintained in serum-free media for 24 hours prior to 
measuring peptide release. Cells were treated with vehicle or 10 µM letrozole for 24 
hours prior to measuring iCGRP release (indicated above the bar graphs) and then 
were exposed to vehicle or 10 µM letrozole in the absence (BASAL; open columns) or 
presence of 30 nM capsaicin (hatched columns). Within each treatment group, a cross 
indicates a significant difference from basal release. 
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 Letrozole does not sensitize iCGRP release from sensory neuron cultures isolated 
from male rats, grown in phenol-red free conditions 
In addition to the potential influence of exogenous steroids present in horse 
serum, F12 media contains the pH indicator dye phenol red, a known estrogen receptor 
agonist that is also a non-competitive antagonist of P2X channels [Berthois Proc Natl 
Acad Sci U S A 1986; King Br J Pharmacol 2005]. To determine whether letrozole alters 
basal or stimulated release of iCGRP in sensory neurons maintained in the absence of 
phenol red, dissociated DRG neuronal cultures were maintained in DMEM-F12 media. 
As described in the methods, antibiotics and mitotic inhibitors were added at the same 
concentrations as used in F12 media and DMEM-F12 media was supplemented with 
10% horse serum and 30 ng/mL NGF. Since mechanical hypersensitivity was observed 
in letrozole-treated animals and CGRP has been localized to TRPV1+ and TRPV1- 
mechano-sensitive DRG neurons, the effect of letrozole on non-selective stimulation of 
iCGRP release from neurons with high extracellular potassium was determined and 
compared to the effect of letrozole on capsaicin-stimulated iCGRP release. 
 
In contrast to capsaicin, high extracellular concentrations of potassium ions result 
in non-selective depolarization of all neurons in a concentration-dependent manner. 
While raising the extracellular potassium concentration evokes depolarization in all 
neurons, depolarization of large diameter neurons that express tetrodotoxin-sensitive 
sodium channels does not generate action potentials, presumably due to depolarization 
block. On the other hand, K+-evoked depolarization generated action potentials in slowly 
conducting nociceptors expressing tetrodotoxin-resistant sodium channels (Jeftinija et 
al., 1993). Thus, it is expected that high extracellular potassium concentrations will 
stimulate the release of CGRP from small diameter neurons expressing this 
neuropeptide. 
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 In preliminary experiments, sensory neuron cultures grown in DMEM-F12 media 
developed grape-like clusters of small, round inclusions when cells were maintained for 
more than 9 days. The inclusions appeared to be a result of degradation of the 
laminin/poly-D-lysine substrate. While these changes did not appear to alter neuron or 
support cell morphology, iCGRP release experiments with DRG neurons maintained in 
DMEM-F12 were performed no later than 9 days after harvesting and plating the cells.  
 
At 72 hours preceding the release experiment, cells were exposed to 10 µM 
letrozole or vehicle (1:10,000 dilution of MPL) by direct addition to the culture media. At 
48 and 24 hours prior to the experiment, media was exchanged containing 10 µM 
letrozole or vehicle. Thus, cells were exposed to the drug or vehicle for 3 days. The 
cultures were washed and then treated with vehicle (1:10,000 dilution of MPL) or 10 μM 
letrozole for 10 min prior to and throughout exposure to 30 nM capsaicin or HEPES 
buffer containing 30 mM KCl. As a positive control for augmentation of capsaicin and 
KCl-stimulated iCGRP release, additional cells in each experiment were treated with 1 
µM PGE2.   
 
Although exposing sensory neuron cultures to 30 nM capsaicin or 30 mM KCl 
resulted in an 8-fold increase in peptide release over release in HEPES buffer, treatment 
with 10 µM letrozole did not alter basal or stimulated iCGRP release (Table 3). Acute 
exposure of neuronal cultures to PGE2 sensitized iCGRP release in response to both 
depolarizing stimuli (Table 3).  The content of iCGRP in sensory neuron cultures 
exposed to 10 µM letrozole acutely (560 ± 26 fmol/well) or chronically (606 ± 23 
fmol/well) was not significantly different from vehicle-treated cultures (588 ± 19 fmol/well) 
(Table 3). 
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 Table 3. Basal and stimulated release of iCGRP from male rat sensory neuron 
cultures treated with 10µM letrozole. 
 
3 days pre-
treatment: 
 
Acute treatment: 
Vehicle 
 
Vehicle 
Vehicle 
 
10 µM 
letrozole 
10 µM 
letrozole 
 
10 µM 
letrozole 
Vehicle 
 
1 µM 
PGE2 
Basal  
iCGRP  
release 
(N=5-18/condition) 
1.4 ± 0.2 1.4 ± 0.1 1.2 ± 0.0 1.6 ± 0.1 
 
iCGRP release 
stimulated by  
30 nM capsaicin 
(N=8-9/condition) 
8.5 ± 0.3 † 8.6 ± 0.3 † 8.9  ± 0.4 † 15.9 ± 0.6 †,* 
 
iCGRP release 
stimulated by 
30 mM KCl 
(N=6-9/condition) 
8.4 ± 0.9 † 8.4  ± 0.6 † 7.5 ± 0.5 † 12.5 ± 0.9 †,* 
Total iCGRP 
content (fmol) 
(N=18/condition) 
588 ± 19 560 ± 26 606 ± 23 599 ± 20 
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 Cells were treated for 3 days prior to measuring iCGRP release (pre-treatment) 
and additionally treated during the experiment to measure basal and stimulated iCGRP 
release (acute treatment). iCGRP release was measured from sequential 10-minute 
incubations during which cells were exposed to HEPES buffer in the presence of the 
indicated acute treatment (basal release), then 30nM capsaicin or 30mM potassium in 
the presence of the indicated acute treatment (stimulated release). Basal and stimulated 
iCGRP release are presented as the mean ± S.E.M. of iCGRP released as percent of 
total content per well. Total iCGRP content is the sum of iCGRP released during the 
experiment and remaining iCGRP measured from cells lysed with 0.1N HCl. Total 
iCGRP content is represented as mean ± S.E.M. femtomoles (fmol) of iCGRP per well. 
Crosses indicate enhanced iCGRP release stimulated by 30 nM capsaicin relative to 
basal release. Asterisks indicate significant difference in capsaicin-stimulated iCGRP 
release in the presence of the indicated treatment versus vehicle-treated controls. 
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 α,β-meATP does not alter iCGRP release from male sensory neuron cultures 
Though letrozole did not directly sensitize iCGRP release stimulated by capsaicin 
or high extracellular potassium, AIs may enhance sensory neuron sensitization by 
algogens. As letrozole and exemestane augmented overt hypernociception in response 
to intraplantar ATP, I hypothesized that letrozole alters sensitization of iCGRP release by 
purinergic receptor agonists. In DRG neurons, estradiol and the GPR30 agonist G1 have 
been shown to reduce α,β-meATP-evoked currents [Ma LifeSci 2005, Lu Endocrinology 
2013]. Therefore, reduced intracellular estrogens as a consequence of aromatase 
inhibition may augment P2X currents in DRG neurons, resulting in changes in stimulated 
release of iCGRP. 
 
In previous studies using sensory neurons cultured from neonatal rats, Huang et 
al. showed that purinergic receptor agonists differentially affected capsaicin-stimulated 
iCGRP release: while the non-selective agonist ATP augmented iCGRP release in a 
concentration-dependent manner, the P2X-selective agonist α,β-meATP inhibited 
capsaicin-stimulated iCGRP release [Huang J Pharmacol Exp Ther 2003]. In acutely 
dissociated DRG neurons from adult rats, α,β-meATP evokes currents in approximately 
70% of capsaicin-sensitive neurons that exhibit bi-exponential decay, characteristic of 
homomeric P2X3 receptors [Ueno BrJPharmacol 1999, Lewis Nature 1995]. This current 
is rapidly desensitized (< 100 milliseconds), displays slow recovery from inactivation, 
and is rapidly run down upon repeated agonist application [Lewis Nature 1995]. Thus, 
the kinetics of the P2X3 receptor current make it unlikely that P2X3 activation can 
sensitize nociceptors. In contrast, α,β-meATP evokes sustained currents in 
approximately 50% of capsaicin-insensitive neurons and the currents retain 
responsiveness to repeated applications of α,β-meATP [Ueno BrJPharmacol 1999]. α,β-
meATP-evoked currents in these neurons resemble those of heteromeric P2X2 and P2X3 
131 
 
 channels [Lewis Nature 1995]. These data suggest that if α,β-meATP can sensitize 
sensory neurons, it is likely due to actions on capsaicin-insensitive cells. Thus, I 
characterized the effect of α,β-meATP on iCGRP release stimulated by non-selective 
depolarization of all neurons using 30 mM KCl. Given that the EC50 for α,β-meATP-
evoked currents is similar between capsaicin-sensitive cells (10 µM) and capsaicin-
insensitive neurons (66 µM), α,β-meATP concentrations for this experiment bounded 
these effective concentrations [Ueno BrJPharmacol 1999]. 
 
Neuronal cultures were prepared from DRGs isolated from male rats and 
maintained in F12 media for 12 days, supplemented with 10% horse serum and 30 
ng/mL NGF. The cultures were washed and then treated with vehicle (HEPES buffer) or 
0.01 to 100 μM α,β-meATP for 10 min to prior to and throughout exposure to 30 mM 
KCl. Basal iCGRP release was not altered at α,β-meATP concentrations up to 100 μM, 
suggesting that activation of homomeric P2X3 channels and heteromeric P2X2/P2X3 
channels does not directly simulate iCGRP release (Figure 22). Exposing cells to 30 mM 
KCl enhanced iCGRP release 7-fold relative to baseline. While KCl-stimulated iCGRP 
release was enhanced by 0.01 μM α,β-meATP, increasing concentrations of α,β-meATP 
did not have a similar effect. 
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Figure 22. α,β-meATP does not alter iCGRP release from rat sensory neurons 
under basal conditions or following stimulation with high potassium. 
The ordinate represent the mean ± S.E.M. release of iCGRP as percent of total 
content per well. iCGRP release was measured from cells sequentially exposed for 
ten minutes to buffer alone (BASAL; open columns), then 30 mM KCl (hatched 
columns) in the presence of vehicle or 0.01 to 100 µM α,β-meATP. Within each 
treatment group, a cross indicates a significant difference in iCGRP release in 
response to high extracellular potassium. An asterisk indicates a difference in cells 
treated with α,β-meATP versus those treated with only 30 mM KCl. 
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 Capsaicin-stimulated release of iCGRP from male sensory neuron cultures is 
sensitized by ATP, but not α,β-meATP 
In the previous experiment to determine the effect of α,β-meATP on KCl-
stimulated iCGRP release, the culture media contained phenol red, a known estrogen 
receptor agonist that was subsequently found to also non-competitively antagonize P2X 
channels [Berthois Proc Natl Acad Sci U S A 1986; King Br J Pharmacol 2005]. Media 
containing phenol red was also used in experiments investigating the effects of α,β-
meATP on release of neuropeptides in embryonic DRG neurons reported by Huang et 
al. [Huang JPET 2003]. Maintaining neuronal cultures in media containing phenol red 
may alter the response to P2X channel activation, thus I determined whether α,β-meATP 
alters iCGRP release under basal conditions and when stimulated by 30nM capsaicin or 
30 mM KCl using sensory neurons isolated from adult rats cultured in phenol red-free 
culture media. Although ATP has been shown to sensitize capsaicin-stimulated iCGRP 
release in a concentration-dependent manner, it is unknown whether it also augments 
iCGRP release in response to high concentrations of extracellular potassium. Therefore, 
I also examined whether ATP sensitizes capsaicin or KCl-stimulated release of iCGRP 
under phenol-red free conditions. 
 
Neuronal cultures were prepared from DRGs isolated from male rats and 
maintained in DMEM/F12 media for 9 days, supplemented with 10% horse serum and 
30 ng/mL NGF. The cultures were washed and then treated with vehicle (HEPES buffer), 
10 μM α,β-meATP, or 10 μM ATP for 10 min to prior to and throughout exposure to 
30nM capsaicin or 30 mM KCl. As a positive control for augmentation of capsaicin and 
KCl-stimulated iCGRP release, additional cells in each experiment were treated with 1 
µM PGE2. Basal iCGRP release was not altered by exposing cells to 10 µM ATP or 10 
µM α,β-meATP, but  was slightly augmented in cells exposed to 1 µM PGE2 (Figure 23). 
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 In vehicle-treated cells, iCGRP release was significantly enhanced by stimulation with 30 
mM KCl and 30 nM capsaicin (difference of 4.9% and 8.3% from baseline, respectively) 
(Figure 23). 
 
Exposing sensory neuron cultures to 30 nM capsaicin resulted in a significant 
increase in iCGRP release from baseline in all culture types (difference of 6.1% to 9.4% 
from baseline; Table 2). Exposing sensory neurons to 10 µM ATP prior to and 
throughout stimulation with 30 nM capsaicin (CAP) increased iCGRP release relative to 
stimulation with 30 nM capsaicin alone (Figure 23). In contrast, 30 mM KCl-stimulated 
iCGRP release (KCl) was unaltered by treatment with 10 µM ATP (Figure 23). In 
comparison to ATP-mediated sensitization of iCGRP release, 10 µM α,β-meATP did not 
alter capsaicin-stimulated iCGRP release or KCl-stimulated iCGRP release (Figure 23). 
Capsaicin and KCl-stimulated iCGRP release was augmented by exposing the same 
neuronal cultures to 1 µM PGE2 (Figure 23). There were no significant differences in 
iCGRP content in response these acute drug exposures (vehicle: 827 ± 39 fmol (n=21), 
10 µM ATP: 759 ± 28 fmol (n=21), 10 µM α,β-meATP: 766 ± 34 fmol (n=21), 1 µM PGE2: 
763 ± 21 fmol (n=21); one-way ANOVA). 
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Figure 23. ATP enhances iCGRP release stimulated by capsaicin, but not high 
potassium. 
The ordinates represent the mean ± S.E.M. release of iCGRP as percent of total 
content per well. iCGRP release was measured from cells sequentially exposed for 
ten minutes to buffer alone (BASAL; open columns), then 30 mM KCl (grey columns) 
or 30 nM capsaicin (black columns) in the presence of vehicle, 10 µM ATP, 10 µM 
α,β-meATP, or 1 µM PGE2. Within each treatment group, crosses indicate enhanced 
iCGRP release in response to 30 mM KCl or 30 nM capsaicin treatment under control 
conditions. A pound symbol indicates augmented basal iCGRP release in the 
presence of the indicated treatment versus controls. Asterisks indicate significant 
differences in capsaicin or KCl-stimulated iCGRP release in the presence of the 
indicated treatment versus controls. 
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 Letrozole does not potentiate the ability of ATP to sensitize sensory neurons in 
culture 
Given that letrozole augmented hypernociception in response to intraplantar 
ATP, I sought to examine whether letrozole alters sensitization of iCGRP release 
secondary to purinergic receptor activation. Since α,β-meATP does not directly stimulate 
iCGRP release or alter capsaicin- or KCl-stimulated iCGRP release in DRG cultures, 
and because ATP selectively alters response to capsaicin, I chose to examine the 
potential interaction between ATP and letrozole exposure on capsaicin-stimulated 
iCGRP release. Secondly, to avoid potential ceiling effects when examining potentiation 
of ATP-induced sensitization by letrozole, cells were exposed to lower ATP 
concentrations and stimulated using lower capsaicin concentrations. 
 
Neuronal cultures were prepared from DRGs isolated from male rats and 
maintained in DMEM/F12 media for 9 days, supplemented with 10% horse serum and 
30 ng/mL NGF. To examine the effects of acute letrozole exposure on ATP-induced 
sensitization, cells were washed and then exposed to vehicle (1:10,000 dilution of MPL), 
10 µM letrozole, 1 µM ATP, and the combination for ten minutes prior to and throughout 
stimulation with 10 nM capsaicin. Exposing sensory neurons to 1 µM ATP alone did not 
alter basal iCGRP release, but augmented capsaicin-stimulated release, as evidenced 
by an increase in iCGRP release relative to controls (Figure 24A). Exposing sensory 
neurons to 10 µM letrozole caused a small enhancement of basal iCGRP release 
relative to controls (vehicle: 0.9% ± 0.1, LET: 1.3% ± 0.1), but did not alter capsaicin-
stimulated iCGRP release relative to vehicle-treated cells (Figure 24A). While letrozole 
treatment alone did not alter capsaicin-induced release of iCGRP, co-treatment with 10 
µM letrozole and 1 µM ATP increased capsaicin-stimulated iCGRP release relative to 
cells treated with 1 µM ATP alone (CAP + ATP: 3.3% ± 0.1, CAP + ATP + LET: 4.0% ± 
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 0.2) (Figure 24A). However, similar to letrozole treatment alone, basal iCGRP release 
from cells treated with letrozole and ATP was significantly increased relative to controls 
(Figure 24A). Thus, a secondary analysis was performed, accounting for the enhanced 
basal release in letrozole-treated cells. After subtracting basal release from capsaicin-
stimulated iCGRP release from each well, letrozole exposure did not enhance the effect 
of ATP alone (CAP + ATP: 2.2% ± 0.1, CAP + ATP + LET: 2.6% ± 0.1) (Figure 24B). 
Finally, iCGRP content was not different between treatment groups (vehicle: 1256 ± 74 
fmol, LET: 1101 ± 77 fmol, ATP: 1147 ± 90 fmol, ATP + LET: 1189 ± 71 fmol; one-way 
ANOVA). 
 
I additionally examined whether long-term letrozole treatment alters ATP-
mediated sensitization of iCGRP release. Cultures were treated with vehicle or 10 µM 
letrozole for three days prior to measuring iCGRP release. During the release 
experiment, cells pre-treated with vehicle were re-exposed to vehicle or 1 µM ATP prior 
to and throughout stimulation with 10 nM capsaicin. Cells pre-treated with letrozole were 
re-exposed to 10 µM letrozole alone or in combination with 1 µM ATP prior to and 
throughout stimulation with 10 nM capsaicin. Capsaicin-stimulated release of iCGRP 
was significantly enhanced by 1 µM ATP from 2.7 ± 0.2 % of total content to 5.2 ± 0.3 % 
of total content (Figure 24C). However, neither basal or capsaicin-stimulated iCGRP 
release was altered in cells treated with 10 µM letrozole and 1 µM ATP relative to cells 
treated with 1 µM ATP alone (Figure 24C). As observed in prior experiments, long-term 
exposure to letrozole did not significantly alter the content of iCGRP in the cultures. Total 
iCGRP content in cultures exposed to vehicle for 3 days was 993 ± 84 fmol/well, 
whereas in cultures exposed to 10 μM letrozole for 3 days, iCGRP content was 885 ± 71 
fmol/well. 
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 Figure 24. ATP-mediated sensitization of iCGRP release from sensory neurons is 
not altered by acute or long-term letrozole treatment. 
The ordinates represent the mean ± S.E.M. release of iCGRP as percent of total content 
per well. A: During sequential ten minute incubations, cells were exposed to vehicle, 10 
µM letrozole, 1 µM ATP, or the combination, in the absence (BASAL; open columns) or 
presence of 10 nM capsaicin (hatched columns). B: The evoked release of iCGRP is 
calculated by subtracting the basal release prior to stimulus exposure from the 
capsaicin-stimulated release. Asterisks indicate significant differences in capsaicin-
evoked iCGRP release in the presence of the indicated treatment versus controls. C: 
Cells were treated with vehicle or letrozole for three days prior to measuring iCGRP 
release (indicated above the bar graphs) and then exposed to vehicle, 10 µM letrozole, 1 
µM ATP, or the combination during the release experiment (indicated below the bar 
graphs) in the absence (BASAL; open columns) and presence of capsaicin (hatched 
columns). In (A) and (C): Within each treatment group, a cross indicates a significant 
difference from basal release. A pound symbol indicates augmented basal release 
versus vehicle controls, whereas an asterisk indicates a difference in cells treated with 
ATP versus those treated with only capsaicin. A double asterisk indicates a significant 
difference in capsaicin-stimulated iCGRP release in the presence of ATP versus ATP 
and letrozole. 
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 Neuropeptide release from spinal cord slices is not altered in male rats treated 
with letrozole 
 
To determine whether letrozole altered release of iCGRP into the spinal cord 
from sensory neuron central terminals, male rats were treated with 5 mg/kg letrozole (n = 
6) or vehicle (750 mg/kg HPβCD; n = 7) daily for 7 to 8 days (Figure 25A). To ensure 
animals used in the slice release experiment had developed mechanical hypersensitivity 
as a result of letrozole treatment, PWT was measured at baseline and following 1, 3, and 
6 days of treatment in all animals that were used in release experiments. Consistent with 
our previous results, 5 mg/kg letrozole significantly reduced the PWT compared to 
vehicle treated controls from 7.0 ± 1.0 grams to 2.7 ± 0.9 grams and 1.6 ± 0.2 at days 3 
and 6 following initiation of treatment (Figure 25B). The day after the last drug dose, 
iCGRP release from spinal cord slices was measured under basal conditions and during 
depolarization with 30 mM KCl. Basal iCGRP release from spinal cord slices isolated 
from letrozole-treated rats (0.040 ± 0.004 % of total content per min) was not 
significantly different from that observed in vehicle-treated rats (0.040 ± 0.003 % of total 
content per min; Figure 26A and Figure 26B). Furthermore, iCGRP release during 
exposure to 30 mM KCl was not altered in spinal cord slices from rats treated with 
letrozole compared to vehicle (vehicle: 0.049 ± 0.005 versus letrozole: 0.048 ± 0.005 % 
of total content per min (Figure 26A and Figure 26B). Consequently, evoked iCGRP 
release from letrozole treated rats (0.008 ± 0.002 % of total content per min) was not 
different from that observed in vehicle treated rats (0.009 ± 0.003 % of total content per 
min; Figure 26B). Additionally, iCGRP content in the lumbar spinal cord was not different 
in male rats administered 5 mg/kg letrozole (407.1 ± 18.99 fmol/mg) versus vehicle 
(433.4 ± 35.56 fmol/mg) (Figure 26C). 
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 As a positive control for sensitization of KCl-stimulated iCGRP release, spinal 
cord slices from additional treatment-naïve rats were acutely exposed to 30 µM PGE2 (n 
= 4) or vehicle (1:2000 dilution of MPL; n = 14). PGE2 augmented basal (0.103 ± 0.009 
% of total content per min), 30 mM KCl stimulated (0.197 ± 0.017 % of total content per 
min), and evoked iCGRP release (0.095 ± 0.024 % of total content per min) relative to 
vehicle controls (basal: 0.051 ± 0.004 % of total content per min, 30 mM KCl: 0.086 ± 
0.011 % of total content per min, evoked: 0.035 ± 0.010 % of total content per min; 
Figure 26D). 
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Figure 25. Daily dosing of 5 mg/kg letrozole induces mechanical hypersensitivity 
in male rats. 
A: Depiction of the experimental design. B: Each point represents the mean ± S.E.M. 
of paw withdrawal thresholds (PWT) in grams. Letrozole or vehicle was administered 
daily on days 0 through 6 or 7 (7-8 total doses) during which behavior was measured. 
An asterisk represents significant differences in PWT between treatment groups (P < 
0.05; t-test). 
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 Figure 26. Release of iCGRP is not altered in spinal cord slices from male rats with 
letrozole-induced mechanical hypersensitivity. 
A: Basal and potassium-stimulated release of iCGRP was measured from spinal cord 
slices isolated from rats following treatment with vehicle or 5 mg/kg letrozole for 7-8 
days. Open columns represent iCGRP released from spinal cord slices perfused with 
HEPES buffer alone for successive 3-minute intervals, whereas black columns represent 
iCGRP released when tissues were perfused with HEPES buffer containing 30 mM 
potassium. The ordinate represents the mean ± S.E.M. of iCGRP released per minute, 
expressed as the percent of total iCGRP content in the spinal cord slice. B: Summary of 
mean ± S.E.M. of iCGRP release as percent of total content/min during basal (minutes 
9-18) and high potassium stimulation (minutes 18-27) in vehicle or letrozole-treated rats 
from (A). Evoked release is calculated as stimulated release minus basal release. C: 
iCGRP content of the perfused slices, normalized by tissue wet weight. iCGRP content 
is sum of peptide released during the release experiment and residual peptide measured 
at the conclusion of the experiment. D: Summary of the mean ± S.E.M. of iCGRP 
release as percent of total content/min from acutely treated spinal cord slices from naïve 
male rats. Spinal cord slices from naïve male rats were perfused with HEPES buffer 
alone for 3 successive 3-minute intervals (minutes 0-9) and then perfused with HEPES 
buffer containing vehicle or 30 µM PGE2 for 9 minutes prior to (minutes 9-18; basal) and 
throughout stimulation with 30 mM KCl (minutes 18-27; stimulated). Evoked release is 
calculated as stimulated release minus basal release. 
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 DISCUSSION 
 
Conclusions 
 
Much circumstantial evidence suggests that AI-induced arthralgia is linked to the 
ability of these drugs to reduce estrogen concentrations secondary to blocking 
aromatase activity (Felson and Cummings, 2005; Henry et al., 2007). This notion is 
supported by clinical observations that painful musculoskeletal syndromes develop in 
patients during periods of low or declining systemic estrogens, such as during the 
transition into menopause (Berecki-Gisolf et al., 2009; Cecil and Archer, 1925; 
Meriggiola et al., 2012) or following discontinuation of estrogen replacement therapy 
(Brunner et al., 2010; Ockene et al., 2005). In addition, studies using male and female 
rats show that estrogen administration produces antinociception in animal models of 
pain (Kuba et al., 2005; Liu and Gintzler, 2000; Mannino et al., 2007; Tsao et al., 1999), 
suggesting that reducing systemic estrogens diminishes endogenous pain suppression. 
Despite the clinical significance of AI-induced arthralgia, few studies have attempted to 
determine the effects of AIs in animal models of nociception. Consequently, I explored 
the hypothesis that AIs produce hypersensitivity to potentially noxious stimuli in rats. The 
behavioral models that I chose to investigate the effect of AIs were among those 
previously shown to be sensitive to estrogen deprivation. To examine whether the 
effects of AIs on nociceptive behaviors are mediated by activation or sensitization of 
sensory neurons, I determined whether letrozole exposure alters release of CGRP from 
isolated sensory neurons and from sensory nerve endings in spinal cord slices. CGRP 
release was examined, in part, because previous studies suggest that estrogens 
regulate CGRP expression in sensory neurons (Gangula et al., 2000). 
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 I first determined the effect of letrozole exposure on nociceptive behaviors using 
ovariectomized (OVX) rats, since these rats exhibit many hormonal and physiological 
alterations consistent with those that occur during menopausal transition in women 
(Hoegh-Andersen et al., 2004; Kalu, 1991; Kobayashi et al., 2000). In OVX rats, 
sensitivity to mechanical stimulation of hind paws was significantly augmented by 
administration of a single dose of 1 or 5 mg/kg letrozole and this effect was maintained 
during thirty subsequent days of behavioral evaluation. In contrast, letrozole treated rats 
did not have altered nocifensive responses to noxious thermal stimulation, suggesting 
that the mechanism by which letrozole augments the nociceptive behavior is limited to 
mechanically sensitive neuronal pathways. I also observed that the PWTs in control 
OVX rats were significantly reduced from baseline throughout the testing period, a 
finding that is consistent with previous studies using OVX animals to examine 
mechanical hypernociception secondary to loss of ovarian-derived estrogens (Dina et 
al., 2001; Ma et al., 2011; Sanoja and Cervero, 2005). Similar to the differential effect of 
AI treatment on hypernociception, responses to noxious thermal stimulation did not 
change over the month of evaluating vehicle-treated OVX rats. Given the impact of OVX 
on basal nociception and its potential to complicate the interpretation of experiments 
involving drug administration after OVX, I evaluated the effect of systemic AI 
administration in male rats, an alternative rat model with very low circulating estrogens. 
 
Similar to OVX rats, male rats treated with letrozole daily for 15 days showed a 
significant reduction in the paw withdrawal threshold to mechanical stimuli without any 
change in withdrawal latency to thermal stimuli. Unlike OVX rats, when letrozole 
injections were stopped in males, mechanical hypersensitivity was reversed within seven 
days. Of interest, the onset of the mechanical sensitivity was similar in male and OVX 
rats despite differences in the amount of cumulative drug administered. 
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 Differences in the duration of letrozole-induced mechanical hypersensitivity 
between the sexes may, in part, be a consequence of pharmacokinetic differences 
between the sexes. The sparse pharmacokinetic measurements of letrozole in serum, 
brain, and DRGs performed in this study are consistent with the long elimination half-life 
of cyclodextrin-complexed letrozole in female rats (Wempe et al., 2007). Median 
letrozole concentrations measured in whole-brain homogenates four days after a single 
dose of 1 mg/kg in OVX rats were over 20,000-fold higher than the reported IC50 for 
aromatase inhibition in cell lines (413 pg/mg in brain versus an IC50 of 70 pM) 
(Bhatnagar et al., 2001). Assuming a conservative elimination half-life of 40 hours and 
first-order elimination kinetics from brain tissue, letrozole concentrations lower than 70 
pM and increasing aromatase activity in peripheral tissues would hypothetically be 
achieved at 15 half-lives, or 25 days, following a single dose of 1 mg/kg in OVX rats. A 
detailed description of tissue drug exposure in OVX and male rats, and preferentially, 
aromatase activity measurements, are needed to verify these approximations. 
Additionally, different mechanisms mediating hypersensitivity in the different sexes may 
contribute to sex differences in drug-induced hypersensitivity. For example, inhibiting 
aromatase eliminates one metabolic pathway of androgen metabolism, and therefore AI 
treatment could alter concentrations or dynamics of other tissue steroids that might 
contribute to hypersensitivity. Indeed, AIs are known to increase blood concentrations of 
the aromatase substrate testosterone in men (Burnett-Bowie et al., 2009; Mauras et al., 
2000), but have a small or no effect in women (Gallicchio et al., 2011; Ingle et al., 2010a; 
Rossi et al., 2009). Understanding changes in sex steroid precursors and their impact on 
nociception may be important to understanding AI-induced hypersensitivity.  
 
Experimentally induced joint inflammation or trauma in animals is consistently 
associated with the development of mechanical hypersensitivity (Malfait et al., 2013). 
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 Arthritic rats and mice display reduced thresholds for hind limb withdrawal reflexes 
evoked by compression of the knee, however, mechanical sensitivity in these models is 
more commonly measured by changes in the reflexive response to application of von 
Frey hairs to the dorsal surface of the hind paw (Neugebauer et al., 2007). Since the 
experimental lesions are typically induced in the knee joint and von Frey sensitivity is 
measured at the paw, mechanical sensitivity in these models is thought to reflect 
referred pain or secondary allodynia. While this logic applies to experimental models 
where the involved joint has been specifically manipulated by the experimenter and joint 
pathology can be shown to be limited to that joint, in the case of AI-induced 
hypersensitivity, potential pathological changes in joints have not yet been 
characterized. Given that the clinical manifestations of the toxicity significantly impact the 
joints, we may speculate that a component of AI-induced hypersensitivity observed in 
rats reflects secondary hyperalgesia. Investigating histopathological changes of the 
joints and muscles of AI-treated rats may lend support to this hypothesis. Interestingly, 
hypersensitivity to noxious thermal temperatures in the hind paw are often detected in 
models associated with involvement of inflammatory mediators, such as carrageenan-
induced arthritis and collagen-induced arthritis (Inglis et al., 2007; Malfait et al., 2013; 
Zhang et al., 2001), but not in models of surgically-induced joint instability (Malfait et al., 
2013). Here I report that OVX and male rats treated with letrozole do not develop 
thermal hypernociception. If distinct hypernociceptive behaviors are associated with 
different types of musculoskeletal lesions, they may share common pathological 
features. Therefore, future mechanistic studies of AI-induced mechanical hypersensitivity 
may utilize prior information on molecular and neuronal pathways known to be engaged 
in mediating other types of musculoskeletal pain that are not associated with changes in 
cutaneous thermal sensation. 
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 Activation of G-protein-coupled P2Y and ionotropic P2X nucleotide receptors 
contributes to inflammatory and neuropathic pain behaviors in rodents and may be an 
important mediator of enhanced mechanosensory transduction in these models (Chen et 
al., 2005; Cockayne et al., 2000; McGaraughty et al., 2003; Souslova et al., 2000; Tsuda 
et al., 1999). Pharmacological activation of purinergic receptors by ATP or α,β-meATP in 
the dermis rapidly induces nocifensive behavioral responses and reduces hind paw 
withdrawal thresholds to von Frey hair stimulation, which is also induced by intrathecal 
administration of either agent (Nakagawa et al., 2007; Okada et al., 2002; Tsuda et al., 
2000). Consistent with previous reports, I observed augmented responses to intraplantar 
ATP injections in OVX rats when compared to intact females (Ma et al., 2011). This 
differential effect of ATP in OVX rats is partially attributed to loss of an inhibitory effect of 
estrogens, as systemic estradiol treatment partially attenuates overt nociceptive 
behaviors in OVX rats induced by ATP (Ma et al., 2011). Estradiol similarly attenuates 
overt nociception induced by the P2X-selective agonist, α,β-me-ATP, when the 
compounds are co-administered in the paw (Lu et al., 2013). Conversely, intraplantar 
administration of estradiol prior to bradykinin injections has also been shown to enhance 
bradykinin-induced thermal sensitivity in OVX rats (Rowan et al., 2010). Intraplantar co-
injection of estradiol with capsaicin potentiates capsaicin-induced nocifensive response 
in male rats (Lu et al., 2009). These experiments do not indicate whether estradiol 
modulates algogen actions at the level of the nociceptive fiber, but do suggest that 
manipulation of sex steroid concentrations in specific anatomical and temporal contexts 
can dramatically influence the activation of nociceptive sensory neurons. Experiments 
presented in this thesis demonstrate that treating male rats systemically with letrozole 
and exemestane augments overt nociceptive responses to intraplantar injection of ATP. 
These data raise the possibility that AIs potentiate nociceptive behavior evoked by ATP 
exposure in the paw by altering physiologic hormone concentrations, either in the paw, 
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 or in other cells responsible for the integrated behavioral response to ATP. My findings 
are consistent with prior studies showing pharmacologic inhibition of aromatase in rats 
and genetic ablation of CYP19 in aromatase knockout mice enhances formalin-induced 
nocifensive behavior. In naïve and OVX female rats, subcutaneous letrozole dosing (5 
mg/kg) enhanced scored phase II behavior to low concentrations, but not high 
concentrations of formalin injected in the hindpaw (Moradi-Azani et al., 2011). Similarly, 
aromatase knockout mice displayed increased grooming during interphase and phase II 
following formalin injections in the lip (Multon et al., 2005). Purinergic signaling is 
implicated in the behavioral response to formalin as P2X2 and P2X3 knockout mice and 
P2X receptor antagonists reduce phases I and II of formalin-induced flinching behavior 
(Cockayne et al., 2000; McGaraughty et al., 2003; Souslova et al., 2000). It is possible 
that the ability of AIs to augment nociceptive response to formalin is mechanistically 
related to enhanced response to the inflammatory mediator ATP.  
 
In studies by Ma et al., mechanical hypernociception in OVX rats was reversed 
by intraplantar injection of the purinoreceptor antagonists 2′,3′-O-(2,4,6-trinitrophenyl) 
adenosine-5′-triphosphate (TNP-ATP) and A-317491, implicating P2X receptor activation 
in the maintenance of mechanical hypersensitivity following ovariectomy (Ma et al., 
2011). Given that activation of P2X receptors by α,β-me-ATP in the dermis or in the 
spinal cord induces tactile hypersensitivity (Tsuda et al., 2000) and that inhibition of P2X 
receptors attenuates tactile allodynia following spinal cord injury and inflammation 
(Chadwick et al., 2004), the data in OVX rats suggests that estrogens may suppress 
mechanoreceptor activation by purines subsequent to purine release by the mechanical 
stimulation. Physical or mechanical forces acting at the membrane, such as stretch or 
distention, pressure, and deformation are known to be potent stimuli for ATP release 
from many cell types, including epithelial cells and neurons (Jo and Schlichter, 1999; 
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 Knight et al., 2002; Patel et al., 2005; Wang et al., 2005; Xia et al., 2012). If 
hypernociceptive behaviors induced by AI described here are mechanistically related, a 
component of mechanosensitivity of the hindpaws during AI administration may be 
mediated by enhanced ATP release or enhanced purinergic receptor activation by 
endogenous purines secondary to mechanical stimulation. Additional experiments are 
needed to determine whether mechanical hypersensitivity in letrozole-treated rats is a 
result of enhanced purinergic receptor activation, either centrally or peripherally. 
 
In the current work, I show that AIs alter nociceptive responses in both OVX and 
male rats. If these effects are mediated by altered endocrine actions of circulating 
estrogens, they result from a reduction in the already very low blood estrogen 
concentrations in both animal models. Alternatively, the AI effects may be a 
consequence of inhibiting the production of estrogens in tissues that disrupts their 
paracrine actions. For example, although blood estrogen concentrations in 
ovariectomized rodents are reduced to concentrations observed in males (i.e., near or 
below sensitivity for analytical detection), (Davidge et al., 2001; Farrell et al., 1988; Zhao 
et al., 2004) aromatase expression and activity in extra-gonadal tissues persists 
following OVX (Zhao et al., 2004). In cells of the vertebrate nervous system, de novo 
synthesis of estrogens also occurs due to aromatase expression (Naftolin et al., 1996). 
In aromatase expressing brain regions, low levels of constitutive basal activity contribute 
to steady-state estrogen exposure. Additionally, aromatase activity and estradiol content 
have been shown to fluctuate in response to physiologic or experimentally induced 
changes in neuronal activity, such as song-driven neuronal responses in the zebra finch 
brain (Remage-Healey et al., 2009). Activity-dependent aromatase activity may 
contribute to the variability in estradiol concentrations in the rat brain regions expressing 
aromatase, which by definition, are not strongly correlated with blood estradiol 
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 concentrations (Konkle and McCarthy, 2011b). Therefore, estrogen-dependent signaling 
processes activated in aromatase-expressing tissues in the nervous system are 
expected to be asynchronous with those mediated by ′endocrine′ sources of estrogens 
from blood. If side effects of AI therapies are secondary to aromatase inhibition, 
neuronal processes modulated by local aromatase activity are likely to be significantly 
altered during AI administration.  
 
In the peripheral nervous system, aromatase immunoreactivity and synthesis of 
3H-estradiol from the steroid precursor 3H-pregnenolone was shown in lumbosacral 
DRGs from rats (Schaeffer et al., 2010). Results presented in this thesis support the 
expression of mRNA encoding CYP19A1 and translation of these transcripts. However, 
given the high CT values obtained for CYP19A1 mRNA in total RNA isolated from DRGs 
and DRG cultures, CYP19A1 transcripts can be described as low abundance under 
physiological conditions. Despite their low abundance, aromatase immunoreactive 
bands corresponding to the predicted molecular weight of the aromatase enzyme, were 
detected in DRG lysates from both OVX female and male rats. Aromatase 
immunoreactive bands were also detected in DRG cultures after 24 hours, and up to 12 
days in culture, suggesting that factors contributing to basal expression of the enzyme 
were maintained in cultures. In DRGs and in DRG cultures, aromatase expression 
coincides with expression of classical nuclear estrogen receptors, ERα and ERβ, and of 
GPR30 (Papka and Storey-Workley, 2002; Takanami et al., 2010; Taleghany et al., 
1999; Vanderhorst et al., 2005). The expression of aromatase and estrogen receptors in 
DRGs and the spinal cord raises the interesting possibility that aromatase activity in 
pain-transduction pathways may modulate the processing of afferent sensory 
information via autocrine or paracrine signaling. Consequently, I first examined whether 
letrozole could augment the release of the peptide neurotransmitter CGRP from sensory 
153 
 
 neurons. The use of sensory neuron cultures for these experiments controls for 
circulating sources of endogenous sex steroids and minimizes the contribution of 
inflammatory mediators and other factors that may be altered following administration of 
AIs to animals. The rationale for examining CGRP release was as follows. 1) CGRP is 
synthesized and released from a number of nociceptive sensory neurons including 
mechanosensitive C-fibers (Dubin and Patapoutian, 2010; Lawson et al., 2002; Lawson 
et al., 1997). 2) Sensory fibers that discharge in response to nonnoxious and noxious 
movements of the knee joint and also express CGRP are particularly abundant in joints, 
where about one-third of articular afferents contain CGRP (Hukkanen et al., 1991; 
Konttinen et al., 1990; Schaible et al., 1986). 3) Release of this peptide in the periphery 
augments inflammation (Brain and Williams, 1985; Richardson and Vasko, 2002) and 
CGRP release is enhanced in experimental models of joint inflammation (Fehrenbacher 
et al., 2003; Ogbonna et al., 2013). 4) Lastly, ERα is co-expressed with CGRP in 
sensory neurons and estradiol increases CGRP mRNA and CGRP content in a 
concentration and time-dependent manner (Gangula et al., 2000; Mowa et al., 2003b). 
 
Contrary to my hypothesis, I did not observe any alterations in basal, capsaicin-
evoked or high extracellular potassium-evoked iCGRP release in sensory neuronal 
cultures after acute exposure to letrozole or after chronic treatment with the AI. These 
results were not impacted by removing media components with known (phenol red) and 
potentially (serum) estrogenic properties that could have interfered with the ability to 
detect the effects of estrogen depletion by letrozole. Additionally, there were no sex-
dependent effects of letrozole exposure on iCGRP release in sensory neuron cultures as 
the drug did not significantly alter iCGRP release in cultures derived from OVX female 
rats or male rats. On the other hand, capsaicin-stimulated release of iCGRP was 
significantly greater in sensory neuron cultures from OVX rats, when compared to 
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 cultures from intact female or male rats. These data suggest that ovariectomy results in 
a significant change in the mechanism of nociceptor excitation or neurotransmitter 
release due to capsaicin stimulation. The effect of OVX to enhance capsaicin sensitivity 
in 12-day old neuronal cultures suggests a permanent change that is independent of 
sustained blood steroid or inflammatory changes that follow ovariectomy in vivo. 
 
Given the effect of systemically administered AIs to augment ATP-induced 
nociception in vivo, I tested whether the effect of purines on sensory neurons in culture 
might also be altered by letrozole exposure. Preliminary experiments to determine 
whether the nonselective (ATP) or P2X3-selective (α,β-meATP) purinergic receptor 
agonists stimulate or sensitize iCGRP release, showed that the ability of these agents to 
alter iCGRP release was dependent on the agonist and on the type of excitation. 
Although exposing isolated sensory neurons to ATP significantly increased capsaicin-
evoked release of iCGRP in the cultures, exposure to ATP did not alter iCGRP release 
stimulated by high extracellular potassium. Furthermore, α,β-meATP had no direct effect 
on iCGRP release and did not sensitize the nociceptors. These results are consistent 
with the ability of ATP and UTP to sensitize CGRP release through P2Y2 receptor 
activation in sensory neuron cultures from embryonic DRGs (Huang et al., 2003). P2X3 
receptors, the primary P2X receptor expressed in small-diameter capsaicin-sensitive 
neurons, are known to rapidly desensitize (<100 ms) following activation by ATP or α,β-
meATP and slowly recover activity (> 20 min) (Lewis et al., 1995; Ueno et al., 1999). 
Although activation of P2X3 receptors by α,β-meATP can induce short bursts of action 
potentials in nociceptors, the inactivation kinetics may limit the ability of this activation to 
stimulate or sensitize the release of neuropeptides. Further specificity for the contribution 
of P2Y2 to sensitization of CGRP release is supported by reduced cation conductance 
through α,β-meATP-activated P2X channels following activation of P2Y2 receptors with 
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 UTP (Mo et al., 2013). Exposing sensory neurons to letrozole acutely or for three days 
prior to the release experiment did not alter basal release of iCGRP or the sensitizing 
actions of ATP on capsaicin-stimulated release.  
 
While previous studies have provided strong evidence for the regulation of CGRP 
expression by exogenous estrogens, I observed no change in total content of iCGRP in 
neuronal cultures exposed to letrozole for up to five days. These results are consistent 
with the notion that cellular events mediated by local aromatase activity may not 
resemble those mediated by exogenous estrogens. However, these results may have 
alternative explanations. First, it is unclear whether the expression of aromatase in DRG 
cultures indicates constitutive enzymatic activity. If the enzyme is constitutively active, 
the low expression level of aromatase may not result in significant estrogen 
concentrations that can be impacted by pharmacologic inhibition. Alternatively, 
aromatase activity in the CNS has been shown to be manipulated by changes in 
neuronal activity, raising the intriguing possibility that the enzymatic activity is 
dynamically regulated in DRGs or DRG cultures. Thus, effects of AI treatments may only 
be observed under conditions associated with high enzymatic activity. My experiments 
showed aromatase immunoreactive bands corresponding to two distinct molecular 
weights, with higher molecular weight bands in sensory neuron cultures. Bands 
corresponding to these molecular weights were also found in ovary lysates from two 
different rats. The observations are consistent with the observation of two aromatase 
isoforms in human placental microsomes with approximate molecular weights of 50 to 51 
and 55 kDa and may reflect differential phosphorylation or glycosylation of the enzyme 
(Balthazart et al., 2001; Balthazart et al., 2003b; Harada, 1988; Mendelson et al., 1985; 
Miller et al., 2008; Sethumadhavan et al., 1991). In addition, these isoforms may 
correspond to different enzymatic activities as post-translational modifications that have 
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 been demonstrated to modulate aromatase activity in the CNS (Balthazart et al., 2001; 
Balthazart et al., 2003b; Miller et al., 2008; Sethumadhavan et al., 1991). Secondly, a 
sufficient spatial relationship between aromatase and estrogen receptors may need to 
be maintained within or between cells for aromatase activity to initiate estrogen-
mediated signaling events. Although neurons in culture grow neurites in the presence of 
NGF, generating a complex network of inter-connected neurites that resembles an 
interlaced mat, anatomical relationships between cells that may allow aromatase-
mediated signaling events may not be recapitulated in the cultures. Finally, cells were 
grown in horse serum that may contain sufficient quantities of estrogens to effectively 
nullify any effect of reduced estrogen synthesis by aromatase inhibition. Experiments to 
evaluate the long-term effects of letrozole exposure on iCGRP release in serum-free 
conditions were not feasible due to the rapid loss of iCGRP content from cultures when 
serum was removed. 
 
To further evaluate the effect of AIs on sensory neurons, I examined whether 
chronic administration of letrozole, which produced mechanical hypersensitivity in the 
rat, would alter release of CGRP in spinal cord slices taken from these animals. Basal 
iCGRP release from spinal cord tissue of letrozole-treated rats was not different than 
vehicle-treated controls, suggesting that letrozole treatment does not result in activation 
of CGRP expressing nociceptors. Additionally, potassium-stimulated iCGRP release was 
not altered in rats treated with letrozole, suggesting aromatase inhibition does not 
sensitize CGRP-expressing sensory neurons to a depolarizing stimulus. Finally, total 
content of iCGRP was not altered in letrozole-treated rats compared to controls, 
suggesting that CGRP content in pre-synaptic terminals of primary afferents is not 
strongly influenced by AIs or aromatase inhibition in vivo. 
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 Taken together, my results do not support the altered release of this 
neuropeptide into the spinal cord as a mediator of letrozole-induced mechanical 
hypersensitivity, but do not preclude a potential effect on other neurotransmitters or 
other sensory neuron populations.  Indeed, a number of mechanosensitive A and C 
sensory neurons do not express CGRP (Dubin and Patapoutian, 2010; Lawson et al., 
2002) and thus the effects we observe on mechanical nociception could be mediated by 
these neurons. Further studies seem warranted to examine whether letrozole alters 
excitability of small, nonpeptideregic C-type sensory neurons or large diameter A-type 
neurons and/or other neurons in the pain pathway. It also is possible that AI-induced 
hypernociception occurs by mechanisms other than, or in addition to, alteration in the 
excitability of sensory neurons. 
 
Future Directions 
 
Based on the results presented in this body of work, consideration should be 
given to the following experiments: 
 
(1) Determine the effect of systemically administered AIs on nociceptive response to 
P2X or P2Y-selectve agonists. 
Intraplantar administration of α,β-meATP and ATP elicit dose-dependent 
nociceptive responses in rats. To identify whether the effect of AIs to augment ATP-
induced nociception is mediated by activation of ionotropic or metabotropic purinergic 
receptors, nociceptive responses should be evaluated in AI-treated rats injected with 
α,β-meATP (activate P2X1/3 receptors) versus UTP (activate P2Y2/4 receptors). 
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 (2) Determine whether rats treated with AIs display changes in mobility or gait. 
One of the symptoms most commonly reported with the therapeutic use of AIs 
are severe early morning stiffness and hand–wrist pain. Patients with these symptoms 
have severely limited mobility in the affected part of the hand or wrist (Thorne, 2007). 
Evaluating the unrestrained mobility or specifically measuring joint motion of AI treated 
animals may be a useful indication of changes in joint stiffness. 
 
(3) Determine whether the effect of AIs to enhance mechanical sensitivity and augment 
ATP-induced nociception is secondary to aromatase inhibition. 
The precipitating mechanism underlying AI-induced toxicities has been largely 
assumed to be due to a reduction in estrogens during AI therapy. However, definitive 
studies to address this fundamental premise are lacking and the possibility that 
additional pharmacologic effects of AIs may contribute to their toxicity (or efficacy) has 
not been given sufficient consideration. The identification of alternative pharmacologic 
targets of AIs could provide new therapeutic approaches to alleviate AI-induced pain or 
provide targets for rational development of new analgesics or agents to prevent the 
onset of this toxicity. In the current work, I demonstrated that rats systemically 
administered two AIs, letrozole and exemestane, displayed augmented nociceptive 
responses to intraplantar ATP injections. AI doses for these studies were chosen to 
achieve maximal systemic aromatase inhibition, based on previously published dose-
response studies. Differences in the molecular structures and the mechanisms by which 
these drugs inhibit aromatase, reduces the probability that engagement of an additional, 
and yet common, pharmacologic target underlies the observed effects on nociceptive 
behaviors. Yet these observations do not exclude the possibility that AIs produce 
hypersensitivity by engaging pharmacological targets other than, or in addition to, 
aromatase. Therfore, studies aimed to determine the potential contribution of additional 
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 pharmacologic effects of AIs should be considered as part of future experiments. To 
address this question, the effect of AI administration on nociceptive responses to 
mechanical stimulation and intraplantar ATP should be determined in CYP19 knockout 
mice (Fisher et al., 1998; Honda et al., 1998). Furthermore, sensory neuron cultures 
produced from these mice could be used in complementary in-vitro experiments aimed 
at determining the contribution of aromatase to sensitization by ATP and measures of 
excitability. 
 
(4) Determine whether aromatase expression is confined to neuronal or non-neuronal 
cells in rat DRGs. 
While experiments investigating aromatase in the CNS and PNS have focused 
on neuronal expression of the enzyme, and early experiments suggest sensory neurons 
of the DRG express the enzyme, the exact cellular localization of this enzymatic complex 
within the different cell populations PNS is still uncertain (Schaeffer et al., 2010). These 
experiments are challenging given the low expression levels of both the mRNA 
transcripts and protein in the nervous system. One approach would be to utilize the 
recently described ′aromatase-IRES-plap-IRES-nuclear lacZ′ or ′aromatase-IPIN′ mouse 
model that has a genetically modified aromatase locus, such that all cells expressing this 
enzyme coexpress two reporters: nuclear targeted LacZ and placental alkaline 
phosphatase (Wu et al., 2009). This mouse model has been used to describe the 
expression pattern of aromatase in the mouse brain and may be useful for further 
investigations in the PNS. Understanding whether aromatase is expressed in glia and its 
expression pattern in neurons relative to known morphological (e.g. small, medium, large 
diameter) or molecular (e.g. TRPV1 positive) may direct future functional studies. 
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 (5) Determine the enzymatic activity of aromatase in excised DRGs and sensory neuron 
cultures, and additionally, whether its activity is altered by depolarizing stimuli. 
The ability of depolarizing stimuli to alter aromatase activity has been 
demonstrated in three separate model systems and preparations: quail hypothalamus 
(Balthazart et al., 2003a), rat hippocampus (Hojo et al., 2004), and zebra finch cortex 
(Remage-Healey et al., 2011; Remage-Healey et al., 2008). Understanding the potential 
dynamic control of estrogen synthesis under excitatory conditions in DRG neurons will 
guide future investigations into the role of aromatase in sensory neurons and the 
potential impact of aromatase inhibitors. Since several inflammatory molecules relevant 
to studies of pain are known to regulate CYP19A1 transcription in other tissues (e.g. 
PGE2), these studies could be coupled with induction or suppression of aromatase 
activity by activating various second messenger cascades (Bulun et al., 2005). 
 
(6) Determine whether sensory neurons exposed to AIs have altered release of 
neurotransmitters other than CGRP and whether they alter the excitability of sensory 
neurons. 
While experiments in this report focused on CGRP release as an endpoint to 
measure sensitization, further insight into the potential effects of AIs may be gained by 
investigating the release of additional neurotransmitters. The amino acid glutamate is the 
major excitatory neurotransmitter in the mammalian central nervous system and it is 
likely synthesized released from the majority of DRG neurons (Hoffman et al., 2010). 
Release of glutamate and neuropeptides are enhanced in the spinal cord in response to 
peripheral injections of algogens (e.g. capsaicin) or inflammation (Sluka and Willis, 1998; 
Warsame Afrah et al., 2004). However, glutamate and CGRP release from sensory 
neurons in culture is known to be differentially influenced by various algogens, such as 
ATP (Gu and MacDermott, 1997; Khodorova et al., 2009). Thus, additional experiment 
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 are warranted to address whether AIs alter release of additional neurotransmitters, such 
as glutamate, from sensory neuron in culture. 
 
(7) Determine whether sensory neurons exposed to AIs have altered excitability, as 
measured by patch-clamp electrophysiology. 
Current-clamp electrophysiology is an additional technique that may be used to 
study the effects of AIs on the excitability of sensory neurons. The ability AIs to alter the 
excitability of sensory neurons in vitro should be examined using current clamp 
electrophysiology. 
 
Summary 
 
A significant fraction of breast cancer patients treated with AIs develop pain in 
joints and/or muscles that results in approximately one-fourth of the afflicted patients 
discontinuing therapy (Henry et al., 2012). Furthermore, AIs are currently being studied 
in the chemoprevention setting and initial trial results have shown that exemestane 
lowers the risk of a new breast cancer in postmenopausal women at high risk (Goss et 
al., 2011). It is expected that AI-induced musculoskeletal pain will also significantly 
impact patient compliance during AI treatment for breast cancer prevention. Critically, 
mechanistic insight and guided interventions are needed to alleviate musculoskeletal 
pain in these patients and allow these patients to persist on AI therapy. Taken together, 
the experiments conducted in this dissertation have provided new experimental models 
for AI-induced hypersensitivity that could be beneficial in delineating the mechanism by 
which AIs augment nociception and developing interventions to prevent or reverse AI-
induced musculoskeletal pain. Additionally, these studies do not support a significant 
role for CGRP expressing small diameter sensory neurons in the pathogenesis of AI-
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 induced pain. These studies provide a scientific basis to direct future investigations into 
altered function of additional sensory neuron populations and the biochemical and 
pharmacologic mechanisms that underlie the effects of estrogens and their modulators 
on musculoskeletal pain. 
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